1
|
Polverelli N, Bonneville EF, de Wreede LC, Koster L, Kröger NM, Schroeder T, Peffault de Latour R, Passweg J, Sockel K, Broers AEC, Clark A, Dreger P, Blaise D, Yakoub-Agha I, Petersen SL, Finke J, Chevallier P, Helbig G, Rabitsch W, Sammassimo S, Arcaini L, Russo D, Drozd-Sokolowska J, Raj K, Robin M, Battipaglia G, Czerw T, Hernández-Boluda JC, McLornan DP. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT. Am J Hematol 2024; 99:993-996. [PMID: 38385579 DOI: 10.1002/ajh.27262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2023] [Revised: 02/07/2024] [Accepted: 02/08/2024] [Indexed: 02/23/2024]
Abstract
Investigating the evaluation of eligibility for transplant in myelofibrosis (MF): The role of HCT-CI and BMI. HCT-CI emerges as a key prognostic factor, while BMI shows limited impact. This study expands insights for better clinical decision-making in MF allo-HCT.
Collapse
Affiliation(s)
- Nicola Polverelli
- Unit of Bone Marrow Transplantation, Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Edouard F Bonneville
- Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
- EBMT Leiden Study Unit, Leiden, The Netherlands
| | - Liesbeth C de Wreede
- Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
| | | | - Nicolaus Martin Kröger
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Thomas Schroeder
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany
| | | | - Jakob Passweg
- Hematology Division, University Hospital, Basel, Switzerland
| | | | | | - Andrew Clark
- Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
| | | | - Didier Blaise
- Programme de Transplantation & Therapie Cellulaire, Marseille, France
| | | | - Soeren Lykke Petersen
- Bone Marrow Transplant Unit, Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark
| | - Jürgen Finke
- Department of Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | | | - Grzegorz Helbig
- Department of Hematology and Bone Marrow Transplantation, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
| | - Werner Rabitsch
- BMT Unit, Internal Medicine I, Medical University of Vienna, Vienna, Austria
| | - Simona Sammassimo
- Onco-Hematology Division, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - Luca Arcaini
- Unit of Bone Marrow Transplantation, Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - Domenico Russo
- Unit of Blood Diseases and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | | | - Kavita Raj
- Department of Haematology and Stem Cell Transplantation, University College London Hospitals NHS Trust, London, UK
| | - Marie Robin
- BMT Unit, Saint-Louis Hospital, Paris, France
| | - Giorgia Battipaglia
- Hematology and Bone Marrow Transplantation Unit, Hematology Department, Federico II University of Naples, Naples, Italy
| | - Tomasz Czerw
- Department of Hematology, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland
| | | | - Donal P McLornan
- Department of Haematology and Stem Cell Transplantation, University College London Hospitals NHS Trust, London, UK
| |
Collapse
|
2
|
Gagelmann N, Hobbs GS, Campodonico E, Helbig G, Novak P, Schroeder T, Schneider A, Rautenberg C, Reinhardt HC, Bosques L, Heuser M, Panagiota V, Thol F, Gurnari C, Maciejewski JP, Ciceri F, Rathje K, Robin M, Pagliuca S, Rubio MT, Rocha V, Funke V, Hamerschlak N, Salit R, Scott BL, Duarte F, Mitrus I, Czerw T, Greco R, Kröger N. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis. Am J Hematol 2024; 99:844-853. [PMID: 38357714 DOI: 10.1002/ajh.27252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2023] [Revised: 01/11/2024] [Accepted: 01/31/2024] [Indexed: 02/16/2024]
Abstract
Splenomegaly is the clinical hallmark of myelofibrosis. Splenomegaly at the time of allogeneic hematopoietic cell transplantation (HCT) is associated with graft failure and poor graft function. Strategies to reduce spleen size before HCT especially after failure to Janus kinase (JAK) inhibition represent unmet clinical needs in the field. Here, we leveraged a global collaboration to investigate the safety and efficacy of splenic irradiation as part of the HCT platform for patients with myelofibrosis. We included 59 patients, receiving irradiation within a median of 2 weeks (range, 0.9-12 weeks) before HCT. Overall, the median spleen size prior to irradiation was 23 cm (range, 14-35). Splenic irradiation resulted in a significant and rapid spleen size reduction in 97% of patients (57/59), with a median decrease of 5.0 cm (95% confidence interval, 4.1-6.3 cm). The most frequent adverse event was thrombocytopenia, with no correlation between irradiation dose and hematological toxicities. The 3-year overall survival was 62% (95% CI, 48%-76%) and 1-year non-relapse mortality was 26% (95% CI, 14%-38%). Independent predictors for survival were severe thrombocytopenia and anemia before irradiation, transplant-specific risk score, higher-intensity conditioning, and present portal vein thrombosis. When using a propensity score matching adjusted for common confounders, splenic irradiation was associated with significantly reduced relapse (p = .01), showing a 3-year incidence of 12% for splenic irradiation versus 29% for patients with immediate HCT and 38% for patients receiving splenectomy. In conclusion, splenic irradiation immediately before HCT is a reasonable approach in patients experiencing JAK inhibition failure and is associated with a low incidence of relapse.
Collapse
Affiliation(s)
- Nico Gagelmann
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Gabriela S Hobbs
- Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Edoardo Campodonico
- Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Hospital, University Vita-Salute San Raffaele, Milan, Italy
| | - Grzegorz Helbig
- Department of Hematology and Bone Marrow Transplantation, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
| | - Polona Novak
- Department of Hematology, University Medical Center Ljubljana, Ljubljana, Slovenia
| | - Thomas Schroeder
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital of Essen, Germany
| | - Artur Schneider
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital of Essen, Germany
| | - Christina Rautenberg
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital of Essen, Germany
| | - Hans Christian Reinhardt
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital of Essen, Germany
| | - Linette Bosques
- Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Michael Heuser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | - Victoria Panagiota
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | - Felicitas Thol
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | - Carmelo Gurnari
- Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA
- Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy
| | - Jaroslaw P Maciejewski
- Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA
- Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | - Fabio Ciceri
- Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Hospital, University Vita-Salute San Raffaele, Milan, Italy
| | - Kristin Rathje
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Marie Robin
- Service d'Hématologie-Greffe, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Simona Pagliuca
- Department of Hematology, Brabois Hospital, Centre Hospitalier Régional Universitaire (CHRU), Nancy, France
| | - Marie-Thérèse Rubio
- Department of Hematology, Brabois Hospital, Centre Hospitalier Régional Universitaire (CHRU), Nancy, France
| | - Vanderson Rocha
- Hospital de Clinicas, Hematology, Transfusion and Cell Therapy Service, University of São Paulo, Sao Paulo, Brazil
| | - Vaneuza Funke
- Blood and Marrow Transplantation Programme, Hospital de Clínicas, Federal University of Parana, Curitiba, Paraná, Brazil; Hospital Nossa Senhora das Graças, Curitiba, Brazil
| | | | - Rachel Salit
- Fred Hutchinson Cancer Research Center, Seattle, USA
| | - Bart L Scott
- Fred Hutchinson Cancer Research Center, Seattle, USA
| | - Fernando Duarte
- Hospital Universitario Walter Cantídio, Universidade Federal do Ceara, Fortaleza, Brazil
| | - Iwona Mitrus
- Hematology Department, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland
| | - Tomasz Czerw
- Hematology Department, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland
| | - Raffaella Greco
- Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Hospital, University Vita-Salute San Raffaele, Milan, Italy
| | - Nicolaus Kröger
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
3
|
Nagler A, Labopin M, Swoboda R, Schroeder T, Hamladji RM, Griskevicius L, Salmenniemi U, Rambaldi A, Mielke S, Kulagin A, Passweg J, Luft T, Gedde-Dahl T, Forcade E, Helbig G, Stelljes M, Castilla-Llorente C, Spyridonidis A, Brissot E, Ciceri F, Mohty M. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2024:10.1038/s41409-024-02284-5. [PMID: 38615143 DOI: 10.1038/s41409-024-02284-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Revised: 04/07/2024] [Accepted: 04/08/2024] [Indexed: 04/15/2024]
Abstract
Post-transplant cyclophosphamide plus calcineurin inhibitor (CNI)(tacrolimus or cyclosporine A) plus mycophenolate mofetil (PTCy/TAC or CSA/MMF) and anti-thymocyte globulin plus CNI (tacrolimus or cyclosporine A) plus methotrexate (ATG/TAC or CSA/MTX) are common graft-versus-host disease (GVHD) prophylaxis regimens. We compared the two regimens in patients with acute myeloid leukemia (AML) undergoing allogeneic transplantation from matched siblings or unrelated donors. 402 received PTCy/TAC or CSA/MMF and 5648 received ATG/TAC or CSA/MTX. Patients in the PTCy-based group were younger (48.7 vs. 51.5 years, p = 0.024) and there was a higher frequency of patient cytomegalovirus seropositivity and female donor to male patient combination in this group (77.8% vs. 71.8%, p = 0.009 and 18.4% vs. 14.4%, p = 0.029, respectively). More patients in the PTCy-based group received reduced-intensity conditioning (51.5% vs. 41%, p < 0.0001). No differences were observed in the incidence of acute GVHD grade II-IV and III-IV (21.2% vs. 20.4%, p = 0.92 and 8.1% vs. 6%, p = 0.1) or 2-year total and extensive chronic GVHD (33.7% vs. 30%, p = 0.09 and 10.7% vs. 11.2%, p = 0.81) between the groups. In the multivariate analysis, all transplant outcomes did not differ between the groups. PTCy/CNI/MMF and ATG/CNI/MTX are alternative regimens for GVHD prophylaxis in AML patients.
Collapse
Affiliation(s)
- Arnon Nagler
- Division of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
| | - Myriam Labopin
- EBMT Paris Study Office; Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France
- Department of Haematology, Saint Antoine Hospital, Sorbonne University; INSERM UMR 938, Paris, France
| | - Ryszard Swoboda
- Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
| | | | | | | | | | - Alessandro Rambaldi
- Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale, Papa Giovanni XXIII, Bergamo, Italy
| | | | - Alexander Kulagin
- RM Gorbacheva Research Institute, Pavlov University, Petersburg, Russia
| | | | - Thomas Luft
- University of Heidelberg, Heidelberg, Germany
| | | | | | | | | | | | - Alexandros Spyridonidis
- Department of Internal Medicine, Bone Marrow Transplantation Unit, University Hospital of Patras, Patras, Greece
| | - Eolia Brissot
- Department of Haematology, Saint Antoine Hospital, Sorbonne University; INSERM UMR 938, Paris, France
| | - Fabio Ciceri
- Department of Haematology and BMT, IRCCS Osspedale San Raffaele; Vita-Salute San Raffaele University, Milano, Italy
| | - Mohamad Mohty
- EBMT Paris Study Office; Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France
- Department of Haematology, Saint Antoine Hospital, Sorbonne University; INSERM UMR 938, Paris, France
| |
Collapse
|
4
|
Schetelig J, Baldauf H, Heidenreich F, Hoogenboom JD, Spellman SR, Kulagin A, Schroeder T, Sengeloev H, Dreger P, Forcade E, Vydra J, Wagner-Drouet EM, Choi G, Paneesha S, Miranda NAA, Tanase A, de Wreede LC, Lange V, Schmidt AH, Sauter J, Fein JA, Bolon YT, He M, Marsh SGE, Gadalla SM, Paczesny S, Ruggeri A, Chabannon C, Fleischhauer K. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight. Front Immunol 2024; 15:1350470. [PMID: 38629074 PMCID: PMC11019434 DOI: 10.3389/fimmu.2024.1350470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Accepted: 03/04/2024] [Indexed: 04/19/2024] Open
Abstract
Optimizing natural killer (NK) cell alloreactivity could further improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). The donor's Killer-cell Immunoglobulin-like Receptor (KIR) genotype may provide important information in this regard. In the past decade, different models have been proposed aiming at maximizing NK cell activation by activating KIR-ligand interactions or minimizing inhibitory KIR-ligand interactions. Alternative classifications intended predicting outcome after alloHCT by donor KIR-haplotypes. In the present study, we aimed at validating proposed models and exploring more classification approaches. To this end, we analyzed samples stored at the Collaborative Biobank from HLA-compatible unrelated stem cell donors who had donated for patients with acute myeloid leukemia (AML) or myelodysplastic neoplasm (MDS) and whose outcome data had been reported to EBMT or CIBMTR. The donor KIR genotype was determined by high resolution amplicon-based next generation sequencing. We analyzed data from 5,017 transplants. The median patient age at alloHCT was 56 years. Patients were transplanted for AML between 2013 and 2018. Donor-recipient pairs were matched for HLA-A, -B, -C, -DRB1, and -DQB1 (79%) or had single HLA mismatches. Myeloablative conditioning was given to 56% of patients. Fifty-two percent of patients received anti-thymocyte-globulin-based graft-versus-host disease prophylaxis, 32% calcineurin-inhibitor-based prophylaxis, and 7% post-transplant cyclophosphamide-based prophylaxis. We tested several previously reported classifications in multivariable regression analyses but could not confirm outcome associations. Exploratory analyses in 1,939 patients (39%) who were transplanted from donors with homozygous centromeric (cen) or telomeric (tel) A or B motifs, showed that the donor cen B/B-tel A/A diplotype was associated with a trend to better event-free survival (HR 0.84, p=.08) and reduced risk of non-relapse mortality (NRM) (HR 0.65, p=.01). When we further dissected the contribution of B subtypes, we found that only the cen B01/B01-telA/A diplotype was associated with a reduced risk of relapse (HR 0.40, p=.04) while all subtype combinations contributed to a reduced risk of NRM. This exploratory finding has to be validated in an independent data set. In summary, the existing body of evidence is not (yet) consistent enough to recommend use of donor KIR genotype information for donor selection in routine clinical practice.
Collapse
Affiliation(s)
- Johannes Schetelig
- Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany
- Clinical Trials Unit, DKMS Group, Dresden, Germany
| | | | - Falk Heidenreich
- Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany
- Clinical Trials Unit, DKMS Group, Dresden, Germany
| | | | - Stephen R. Spellman
- Center for International Blood and Marrow Transplant Research, National Marrow Donor Program (NMDP), Minneapolis, MN, United States
| | - Alexander Kulagin
- RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia
| | - Thomas Schroeder
- Klinik für Hämatologie und Stammzelltransplantation, Universitätsklinikum Essen, Essen, Germany
| | - Henrik Sengeloev
- Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
| | - Peter Dreger
- Department of Medicine V, University of Heidelberg, Heidelberg, Germany
| | - Edouard Forcade
- Service Hématologie clinique de Thérapie cellulaire, Centre Hospitalier Universitaire Bordeaux, Université de Bordeaus, Bordeaux, France
| | - Jan Vydra
- Transplant Unit and Intensive Care Unit, Institute of Hematology and Bood Transfusion, Prague, Czechia
| | - Eva Maria Wagner-Drouet
- Center for Cellular Immunotherapy and Stem Cell Transplantation, Third Medical Department, Hematology and Oncology, University Cancer Center Mainz, Mainz, Germany
| | - Goda Choi
- University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Shankara Paneesha
- Department of Haematology & Stem Cell Transplantation, Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - Nuno A. A. Miranda
- Department of Hematology, Instituto Português de Oncologia de Lisboa, Lisboa, Portugal
| | - Alina Tanase
- Department of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, Romania
| | | | | | | | | | - Joshua A. Fein
- Department of Hematology & Medical Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, United States
| | - Yung-Tsi Bolon
- Center for International Blood and Marrow Transplant Research, National Marrow Donor Program (NMDP), Minneapolis, MN, United States
| | - Meilun He
- Center for International Blood and Marrow Transplant Research, National Marrow Donor Program (NMDP), Minneapolis, MN, United States
| | - Steven G. E. Marsh
- Anthony Nolan Research Institute, Royal Free Hospital, London & Cancer Institute, University College London, London, United Kingdom
| | - Shahinaz M. Gadalla
- National Cancer Institute, Division of Cancer Epidemiology & Genetics, Bethesda, MD, United States
| | - Sophie Paczesny
- Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States
| | | | - Christian Chabannon
- Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer, Marseille, France
| | | |
Collapse
|
5
|
Salas MQ, Eikema DJ, Koster L, Maertens J, Passweg J, Finke J, Broers AEC, Koc Y, Kröger N, Ozkurt ZN, Pascual-Cascon MJ, Platzbecker U, Van Gorkom G, Schroeder T, López-Lorenzo JL, Martino M, Chiusolo P, Kaufmann M, Onida F, Gurnari C, Scheid C, Drozd-Sokolowska J, Raj K, Robin M, McLornan DP. Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant 2024; 59:479-488. [PMID: 38253869 DOI: 10.1038/s41409-023-02159-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Revised: 11/15/2023] [Accepted: 11/21/2023] [Indexed: 01/24/2024]
Abstract
We retrospectively compared outcomes of 404 MDS patients undergoing 1st matched sibling donor allo-HCT receiving either PTCy-based (n = 66) or other "conventional prophylaxis" (n = 338; mostly calcineurin inhibitor + methotrexate or MMF). Baseline characteristics were balanced, except for higher use of myeloablative regimens in the PTCy group (52.3% vs. 38.2%, p = 0.047). Incidences of neutrophil (Day +28: 89% vs. 97%, p = 0.011) and platelet (Day +100: 89% vs. 97%, p < 0.001) engraftment were lower for PTCy-based. Day +100 cumulative incidences of grade II-IV and III-IV aGVHD, and 5-year CI of extensive cGVHD were 32%, 18% and 18% for PTCy-based and 25% (p = 0.3), 13% (p = 0.4) and 31% (p = 0.09) for the conventional cohort. Five-year OS (51% vs. 52%, p = 0.6) and GRFS (33% vs. 25%, p = 0.6) were similar between groups. Patients receiving PTCy had a trend to a lower cumulative incidence of relapse (20% vs. 33%, p = 0.06), not confirmed on multivariable analysis (p = 0.3). Although higher NRM rates were observed in patients receiving PTCy (32% vs. 21%, p = 0.02) on univariate analysis, this was not confirmed on multivariate analysis (HR 1.46, p = 0.18), and there was no resultant effect on OS (HR 1.20, p = 0.5). Based on these data, PTCy prophylaxis appears to be an attractive option for patients with MDS undergoing MSD allo-HCT.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Yener Koc
- Medicana International Hospital Istanbul, Istanbul, Turkey
| | | | | | | | | | | | | | | | - Massimo Martino
- Grande Ospedale Metropolitano Bianchi Melacrino Morelli - Centro Unico Trapianti A. Neri, Reggio C, Italy
| | | | | | - Francesco Onida
- Fondazione IRCCS - Ca' Granda - Ospedale Maggiore Policlinico IRCCS, Milan, Italy
| | - Carmelo Gurnari
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
- Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA
| | | | | | - Kavita Raj
- University College London Hospitals NHS Trust, London, UK
| | - Marie Robin
- Hopital Saint-Louis, APHP, Université de Paris Cité, Paris, France
| | | |
Collapse
|
6
|
Maffini E, Labopin M, Kröger N, Finke J, Stelljes M, Schroeder T, Einsele H, Tischer J, Bornhäuser M, Bethge W, Brecht A, Rösler W, Dreger P, Schäfer-Eckart K, Passweg J, Blau IW, Nagler A, Ciceri F, Mohty M. Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2024:10.1038/s41409-024-02275-6. [PMID: 38555412 DOI: 10.1038/s41409-024-02275-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2024] [Revised: 03/20/2024] [Accepted: 03/21/2024] [Indexed: 04/02/2024]
Abstract
Older adults with acute myeloid leukemia (AML) refractory to initial or reinduction chemotherapy have a dismal prognosis if they do not undergo hematopoietic stem-cell transplantation (HCT). However, data assessing HCT outcomes from different donors are scarce. We evaluated results from a retrospective analysis on patients aged ≥70 years, with AML not in remission who received an allogeneic HCT from HLA-matched sibling donor (MSD), HLA-10/10 matched unrelated donor (MUD), or T-cell replete haploidentical (Haplo) donor, from 2010 to 2021, reported to the ALWP-EBMT database. A total of 360 patients (median age 72 years, range 70-79) were included in the analysis. Median follow-up for the entire population was 35.5 months. Donors were MSD (n = 58), 10/10 HLA-MUD (n = 228), and Haplo (n = 74). A total of 213 (59.2%) patients were primary induction failures, while 147 (40.8%) were in first or subsequent relapse. Graft source was peripheral blood in 92% of the patients. Patients transplanted from Haplo donors more frequently received marrow grafts (p < 0.01) and presented the combination female donor to male recipient (p < 0.01). The overall 2-year rates of overall survival (OS) and leukemia-free survival (LFS) were: 62.4% (95% CI 47.2-74.3) and 47.6% (95% CI 33.1-60.8) for MSD, 43% (95% CI 35.8-49.9), and 37.5% (95% CI 30.7-44.4) for MUD, and 25.9% (95% CI 15.8-37.2), and 26.5% (95% CI 16.3-37.8) for recipients of Haplo transplants. The 2-year cumulative incidence of relapse (RI) was slightly lower for Haplo recipients at 29.6% (95% CI 19-40.9), for MUD it was 30.2% (95% CI 23.9-36.7), and for MSD 34.9% (95% CI 22-48.2); counterbalanced by a higher incidence of non-relapse mortality (NRM) of 43.9% (95% CI 31.6-55.6) for Haplo recipients, 32.2% (95% CI 26-33.1) for MUD and 17.5% (95% CI 8.4-29.3) for MSD. Graft-versus-host disease (GVHD-free, relapse-free survival (GRFS) was 35.3% (95% CI 22.3-48.5) for MSD, 29.6% (95% CI 23.2-36.2) for MUD, and 19.2% (95% CI 10.7-29.6) for Haplo patients. In the multivariate model, compared to the referent group of MSD recipients, the risk of NRM was higher among patients transplanted from Haplo donors ([hazard ratio] HR 5.1, 95% CI 2.23-11.61, p < 0.001) and MUD (HR 3.21, 95% CI 1.48-0.6.94, p = 0.003). Furthermore, both Haplo and MUD were associated with inferior OS, (HR 3.6, 95% CI 1.98-0.6.56, p < 0.001, and HR 2.3, 95% CI 1.37-0.3.88, p = 0.002, respectively), and LFS (HR 2.24, 95% CI 1.31-0.3.84, p = 0.003, and HR 1.64, 95% CI 1.04-0.2.60, p = 0.034, respectively). Patients transplanted from Haplo donors were also associated with worse GFRS (HR 1.72, 95% CI 1.07-2.77, p:0.025) compared with MSD patients. Older adult AML patients with active disease transplanted from MSD experienced prolonged OS and LFS compared to 10/10 MUD and Haplo due to lower NRM. Prospective clinical trials are warranted.
Collapse
Affiliation(s)
- Enrico Maffini
- IRCCS Azienda Ospedaliero-Universitaria di Bologna; Istituto "L. e A. Seràgnoli", Bologna, Italy.
| | | | - Nicolaus Kröger
- University Medical Center Hamburg, Department for Stem Cell Transplantation, Hamburg, Germany
| | - Jürgen Finke
- Department of Medicine -Hematology Oncology, University of Freiburg, Freiburg, Germany
| | - Matthias Stelljes
- Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany
| | - Thomas Schroeder
- University Hospital, Department of Bone Marrow Transplantation, Essen, Germany
| | - Herman Einsele
- Universitaetsklinikum Wuerzburg, Med. Klinik und Poliklinik II, Wuerzburg, Germany
| | - Johanna Tischer
- Klinikum Grosshadern, Medizinische Klinik III, Munich, Germany
| | - Martin Bornhäuser
- Universitaetsklinikum Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany
| | - Wolfgang Bethge
- Universitaet Tuebingen Medizinische Klinik, Tuebingen, Germany
| | - Arne Brecht
- Deutsche Klinik fuer Diagnostik, KMT Zentrum, Wiesbaden, Germany
| | - Wolf Rösler
- University Hospital Erlangen, Department of Internal Medicine 5, Erlangen, Germany
| | - Peter Dreger
- University of Heidelberg, Medizinische Klinik u. Poliklinik V, Heidelberg, Germany
| | | | | | - Igor Wolfgang Blau
- Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Charité Universitätsmedizin, Berlin, Germany
| | - Arnon Nagler
- Sheba Medical Center, Tel-Hashomer, Tel-Aviv University, Ramat-Gan, Israel
| | - Fabio Ciceri
- Ospedale San Raffaele s.r.l., Haematology and BMT, Milano, Italy
| | - Mohamad Mohty
- Sorbonne University, Clinical Hematology and Cellular Therapy Department, Saint Antoine Hospital, INSERM UMRs 938, Paris, France
| |
Collapse
|
7
|
Robin M, Iacobelli S, Koster L, Passweg J, Avenoso D, Wilson KMO, Salmenniemi U, Dreger P, von dem Borne P, Snowden JA, Robinson S, Finazzi MC, Schroeder T, Collin M, Eder M, Forcade E, Loschi M, Bramanti S, Pérez-Simón JA, Czerw T, Polverelli N, Drozd-Sokolowska J, Raj K, Hernández-Boluda JC, McLornan DP. Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant 2024:10.1038/s41409-024-02269-4. [PMID: 38491198 DOI: 10.1038/s41409-024-02269-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Revised: 03/05/2024] [Accepted: 03/07/2024] [Indexed: 03/18/2024]
Abstract
We aimed to compare outcomes following treosulfan (TREO) or busulfan (BU) conditioning in a large cohort of myelofibrosis (MF) patients from the EBMT registry. A total of 530 patients were included; 73 received TREO and 457 BU (BU ≤ 6.4 mg/kg in 134, considered RIC, BU > 6.4 mg/kg in 323 considered higher dose (HD)). Groups were compared using adjusted Cox models. Cumulative incidences of engraftment and acute GVHD were similar across the 3 groups. The TREO group had significantly better OS than BU-HD (HR:0.61, 95% CI: 0.39-0.93) and a trend towards better OS over BU-RIC (HR: 0.66, 95% CI: 0.41-1.05). Moreover, the TREO cohort had a significantly better Progression-Free-Survival (PFS) than both the BU-HD (HR: 0.57, 95% CI: 0.38-0.84) and BU-RIC (HR: 0.60, 95% CI: 0.39-0.91) cohorts, which had similar PFS estimates. Non-relapse mortality (NRM) was reduced in the TREO and BU-RIC cohorts (HR: 0.44, 95% CI: 0.24-0.80 TREO vs BU-HD; HR: 0.54, 95% CI: 0.28-1.04 TREO vs BU-RIC). Of note, relapse risk did not significantly differ across the three groups. In summary, within the limits of a registry-based study, TREO conditioning may improve PFS in MF HSCT and have lower NRM than BU-HD with a similar relapse risk to BU-RIC. Prospective studies are needed to confirm these findings.
Collapse
Affiliation(s)
- Marie Robin
- Hôpital Saint-Louis, APHP, Université de Paris Cité, Paris, France.
| | - Simona Iacobelli
- Deptartment of Biology, University of Rome Tor Vergata, Rome, Italy
| | | | | | | | | | | | | | | | - John A Snowden
- Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| | | | | | | | - Matthew Collin
- Northern Centre for Bone Marrow Transplantation, Newcastle, England
| | | | - Edouard Forcade
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, F-33000, Bordeaux, France
| | | | - Stefania Bramanti
- Department of Oncology/Hematology, IRCCS Humanitas Research Hospital, via Manzoni 56, Rozzano, 20089, Milan, Italy
| | - Jose Antonio Pérez-Simón
- Instituto de Biomedicina de Sevilla IBIS, CSIC, Hospital Universitario Virgen del Rocío Universidad de Sevilla, Sevilla, Spain
| | - Tomasz Czerw
- Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland
| | - Nicola Polverelli
- Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia-ASST Spedali Civili, Brescia, Italy
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | | | - Kavita Raj
- University College London Hospitals NHS Trust, London, UK
| | | | | |
Collapse
|
8
|
Moutzoukis G, Lorenz MK, Schroeder T, Schulte-Steinberg B, Chow K, Kellman P, Bekeredjian R, Schmid N, Mahrholdt H, Seitz A. Systematic underestimation of myocardial perfusion reserve by regadenoson stress perfusion CMR-when haste makes waste. Clin Res Cardiol 2024:10.1007/s00392-024-02405-6. [PMID: 38466348 DOI: 10.1007/s00392-024-02405-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Accepted: 02/14/2024] [Indexed: 03/13/2024]
Affiliation(s)
- Georgios Moutzoukis
- Department of Cardiology and Angiology, Robert Bosch Medical Center, Auerbachstrasse 110, 70376, Stuttgart, Germany
| | - Marie K Lorenz
- Department of Cardiology and Angiology, Robert Bosch Medical Center, Auerbachstrasse 110, 70376, Stuttgart, Germany
| | - Thomas Schroeder
- Department of Medical Informatics, Bosch Health Campus, Stuttgart, Germany
| | - Benedict Schulte-Steinberg
- Department of Cardiology and Angiology, Robert Bosch Medical Center, Auerbachstrasse 110, 70376, Stuttgart, Germany
| | - Kelvin Chow
- Cardiovascular MR R&D, Siemens Medical Solutions USA, Inc., Chicago, IL, USA
| | - Peter Kellman
- National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
| | - Raffi Bekeredjian
- Department of Cardiology and Angiology, Robert Bosch Medical Center, Auerbachstrasse 110, 70376, Stuttgart, Germany
| | - Nico Schmid
- Department of Medical Informatics, Bosch Health Campus, Stuttgart, Germany
| | - Heiko Mahrholdt
- Department of Cardiology and Angiology, Robert Bosch Medical Center, Auerbachstrasse 110, 70376, Stuttgart, Germany.
| | - Andreas Seitz
- Department of Cardiology and Angiology, Robert Bosch Medical Center, Auerbachstrasse 110, 70376, Stuttgart, Germany
| |
Collapse
|
9
|
Sadowska-Klasa A, Zaucha JM, Labopin M, Bourhis JH, Blaise D, Yakoub-Agha I, Salmenniemi U, Passweg J, Fegueux N, Schroeder T, Giebel S, Brissot E, Ciceri F, Mohty M. Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registry. Bone Marrow Transplant 2024; 59:387-394. [PMID: 38195982 DOI: 10.1038/s41409-023-02192-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Revised: 12/16/2023] [Accepted: 12/20/2023] [Indexed: 01/11/2024]
Abstract
Secondary acute lymphoblastic leukemia (s-ALL) comprises up to 10% of ALL patients. However, data regarding s-ALL outcomes is limited. To answer what is the role of allogeneic hematopoietic cell transplantation (HCT) in s-ALL, a matched-pair analysis in a 1:2 ratio was conducted to compare outcomes between s-ALL and de novo ALL (dn-ALL) patients reported between 2000-2021 to the European Society for Blood and Marrow Transplantation registry. Among 9720 ALL patients, 351 (3.6%) were s-ALL, of which 80 were in first complete remission (CR1) with a known precedent primary diagnosis 58.8% solid tumor (ST), 41.2% hematological diseases (HD). The estimated 2-year relapse incidence (RI) was 19.1% (95%CI: 11-28.9), leukemia-free survival (LFS) 52.1% (95%CI: 39.6-63.2), non-relapse mortality (NRM) 28.8% (95%CI: 18.4-40), GvHD-free, relapse-free survival (GRFS) 39.4% (95%CI: 27.8-50.7), and overall survival (OS) 60.8% (95%CI: 47.9-71.4), and did not differ between ST and HD patients. In a matched-pair analysis, there was no difference in RI, GRFS, NRM, LFS, or OS between s-ALL and dn-ALL except for a higher incidence of chronic GvHD (51.9% vs. 31.4%) in s-ALL. To conclude, patients with s-ALL who received HCT in CR1 have comparable outcomes to patients with dn-ALL.
Collapse
Affiliation(s)
- A Sadowska-Klasa
- Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland.
| | - J M Zaucha
- Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland.
| | - M Labopin
- Department of Hematology, Sorbonne University, Hopital Saint Antoine, Paris, France
| | - J H Bourhis
- Department of Hematology, Gustave Roussy Cancer Campus, BMT Service, Villejuif, France
| | - D Blaise
- Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France
| | - I Yakoub-Agha
- CHU de Lille, LIRIC, INSERM U995, Université de Lille, Lille, France
| | - U Salmenniemi
- HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland
| | - J Passweg
- University Hospital, Hematology, Basel, Switzerland
| | - N Fegueux
- CHU Lapeyronie, Département d'Hématologie Clinique, Montpellier, France
| | - T Schroeder
- Department of Bone Marrow Transplantation, University Hospital, Essen, Germany
| | - S Giebel
- Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
| | - E Brissot
- Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne University, and INSERM UMRs 938, Paris, France
| | - F Ciceri
- Ospedale San Raffaele, Haematology and BMT, Milan, Italy
| | - M Mohty
- Department of Hematology, Sorbonne University, Hopital Saint Antoine, Paris, France
| |
Collapse
|
10
|
Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, Wagner-Drouet EM, Versluis J, Schroeder T, Blau IW, Wulf GG, Dreger P, Olesen G, Sengeloev H, Kröger N, Potter V, Forcade E, Passweg J, de Latour RP, Maertens J, Wilson KMO, Bourhis JH, Finke J, Brissot E, Bazarbachi A, Giebel S, Savani BP, Nagler A, Ciceri F, Mohty M. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2024; 59:217-223. [PMID: 37978322 PMCID: PMC10849946 DOI: 10.1038/s41409-023-02139-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2023] [Revised: 10/05/2023] [Accepted: 10/18/2023] [Indexed: 11/19/2023]
Abstract
The intensity of the conditioning regimen given before allogeneic hematopoietic cell transplantation (allo-HCT) can vary substantially. To confirm the ability of the recently developed transplant conditioning intensity (TCI) score to stratify the preparative regimens of allo-HCT, we used an independent and contemporary patient cohort of 4060 transplant recipients with acute myeloid leukemia meeting inclusion criteria from the discovery study (allo-HCT in first complete remission, matched donor), but who were allografted in a more recent period (2018-2021) and were one decade older (55-75 years, median 63.4 years), we assigned them to a TCI category (low n = 1934, 48%; intermediate n = 1948, 48%, high n = 178, 4%) according to the calculated TCI score ([1-2], [2.5-3.5], [4-6], respectively), and examined the validity of the TCI category in predicting early non-relapse mortality (NRM), 2-year NRM and relapse (REL). In the unadjusted comparison, the TCI index provided a significant risk stratification for d100 and d180 NRM, NRM and REL risk. In the multivariate analysis adjusted for significant variables, there was an independent association of TCI with early NRM, NRM and REL. In summary, we confirm in contemporary treated patients that TCI reflects the conditioning regimen related morbidity and anti-leukemic efficacy satisfactorily and across other established prognostic factors.
Collapse
Affiliation(s)
- Alexandros Spyridonidis
- Bone Marrow Transplantation Unit and Institute of Cellular Therapy, University of Patras, Patras, Greece.
| | - Myriam Labopin
- EBMT Unit, Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France
| | - Tobias Gedde-Dahl
- Oslo University Hospital, Rikshospitalet Clinic for Cancer Medicine, Hematology Dept. Section for Stem Cell Transplantation, Oslo, Norway
| | - Arnold Ganser
- Hannover Medical School, Department of Haematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany
| | | | - Charles Craddock
- University Hospital Birmingham NHSTrust, Queen Elizabeth Medical Centre, Edgbaston, Dept. of Haematology, Birmingham, United Kingdom
| | - Eva Maria Wagner-Drouet
- University Medical Center Mainz, Department of Hematology, Oncology and Pneumology, Mainz, Germany
| | - Jurjen Versluis
- Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Hematology, Rotterdam, Netherlands
| | - Thomas Schroeder
- University Hospital Essen, Dept. of Bone Marrow Transplantation, Essen, Germany
| | - Igor Wolfgang Blau
- Charité Universitätsmedizin Berlin, Onkologie und Tumorimmunologie, Berlin, Germany
| | - Gerald G Wulf
- Universitaetsklinikum Goettingen, Abteilung Hämatologie und Onkologie, Goettingen, Germany
| | - Peter Dreger
- University of Heidelberg, Medizinische Klinik u. Poliklinik V, Heidelberg, Germany
| | | | - Henrik Sengeloev
- National University Hospital, Bone Marrow Transplant Unit, Copenhagen, Denmark
| | - Nicolaus Kröger
- University Hospital Eppendorf, Bone Marrow Transplantation Centre, Hamburg, Germany
| | - Victoria Potter
- Kings College Hospital, Dept. of Haematological Medicine, King's Denmark Hill Campus, London, United Kingdom
| | | | - Jakob Passweg
- University Hospital Basel, Dept of Hematology, Basel, Switzerland
| | | | - Johan Maertens
- University Hospital Gasthuisberg Dept. of Hematology, Leuven, Belgium
| | - Keith M O Wilson
- University Hospital of Wales, Department of Haematology, Cardiff, United Kingdom
| | - Jean Henri Bourhis
- Gustave Roussy Cancer Campus, Department of Hematology, Villejuif, France
| | - Juergen Finke
- University of Freiburg, Department of Hematology/Oncology, Freiburg, Germany
| | - Eolia Brissot
- Hospital Saint Antoine, Department of Hematology, Paris, France
| | - Ali Bazarbachi
- American University of Beirut-Medical Center, Department of Internal Medicine-Bone Marrow Transplantation Program, Beirut, Lebanon
| | - Sebastian Giebel
- Maria Sklodowska-Curie National Research Institute of Oncology, Department of Hematology, Gliwice, Poland
| | - Bipin P Savani
- Vanderbilt University Medical Center, Department of Hematology, Nashville, TN, USA
| | - Arnon Nagler
- Chaim Sheba Medical Center, Department of Hematology, Tel-Hashomer, Israel
| | - Fabio Ciceri
- Hematology Division, Ospedale San Raffaele s.r.l., Haematology and BMT, Milano, Italy
| | - Mohamad Mohty
- EBMT Unit, Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France
- Hospital Saint Antoine, Department of Hematology, Paris, France
| |
Collapse
|
11
|
Mussetti A, Rius-Sansalvador B, Moreno V, Peczynski C, Polge E, Galimard JE, Kröger N, Blaise D, Peffault de Latour R, Kulagin A, Mousavi A, Stelljes M, Hamladji RM, Middeke JM, Salmenniemi U, Sengeloev H, Forcade E, Platzbecker U, Reményi P, Angelucci E, Chevallier P, Yakoub-Agha I, Craddock C, Ciceri F, Schroeder T, Aljurf M, Ch K, Moiseev I, Penack O, Schoemans H, Mohty M, Glass B, Sureda A, Basak G, Peric Z. Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study. Bone Marrow Transplant 2024; 59:232-238. [PMID: 38007531 DOI: 10.1038/s41409-023-02147-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 10/04/2023] [Accepted: 11/03/2023] [Indexed: 11/27/2023]
Abstract
Allogeneic haematopoietic cell transplantation (alloHCT) has curative potential counterbalanced by its toxicity. Prognostic scores fail to include current era patients and alternative donors. We examined adult patients from the EBMT registry who underwent alloHCT between 2010 and 2019 for oncohaematological disease. Our primary objective was to develop a new prognostic score for overall mortality (OM), with a secondary objective of predicting non-relapse mortality (NRM) using the OM score. AI techniques were employed. The model for OM was trained, optimized, and validated using 70%, 15%, and 15% of the data set, respectively. The top models, "gradient boosting" for OM (AUC = 0.64) and "elasticnet" for NRM (AUC = 0.62), were selected. The analysis included 33,927 patients. In the final prognostic model, patients with the lowest score had a 2-year OM and NRM of 18 and 13%, respectively, while those with the highest score had a 2-year OM and NRM of 82 and 93%, respectively. The results were consistent in the subset of the haploidentical cohort (n = 4386). Our score effectively stratifies the risk of OM and NRM in the current era but do not significantly improve mortality prediction. Future prognostic scores can benefit from identifying biological or dynamic markers post alloHCT.
Collapse
Affiliation(s)
- A Mussetti
- Department of Haematology, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain.
| | - B Rius-Sansalvador
- Biomarkers and Susceptibility Unit (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain
- ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - V Moreno
- Biomarkers and Susceptibility Unit (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain
- ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - C Peczynski
- EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM Unité Mixte de Recherche (UMR)-S 938, Sorbonne University, Paris, France
| | - E Polge
- EBMT Global Committee (Shanghai and Paris Offices) and Acute Leukaemia Working Party, Hospital Saint-Antoine APHP and Sorbonne University, Paris, France
| | | | - N Kröger
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - D Blaise
- Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France
| | - R Peffault de Latour
- Service d'Hématologie-Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
- Université Paris Diderot, Institut Universitaire d'Hématologie, Sorbonne Paris Cité, Paris, France
| | - A Kulagin
- Raisa Memorial (RM) Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia
| | - A Mousavi
- Shariati Hospital, Haematology-Oncology and BMT Research, Tehran, Islamic Republic of Iran
| | - M Stelljes
- Department of Medicine A, University Hospital Münster, Münster, Germany
| | - R M Hamladji
- Centre Pierre et Marie Curie, Service Hématologie Greffe de Moëlle, Alger, Algeria
| | - J M Middeke
- Med. Klinik I, University Hospital, TU Dresden, Germany
| | - U Salmenniemi
- HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland
| | - H Sengeloev
- Bone Marrow Transplant Unit Copenhagen, Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - E Forcade
- CHU Bordeaux, Service d'hématologie Clinique et Thérapie Cellulaire, 33000, Pessac, France
| | | | - P Reményi
- Department of Haematology and Stem Cell Transplant, Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet, Budapest, Hungary
| | - E Angelucci
- Haematology and Cellular Therapy Unit. IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | | | - I Yakoub-Agha
- CHU de Lille LIRIC, INSERM U995, Université de Lille, Lille, France
| | - C Craddock
- Department of Haematology, University Hospital Birmingham NHS Trust, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, UK
| | - F Ciceri
- Haematology & Bone Marrow Transplant, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - T Schroeder
- Department of Bone Marrow Transplantation, University Hospital, Essen, Germany
| | - M Aljurf
- Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | | | - I Moiseev
- R.M.Gorbacheva Memorial Institute of Oncology, Haematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russian Federation
| | - O Penack
- Department of Haematology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - H Schoemans
- Department of Haematology, University Hospitals Leuven, Leuven, Belgium
- Department of Public Health and Primary Care, ACCENT VV, KU Leuven - University of Leuven, Leuven, Belgium
| | - M Mohty
- Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France
| | - B Glass
- Klinik für Hämatologie und Stammzelltransplantation, HELIOS Klinikum Berlin-Buch, Berlin, Germany
| | - A Sureda
- Department of Haematology, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain
| | - G Basak
- Department of Haematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
| | - Z Peric
- School of medicine, University of Zagreb and University Hospital Centre Zagreb, Zagreb, Croatia
| |
Collapse
|
12
|
Gjærde LK, Ruutu T, Peczynski C, Boreland W, Kröger N, Blaise D, Schroeder T, Peffault de Latour R, Gedde-Dahl T, Kulagin A, Sengeløv H, Yakoub-Agha I, Finke J, Eder M, Basak G, Moiseev I, Schoemans H, Koenecke C, Penack O, Perić Z. The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party. Bone Marrow Transplant 2024; 59:255-263. [PMID: 38062242 PMCID: PMC10849948 DOI: 10.1038/s41409-023-02154-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 11/02/2023] [Accepted: 11/13/2023] [Indexed: 02/09/2024]
Abstract
Obesity and diabetes can modulate immune responses, which may impact allogeneic HCT outcomes and GvHD. From the EBMT registry, we included 36,539 adult patients who underwent allogeneic HCT for a hematological malignancy between 2016 and 2020. Of these, 5228 (14%) had obesity (BMI ≥ 30 kg/m2), 1415 (4%) had diabetes (requiring treatment with insulin or oral hypoglycemics), and 688 (2%) had obesity + diabetes pre-transplantation. Compared with patients without diabetes or obesity, the hazard ratio (HR) of grade II-IV acute GvHD was 1.00 (95% confidence interval [CI] 0.94-1.06, p = 0.89) for patients with obesity, 0.95 (CI 0.85-1.07, p = 0.43) for patients with diabetes, and 0.96 (CI 0.82-1.13, p = 0.63) for patients with obesity + diabetes. Non-relapse mortality was higher in patients with obesity (HR 1.08, CI 1.00-1.17, p = 0.047), diabetes (HR 1.40, CI 1.24-1.57, p < 0.001), and obesity + diabetes (HR 1.38, CI 1.16-1.64, p < 0.001). Overall survival after grade II-IV acute GvHD was lower in patients with diabetes (HR 1.46, CI 1.25-1.70, p < 0.001). Pre-transplantation diabetes and obesity did not influence the risk of developing acute GvHD, but pre-transplantation diabetes was associated with poorer survival after acute GvHD.
Collapse
Affiliation(s)
- Lars Klingen Gjærde
- Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
| | - Tapani Ruutu
- Clinical Research Institute, Helsinki University Hospital, Helsinki, Finland
| | | | | | | | | | | | | | | | - Aleksandr Kulagin
- First State Pavlov Medical University of St. Petersburg, St., Petersburg, Russia
| | - Henrik Sengeløv
- Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | | | | | | | - Grzegorz Basak
- University Clinical Center of the Medical University of Warsaw, Warsaw, Poland
| | - Ivan Moiseev
- First State Pavlov Medical University of St. Petersburg, St., Petersburg, Russia
| | | | | | - Olaf Penack
- Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Zinaida Perić
- University of Zagreb, Zagreb, Croatia
- University Hospital Centre Zagreb, Zagreb, Croatia
| |
Collapse
|
13
|
Potter V, Gras L, Koster L, Kroger N, Sockel K, Ganser A, Finke J, Labussiere-Wallet H, Peffault de Latour R, Koc Y, Salmenniemi U, Smidstrup Friis L, Jindra P, Schroeder T, Tischer J, Arat M, Pascual Cascon M, de Wreede LC, Hayden P, Raj K, Drozd-Sokolowska J, Scheid C, McLornan DP, Robin M, Yakoub-Agha I. Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT. Bone Marrow Transplant 2024; 59:224-231. [PMID: 37993503 DOI: 10.1038/s41409-023-02111-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2023] [Revised: 06/27/2023] [Accepted: 09/15/2023] [Indexed: 11/24/2023]
Abstract
The optimal conditioning for patients with higher risk MDS receiving potentially curative allogeneic haematopoietic stem cell transplant(allo-HCT) remains to be defined. This is particularly the case for patients with excess of blasts at time of allo-HCT. Sequential (Seq) conditioning, whereby chemotherapy is followed rapidly by transplant conditioning, offers an opportunity to decrease disease burden, potentially improving outcomes allo-HCT outcomes. Herein we present the only analysis comparing Seq to myeloablative (MAC) and reduced intensity conditioning (RIC) specifically focussed on MDS patients with excess of blasts at allo-HCT. 303 patients were identified in the EBMT registry, receiving RIC (n = 158), Seq (n = 105), and MAC (n = 40). Median follow-up was 67.2 months and median age at allo-HCT was 59.5 years (IQR 53.5-65.6). For the entire cohort, 3 y overall survival (OS) was 50% (95% CI 45-56%) and relapse free survival (RFS) 45% (95% CI 40-51%). No significant differences in OS (log-rank p = 0.13) and RFS (log-rank p = 0.18) were observed between conditioning protocols. On multivariable analysis, lower performance status, worse IPSS-R cytogenetics, sibling donor (compared to 8/8 MUD) and ≥20% blasts at allo-HCT were associated with worse outcomes. In conclusion, the Seq protocol did little to influence the outcome in this high-risk group of patients, with outcomes mostly determined by baseline disease risk and patient characteristics such as performance status.
Collapse
Affiliation(s)
- V Potter
- Kings College Hospital NHS Foundation Trust, London, UK.
| | - L Gras
- EBMT Statistical Unit, Leiden, Netherlands
| | - L Koster
- EBMT Leiden Study Unit, Leiden, Netherlands
| | - N Kroger
- University Hospital Eppendorf, Hamburg, Germany
| | - K Sockel
- Universitaetsklinikum Dresden, Dresden, Germany
| | - A Ganser
- Hannover Medical School, Hannover, Germany
| | - J Finke
- University of Freiburg, Freiburg, Germany
| | | | | | - Y Koc
- Medicana International Hospital Istanbul, Istanbul, Turkey
| | | | | | - P Jindra
- Charles University Hospital, Pilsen, Czech Republic
| | - T Schroeder
- University Hospital Essen, Dusseldorf, Germany
| | - J Tischer
- Klinikum Grosshadern, Munich, Germany
| | - M Arat
- Demiroglu Bilim University Istanbul Florence Nightingale Hospital, Stanbul, Turkey
| | | | - L C de Wreede
- Leiden University Medical Center, Dept of Biomedical Data Sciences, Leiden, Netherlands
| | - P Hayden
- Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland
| | - K Raj
- University College London Hospitals NHS Trust, London, UK
| | | | - C Scheid
- University of Cologne, Cologne, Germany
| | - D P McLornan
- University College London Hospitals NHS Trust, London, UK
| | - M Robin
- Saint-Louis Hospital, BMT Unit, Paris, France
| | - I Yakoub-Agha
- CHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000, Lille, France
| |
Collapse
|
14
|
Weller JF, Lengerke C, Finke J, Schetelig J, Platzbecker U, Einsele H, Schroeder T, Faul C, Stelljes M, Dreger P, Blau IW, Wulf G, Tischer J, Scheid C, Elmaagacli A, Neidlinger H, Flossdorf S, Bornhäuser M, Bethge W, Fleischhauer K, Kröger N, De Wreede LC, Christopeit M. Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study. Haematologica 2024; 109:431-443. [PMID: 37646665 PMCID: PMC10831926 DOI: 10.3324/haematol.2023.283175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Accepted: 08/11/2023] [Indexed: 09/01/2023] Open
Abstract
Incidences of diseases treated with transplantation frequently peak at higher age. The contribution of age to total risk of transplantation has not been estimated amidst an aging society. We compare outcomes of 1,547 patients aged 70-79 years and 9,422 patients aged 60-69 years transplanted 1998-2018 for myeloid, lymphoid and further neoplasia in Germany. To quantify the contribution of population mortality to survival, we derive excess mortality based on a sex-, year- and agematched German population in a multistate model that incorporates relapse and graft-versus-host-disease (GvHD). Overall survival, relapse-free survival (RFS) and GvHD-free-relapse-free survival (GRFS) is inferior in patients aged 70-79 years, compared to patients aged 60-69 years, with 36% (95% Confidence Interval [CI]: 34-39%) versus 43% (41-44%), 32% (30- 35%) versus 36% (35-37%) and 23% (21-26%) versus 27% (26-28%) three years post-transplant (P<0.001). Cumulative incidences of relapse at three years are 27% (25-30%) for patients aged 70-79 versus 29% (29-30%) (60-69 years) (P=0.71), yet the difference in non-relapse mortality (NRM) (40% [38-43%] vs. 35% [34-36%] in patients aged 70-79 vs. 60-69 years) (P<0.001) translates into survival differences. Median OS of patients surviving >1 year relapse-free is 6.7 (median, 95% CI: 4.5-9.4, 70-79 years) versus 9 (8.4-10.1, 60-69 years) years since landmark. Three years after RFS of one year, excess NRM is 14% (95% CI: 12-18%) in patients aged 70-79 versus 12% [11-13%] in patients aged 60-69, while population NRM is 7% (6-7%) versus 3% (3-3%). Mortality for reasons other than relapse, GvHD, or age is as high as 27% (24-29%) and 22% (22-23%) four years after transplantation. In conclusion, survival amongst older patients is adequate after allogeneic stem cell transplantation.
Collapse
Affiliation(s)
- Jan Frederic Weller
- Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen
| | - Claudia Lengerke
- Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen
| | - Jürgen Finke
- University Medical Center Freiburg, Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Freiburg
| | - Johannes Schetelig
- Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden
| | - Uwe Platzbecker
- Medical Clinic and Policlinic I, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig
| | - Hermann Einsele
- Department of Internal Medicine II, University Hospital of Würzburg, Würzburg
| | - Thomas Schroeder
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, Essen
| | - Christoph Faul
- Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen
| | | | - Peter Dreger
- Department of Medicine V, University of Heidelberg, Heidelberg
| | - Igor W Blau
- Medical Clinic, Charité University Medicine Berlin, Berlin
| | - Gerald Wulf
- Hematology and Medical Oncology, University Medicine Göttingen, Göttingen
| | - Johanna Tischer
- Internal Medicine III, Hematology/ Oncology/ Stem Cell Transplantation, Ludwig-Maximilians-University, Munich
| | - Christoph Scheid
- Faculty of Medicine and Cologne University Hospital, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), University of Cologne, Cologne
| | - Ahmet Elmaagacli
- Department of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St. Georg, Hamburg
| | | | - Sarah Flossdorf
- German Registry for Stem Cell Transplantation, DRST, Ulm, Germany; Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University of Duisburg-Essen, Essen
| | - Martin Bornhäuser
- Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden
| | - Wolfgang Bethge
- Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen
| | - Katharina Fleischhauer
- German Registry for Stem Cell Transplantation, DRST, Ulm, Germany; Institute for Experimental Cellular Therapy, University Hospital Essen, Essen
| | - Nicolaus Kröger
- German Registry for Stem Cell Transplantation, DRST, Ulm, Germany; Department of Stem Cell Transplantation, University Medical Center Eppendorf, Hamburg
| | - Liesbeth C De Wreede
- Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands; DKMS Clinical Trials Unit, Dresden
| | - Maximilian Christopeit
- Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen.
| |
Collapse
|
15
|
Bogun L, Koch A, Scherer B, Fenk R, Maus U, Bormann F, Köhrer K, Petzsch P, Wachtmeister T, Zukovs R, Dietrich S, Haas R, Schroeder T, Jäger PS, Geyh S. Stromal alterations in patients with MGUS, smoldering myeloma and multiple myeloma. Blood Adv 2024:bloodadvances.2023011632. [PMID: 38241490 DOI: 10.1182/bloodadvances.2023011632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 12/27/2023] [Accepted: 01/09/2024] [Indexed: 01/21/2024] Open
Abstract
The hallmark of multiple myeloma (MM) is a clonal plasma cell infiltration in the bone marrow accompanied by myelosuppression and osteolysis. Premalignant stages like monoclonal gammopathy of undetermined significance (MGUS) and asymptomatic stages like smoldering myeloma (SMM) can progress to multiple myeloma (MM). Mesenchymal stromal cells (MSC) are an integral component of the bone marrow microenvironment and play an important role for osteoblast differentiation and hematopoietic support. While stromal alterations have been reported in MM contributing to hematopoietic insufficiency and osteolysis, it is not clear whether alterations in MSC already occur in MGUS or SMM. In this study we analyzed MSC from MGUS, SMM and MM towards their properties and functionality and performed mRNA sequencing to find underlying molecular signatures in different disease stages. A high number of senescent cells and a reduced osteogenic differentiation capacity and hematopoietic support was already present in MGUS MSC. As shown by RNA sequencing there was a broad spectrum of differentially expressed genes including genes of the BMP/TGF-signaling pathway, detected already in MGUS and that clearly increases in SMM and MM patients. Our data may help to block these signaling pathways in the future to hinder progression to multiple myeloma.
Collapse
Affiliation(s)
| | | | - Bo Scherer
- University of Duesseldorf, Duesseldorf, Germany
| | - Roland Fenk
- Universityhospital Duesseldorf, Duesseldorf, Germany
| | - Uwe Maus
- University of Duesseldorf, Duesseldorf, Germany
| | | | - Karl Köhrer
- Biological and Medical Research Center, Genomics and Transcriptomics Laboratory, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Patrick Petzsch
- Biological and Medical Research Center, Genomics and Transcriptomics Laboratory, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Thorsten Wachtmeister
- Biological and Medical Research Center, Genomics and Transcriptomics Laboratory, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | | | | | | | | | | | | |
Collapse
|
16
|
Penack O, Luft T, Peczynski C, Benner A, Sica S, Arat M, Itäla-Remes M, Corral LL, Schaap NPM, Karas M, Raida L, Schroeder T, Dreger P, Metafuni E, Ozcelik T, Sandmaier BM, Kordelas L, Moiseev I, Schoemans H, Koenecke C, Basak GW, Peric Z. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study. J Immunother Cancer 2024; 12:e007635. [PMID: 38199608 PMCID: PMC10806535 DOI: 10.1136/jitc-2023-007635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/18/2023] [Indexed: 01/12/2024] Open
Abstract
BACKGROUND We previously reported that the "Endothelial Activation and Stress Index" (EASIX; ((creatinine×lactate dehydrogenase)÷thrombocytes)) measured before start of conditioning predicts mortality after allogeneic hematopoietic stem cell transplantation (alloSCT) when used as continuous score. For broad clinical implementation, a prospectively validated EASIX-pre cut-off is needed that defines a high-risk cohort and is easy to use. METHOD In the current study, we first performed a retrospective cohort analysis in n=2022 alloSCT recipients and identified an optimal cut-off for predicting non-relapse mortality (NRM) as EASIX-pre=3. For cut-off validation, we conducted a multicenter prospective study with inclusion of n=317 first alloSCTs from peripheral blood stem cell in adult patients with acute leukemia, lymphoma or myelodysplastic syndrome/myeloproliferative neoplasms in the European Society for Blood and Marrow Transplantation network. RESULTS Twenty-three % (n=74) of alloSCT recipients had EASIX-pre ≥3 taken before conditioning. NRM at 2 years was 31.1% in the high EASIX group versus 11.5% in the low EASIX group (p<0.001). Patients with high EASIX-pre also had worse 2 years overall survival (51.6% vs 70.9%; p=0.002). We were able to validate the cut-off and found that EASIX ≥3 was associated with more than twofold increased risk for NRM in multivariate analysis (HR=2.18, 95% CI 1.2 to 3.94; p=0.01). No statistically significant difference could be observed for the incidence of relapse. CONCLUSIONS The results of this study provide a prospectively validated standard laboratory biomarker index to estimate the transplant-related mortality risk after alloSCT. EASIX ≥3 taken before conditioning identifies a population of alloSCT recipients who have a more than twofold increased risk of treatment-related mortality.
Collapse
Affiliation(s)
- Olaf Penack
- Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin, Germany
- EBMT Transplant Complications Working Party, Heidelberg, Germany
| | - Thomas Luft
- Medicine V, University Hospital Heidelberg, Heidelberg, Germany
| | - Christophe Peczynski
- EBMT Transplant Complications Working Party, Paris, France
- Department of Haematology, Sorbonne University, Paris, France
| | - Axel Benner
- German Cancer Research Centre, Heidelberg, Germany
| | - Simona Sica
- Istituto di Ematologia, Universita Cattolica S. Cuore, Rome, Italy
| | - Mutlu Arat
- Florence Nightingale Hospital, Hematopoietic SCT Unit, Demiroglu Bilim University Istanbul, Istanbul, Turkey
| | | | - Lucia López Corral
- Department for Haematology, Hospital Clinico San Carlos, Salamanca, Spain
| | | | - Michal Karas
- Hospital Dept. of Hematology/Oncology, Charles University, Pilsen, Czech Republic
| | - Ludek Raida
- Olomouc University Social Health Institute, Olomouc, Czech Republic
| | - Thomas Schroeder
- Dept. of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany
| | - Peter Dreger
- Medicine V, University Hospital Heidelberg, Heidelberg, Germany
| | | | - Tulay Ozcelik
- Florence Nightingale Hospital, Hematopoietic SCT Unit, Demiroglu Bilim University Istanbul, Istanbul, Turkey
| | | | - Lambros Kordelas
- Dept. of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany
| | - Ivan Moiseev
- EBMT Transplant Complications Working Party, Paris, France
- First Pavlov State Medical University of St Petersburg, St Petersburg, Russian Federation
| | - Hélène Schoemans
- EBMT Transplant Complications Working Party, Paris, France
- Department of Hematology, University Hospitals Leuven and KU Leuven, Leuven, Belgium
| | - Christian Koenecke
- Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | - Grzegorz W Basak
- EBMT Transplant Complications Working Party, Paris, France
- Department of Hematology, Oncology and Internal Medicine, the Medical University of Warsaw, Warsaw, Poland
| | - Zinaida Peric
- EBMT Transplant Complications Working Party, Paris, France
- Department of Hematology, University of Rijeka, Rijeka, Croatia
| |
Collapse
|
17
|
Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernandez-Boluda JC, Koschmieder S, Jain T, Mascarenhas J, Mesa R, Popat UR, Passamonti F, Polverelli N, Rambaldi A, Robin M, Salit RB, Schroeder T, Scott BL, Tamari R, Tefferi A, Vannucchi AM, McLornan DP, Barosi G. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol 2024; 11:e62-e74. [PMID: 38061384 DOI: 10.1016/s2352-3026(23)00305-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 09/26/2023] [Accepted: 10/03/2023] [Indexed: 12/24/2023]
Abstract
New options for medical therapy and risk scoring systems containing molecular data are leading to increased complexity in the management of patients with myelofibrosis. To inform patients' optimal care, we updated the 2015 guidelines on indications for and management of allogeneic haematopoietic stem-cell transplantation (HSCT) with the support of the European Society for Blood and Marrow Transplantation (EBMT) and European LeukemiaNet (ELN). New recommendations were produced using a consensus-building methodology after a comprehensive review of articles released from January, 2015 to December, 2022. Seven domains and 18 key questions were selected through a series of questionnaires using a Delphi process. Key recommendations in this update include: patients with primary myelofibrosis and an intermediate-2 or high-risk Dynamic International Prognostic Scoring System score, or a high-risk Mutation-Enhanced International Prognostic Score Systems (MIPSS70 or MIPSS70-plus) score, or a low-risk or intermediate-risk Myelofibrosis Transplant Scoring System score should be considered candidates for allogeneic HSCT. All patients who are candidates for allogeneic HSCT with splenomegaly greater than 5 cm below the left costal margin or splenomegaly-related symptoms should receive a spleen-directed treatment, ideally with a JAK-inhibitor; HLA-matched sibling donors remain the preferred donor source to date. Reduced intensity conditioning and myeloablative conditioning are both valid options for patients with myelofibrosis. Regular post-transplantation driver mutation monitoring is recommended to detect and treat early relapse with donor lymphocyte infusion. In a disease where evidence-based guidance is scarce, these recommendations might help clinicians and patients in shared decision making.
Collapse
Affiliation(s)
- Nicolaus Kröger
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
| | - Andrea Bacigalupo
- Department of Hematology, Fondazione Policlinico Universitario Gemelli IRCCS, Universita' Cattolica del Sacro Cuore, Rome, Italy
| | - Tiziano Barbui
- FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - Markus Ditschkowski
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany
| | - Nico Gagelmann
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Martin Griesshammer
- University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
| | - Vikas Gupta
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - Nada Hamad
- School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia; Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia; School of Medicine, University of Notre Dame, Sydney, NSW, Australia
| | | | | | - Steffen Koschmieder
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Aachen, Germany; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
| | - Tania Jain
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
| | - John Mascarenhas
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Ruben Mesa
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA
| | - Uday R Popat
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Francesco Passamonti
- Università degli Studi di Milano; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Nicola Polverelli
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Alessandro Rambaldi
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
| | - Marie Robin
- Department of Hematology, University Hospital of Saint Louis, Paris, France
| | | | - Thomas Schroeder
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany
| | | | - Roni Tamari
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Ayalew Tefferi
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
| | - Alessandro M Vannucchi
- Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Donal P McLornan
- Department of Haematology and Stem Cell Transplantation, University College London Hospitals NHS Trust, London, UK
| | - Giovanni Barosi
- Center for the Study of Myelofibrosis, IRCCS Policlinico S Matteo, Pavia, Italy
| |
Collapse
|
18
|
Nagler A, Labopin M, Kröger N, Schroeder T, Gedde-Dahl T, Eder M, Franke GN, Blau IW, Salmenniemi U, Socie G, Schetelig J, Stelljes M, Ciceri F, Mohty M. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT. Bone Marrow Transplant 2023; 58:1339-1347. [PMID: 37660157 DOI: 10.1038/s41409-023-02095-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Revised: 08/09/2023] [Accepted: 08/18/2023] [Indexed: 09/04/2023]
Abstract
We compared outcomes, of 1609 patients with secondary acute myeloid leukemia (sAML) undergoing allogeneic transplantation (HSCT) in first complete remission (CR1) from matched unrelated donors (MUD) from 2010 to 2021, receiving or not receiving anti-thymocyte globulin (ATG) (ATG-1308, no ATG-301). Median age was 60.9 (range, 18.5-77.8) and 61.1 (range, 21.8-75.7) years, (p = 0.3). Graft versus host disease (GVHD) prophylaxis was cyclosporin-A with methotrexate (41%) or mycophenolate mofetil (38.2%), without significant differences between groups. Day 28, engraftment (ANC > 0.5 × 109/L) was 92.3% vs 95.3% (p = 0.17), respectively. On multivariate analysis, ATG was associated with lower incidence of grade II-IV and grade III-IV acute GVHD (p = 0.002 and p = 0.015), total and extensive chronic GVHD (p = 0.008 and p < 0.0001), and relapse incidence (RI) (p = 0.039), while non-relapse mortality (NRM) did not differ (p = 0.51). Overall survival (OS), and GVHD-free, relapse-free survival (GRFS) were significantly higher in the ATG vs no ATG group, HR = 0.76 (95% CI 0.61-0.95, p = 0.014) and HR = 0.68 (95% CI 0.57-0.8, p < 0.0001), with a tendency for better leukemia-free survival (LFS), HR = 0.82 (95% CI 0.67-1, p = 0.051). The main causes of death were the original disease, infection, and GVHD. In conclusion, ATG reduces GVHD and improves LFS, OS, and GRFS in sAML patients without increasing the RI, despite sAML being a high-risk disease.
Collapse
Affiliation(s)
- Arnon Nagler
- Division of Hematology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
| | - Myriam Labopin
- EBMT Paris study office; Department of Haematology, Saint Antoine Hospital, Sorbonne University, INSERM UMR 938, Paris, France
- Sorbonne University, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Paris, France
| | - Nicolaus Kröger
- Department of Stem Cell Transplantation, University Medical Center, Hamburg, Germany
| | - Thomas Schroeder
- University Hospital, Department of Bone Marrow Transplantation, Essen, Germany
| | - Tobias Gedde-Dahl
- Oslo University Hospital, Rikshospitalet Clinic for Cancer Medicine, Hematology Department, Section for Stem Cell Transplantation, Oslo, Norway
| | - Matthias Eder
- Hannover Medical School, Department of Haematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany
| | - Georg-Nikolaus Franke
- Medical Clinic and Policinic 1, Hematology and Cellular Therapy University hospital Leipzig, Leipzig, Germany
| | - Igor Wolfgang Blau
- Charité, University medicine Berlin, Department of Hematology, BMT Unit, Berlin, Germany
| | - Urpu Salmenniemi
- HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland
| | - Gerard Socie
- Hopital St. Louis, Department of Hematology-BMT, Paris, France
| | - Johannes Schetelig
- Universitaetsklinikum Dresden Medizinische Klinik und Poliklinik I, Dresden, Germany
| | - Matthias Stelljes
- University of Muenster Department of Hematol. /Oncol., Muenster, Germany
| | - Fabio Ciceri
- Hematology & Bone Marrow Transplant, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Mohamad Mohty
- EBMT Paris study office; Department of Haematology, Saint Antoine Hospital, Sorbonne University, INSERM UMR 938, Paris, France
- Sorbonne University, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Paris, France
| |
Collapse
|
19
|
Ruutu T, Peczynski C, Houhou M, Polge E, Mohty M, Kröger N, Moiseev I, Penack O, Salooja N, Schoemans H, Duarte RF, Schroeder T, Passweg J, Wulf GG, Ganser A, Sica S, Arat M, Salmenniemi U, Broers AEC, Bourhis JH, Rambaldi A, Maertens J, Halaburda K, Zuckerman T, Labussière-Wallet H, Basak G, Koenecke C, Perić Z. Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study. Bone Marrow Transplant 2023; 58:1209-1214. [PMID: 37573397 PMCID: PMC10622315 DOI: 10.1038/s41409-023-02077-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 07/12/2023] [Accepted: 07/26/2023] [Indexed: 08/14/2023]
Abstract
The current incidence, diagnostic policy, management, and outcome of VOD/SOS at EBMT centers were studied. All centers that had performed allogeneic HSCTs in adult patients within one defined year were invited to the study. Seventy-one centers participated with a total of 2886 allogeneic transplantations and 93 cases of VOD/SOS in 2018. The cumulative incidence of VOD/SOS at day 21 was 1.8% and at day 100 2.4%. Of 67 cases with detailed data, 52 were classical and 15 (22%) late onset (>day 21). According to the EBMT criteria, 65/67 patients had at least two VOD/SOS risk factors. The severity grades were: mild 0, moderate 3, severe 29, very severe 35. Fifty-four patients were treated with defibrotide. VOD/SOS resolved in 58% of the patients, 3/3 with moderate, 22/28 with severe, and 12/33 with very severe grade (p < 0.001). By day 100, 57% of the patients were alive; 3/3 with moderate, 22/29 with severe, and 13/35 with very severe VOD/SOS (p = 0.002). In conclusion, the incidence of VOD/SOS was low. Severe and very severe grades dominated. Very severe grade predicted poor outcome compared to severe grade further supporting the concept of early diagnosis and treatment to avoid a dismal outcome.
Collapse
Affiliation(s)
- Tapani Ruutu
- Clinical Research Institute, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
| | - Christophe Peczynski
- EBMT, Transplant Complications Working Party, Hopital Saint Antoine, Department of Hematology, Paris, France
| | - Mohamed Houhou
- EBMT, Sorbonne University, Hopital Saint Antoine, Department of Hematology, Paris, France
| | - Emmanuelle Polge
- EBMT, Sorbonne University, Hopital Saint Antoine, Department of Hematology, Paris, France
| | - Mohamad Mohty
- EBMT, Sorbonne University, Hopital Saint Antoine, Department of Hematology, Paris, France
| | | | - Ivan Moiseev
- RM Gorbacheva Research Institute, Pavlov University, Saint Petersburg, Russian Federation
| | - Olaf Penack
- Medical Clinic, Department of Haematology, Oncology and Tumor Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Nina Salooja
- Centre for Haematology, Imperial College, London, UK
| | - Hélène Schoemans
- Department of Hematology, University Hospitals Leuven and KU Leuven, Leuven, Belgium
| | - Rafael F Duarte
- Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | - Thomas Schroeder
- University Hospital, Department of Hematology and Stem Cell Transplantation, Essen, Germany
| | | | - Gerald G Wulf
- University Medicine Goettingen, Department of Haematology and Medical Oncology, Goettingen, Germany
| | - Arnold Ganser
- Hannover Medical School, Department of Hematology, Hemostasis, and Oncology, Hannover, Germany
| | - Simona Sica
- Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Università Cattolica Sacro Cuore, Rome, Italy
| | - Mutlu Arat
- Demiroglu Bilim University, Istanbul Florence Nightingale Hospital, Hematopoietic SCT Unit, Istanbul, Turkey
| | - Urpu Salmenniemi
- HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland
| | - Annoek E C Broers
- Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Jean Henri Bourhis
- Gustave Roussy Cancer Campus, BMT Service, Department of Hematology, Villejuif, France
| | - Alessandro Rambaldi
- Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
| | - Johan Maertens
- University Hospital Gasthuisberg, Department of Hematology, Leuven, Belgium
| | | | - Tsila Zuckerman
- Rambam Medical Center, Department of Hematology and Bone Marrow Transplantation, Haifa, Israel
| | | | - Grzegorz Basak
- Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
| | - Christian Koenecke
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | - Zinaida Perić
- Department of Hematology, University Hospital Center Zagreb, Zagreb, Croatia
| |
Collapse
|
20
|
Schroeder T, Stelljes M, Christopeit M, Esseling E, Scheid C, Mikesch JH, Rautenberg C, Jäger P, Cadeddu RP, Drusenheimer N, Holtick U, Klein S, Trenschel R, Haas R, Germing U, Kröger N, Kobbe G. Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial. Haematologica 2023; 108:3001-3010. [PMID: 37259567 PMCID: PMC10620594 DOI: 10.3324/haematol.2022.282570] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Accepted: 05/23/2023] [Indexed: 06/02/2023] Open
Abstract
Azacitidine (Aza) combined with donor lymphocyte infusions (DLI) is an established treatment for relapse of myeloid malignancies after allogeneic transplantation. Based on its immunomodulatory and anti-leukemic properties we considered Lenalidomide (Lena) to act synergistically with Aza/DLI to improve outcome. We, therefore, prospectively investigated tolerability and efficacy of this combination as first salvage therapy for adults with post-transplant relapse of acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia. Patients were scheduled for eight cycles Aza (75 mg/m2 day 1-7), Lena (2.5 or 5 mg, days 1-21) and up to three DLI with increasing T-cell dosages (0.5×106-1.5×107 cells/kg). Primary endpoint was safety, while secondary endpoints included response, graft-versus-host disease (GvHD) and overall survival (OS). Fifty patients with molecular (52%) or hematological (48%) relapse of myelodysplastic syndromes (n=24), acute myeloid leukemia (n=23) or chronic myelomonocytic leukemia (n=3) received a median of seven (range, 1-8) cycles including 14 patients with 2.5 mg and 36 with 5 mg Lena daily dosage. Concomitantly, 34 patients (68%) received at least one DLI. Overall response rate was 56% and 25 patients (50%) achieved complete remission being durable in 80%. Median OS was 21 months and 1-year OS rate 65% with no impact of type of or time to relapse and Lena dosages. Treatment was well tolerated indicated by febrile neutropenia being the only grade ≥3 non-hematologic adverse event in >10% of patients and modest acute (grade 2-4 24%) and chronic (moderate/severe 28%) GvHD incidences. In summary, Lena can be safely added to Aza/DLI without excess of GvHD and toxicity. Its significant anti-leukemic activity suggests that this combination is a novel salvage option for post-transplant relapse (clinicaltrials gov. Identifier: NCT02472691).
Collapse
Affiliation(s)
- Thomas Schroeder
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, Essen, Germany; Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf.
| | - Matthias Stelljes
- Department of Medicine A, Hematology and Oncology, University of Muenster, Muenster
| | | | - Eva Esseling
- Department of Medicine A, Hematology and Oncology, University of Muenster, Muenster
| | - Christoph Scheid
- Department I of Internal Medicine, Medical Faculty and University Hospital, University of Cologne, Cologne
| | - Jan-Henrik Mikesch
- Department of Medicine A, Hematology and Oncology, University of Muenster, Muenster
| | - Christina Rautenberg
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, Essen
| | - Paul Jäger
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf
| | - Ron-Patrick Cadeddu
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf
| | - Nadja Drusenheimer
- Coordination Center for Clinical Trials, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf
| | - Udo Holtick
- Department I of Internal Medicine, Medical Faculty and University Hospital, University of Cologne, Cologne
| | - Stefan Klein
- Department of Hematology and Oncology, University Hospital Mannheim, Mannheim
| | - Rudolf Trenschel
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, Essen
| | - Rainer Haas
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf
| | - Ulrich Germing
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf
| | - Nicolaus Kröger
- University Hospital Hamburg-Eppendorf, Clinic for Stem Cell Transplantation, Hamburg
| | - Guido Kobbe
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf
| |
Collapse
|
21
|
Gavriilaki E, Sakellari I, Labopin M, Bornhäuser M, Hamladji RM, Casper J, Edinger M, Zák P, Yakoub-Agha I, Ciceri F, Schroeder T, Zuckerman T, Kobbe G, Yeshurun M, Narni F, Finke J, Diez-Martin JL, Berceanu A, Hilgendorf I, Verbeek M, Olivieri A, Savani B, Spyridonidis A, Nagler A, Mohty M. Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). Bone Marrow Transplant 2023; 58:1084-1088. [PMID: 37420011 DOI: 10.1038/s41409-023-02028-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 06/02/2023] [Accepted: 06/26/2023] [Indexed: 07/09/2023]
Abstract
We compared FT14 (fludarabine 150-160 mg/m2, treosulfan 42 g/m2) versus FB4 (fludarabine 150-160 mg/m2, busulfan 12.8 mg/kg) in acute myeloid leukemia (AML) transplanted at primary refractory/relapsed disease. We retrospectively studied: (a) adults diagnosed with AML, (b) recipients of first allogeneic hematopoietic stem cell transplantation (HSCT) from unrelated/sibling donor (2010-2020), (c) HSCT with primary refractory/relapsed disease, (d) conditioning regimen with FT14 or FB4. We studied 346 patients, 113 transplanted with FT14, and 233 with FΒ4. FT14 patients were significantly older, more frequently had an unrelated donor and had received a lower dose of fludarabine. Cumulative incidence (CI) of acute graft-versus-host disease (GVHD) grade III-IV and extensive chronic GVHD was similar. With a median follow-up of 28.7 months, 2-year CI of relapse was 43.4% in FT14 versus 53.2% in FB4, while non-relapse mortality (NRM) was respectively 20.8% versus 22.6%. This led to 2-year leukemia-free survival (LFS) of 35.8% for FT14 versus 24.2% in FB4, and overall survival (OS) of 44.4% versus 34%. Adverse cytogenetics and conditioning regimen independently predicted CI of relapse. Furthermore, conditioning regimen was the only independent predictor of LFS, OS, and GVHD-free/relapse-free survival. Therefore, our real-world multicenter study suggests that FT14 is associated with better outcomes in primary refractory/relapsed AML.
Collapse
Affiliation(s)
- Eleni Gavriilaki
- Hematology Department-BMT Unit, G Papanikolaou Hospital, Thessaloniki, Greece.
| | - Ioanna Sakellari
- Hematology Department-BMT Unit, G Papanikolaou Hospital, Thessaloniki, Greece
| | - Myriam Labopin
- Service d' Hématologie Clinique et Thérapie Cellulaire, Hospital Saint-Antoine, Sorbonne Université, Centre de Recherche Saint-Antoine (CRSA), Paris, France
| | - Martin Bornhäuser
- University Hospital Dresden, Medizinische Klinik und Poliklinik I, TU, Dresden, Germany
| | - Rose-Marie Hamladji
- Centre Pierre et Marie Curie, Service Hématologie Greffe de Moëlle, Alger, Algeria
| | - Jochen Casper
- Klinikum Oldenburg, Abt. Onkologie/Hämatologie, Oldenburg, Germany
| | - Matthias Edinger
- Department. of Hematology and Oncology, University Regensburg, Regensburg, Germany
| | - Pavel Zák
- Charles University Hospital, 4th Department of Internal Medicine - Hematology, Hradec_Kralove, Czech Republic
| | | | - Fabio Ciceri
- Ospedale San Raffaele s.r.l. Haematology and BMT, Milano, Italy
| | - Thomas Schroeder
- University Hospital Dept. of Bone Marrow Transplantation, Essen, Germany
| | - Tsila Zuckerman
- Dept. of Hematology & BMT, Rambam Medical Center, Haifa, Israel
| | - Guido Kobbe
- Heinrich Heine Universitaet, Klinik für Hämat,Onkol,Klin.Immun, Duesseldorf, Germany
| | - Moshe Yeshurun
- Hematology and BMT Department, Beilinson Hospital, Petach_Tikva, Israel
| | - Franco Narni
- Azienda Ospedaliero Universitaria di Modena Policlinico, Ematologia, Modena, Italy
| | - Jürgen Finke
- Department. of Medicine -Hematology, Oncology, University of Freiburg, Freiburg, Germany
| | | | - Ana Berceanu
- Hopital Jean Minjoz, Service d'Hématologie, Besancon, France
| | - Inken Hilgendorf
- Universitaetsklinikum Jena, Klinik für Innere Medizin II, (Abt. Hämatologie und Onkologie), Am Klinikum 1, Jena, Germany
| | - Mareike Verbeek
- Klinikum Rechts der Isar, III Med Klinik der TU, Munich, Germany
| | - Attilio Olivieri
- Azienda Ospedali Riuniti di Ancona, Department of Hematology, Ancona University, Ancona, Italy
| | - Bipin Savani
- Department of Hematology-Oncology, Vanderbilt University, Medical Center, Nashville, TN, USA
| | - Alexandros Spyridonidis
- Department of Internal Medicine, Bone Marrow Transplantation Unit, University Hospital of Patras, Patras, Greece
| | - Arnon Nagler
- Department of Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel
| | - Mohamad Mohty
- Service d' Hématologie Clinique et Thérapie Cellulaire, Hospital Saint-Antoine, Sorbonne Université, Centre de Recherche Saint-Antoine (CRSA), Paris, France
| |
Collapse
|
22
|
Jäger P, Rautenberg C, Kaivers J, Kasprzak A, Geyh S, Baermann BN, Haas R, Germing U, Schroeder T, Kobbe G. Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience. Sci Rep 2023; 13:10774. [PMID: 37402862 PMCID: PMC10319811 DOI: 10.1038/s41598-023-38037-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Accepted: 07/01/2023] [Indexed: 07/06/2023] Open
Abstract
Patients with acute myeloid leukemia (AML) and nucleophosmin 1 gene mutations (NPM1mut) show a favorable prognosis with chemotherapy (CT) in the absence of negative prognostic genetic abnormalities. Between 2008 and 2021 64 patients with NPM1mutAML received alloHSCT because of additional adverse prognostic factors (1st line), inadequate response to or relapse during or after CT (2nd line). To expand the evidence in alloTX in NPM1mut AML, clinical and molecular data were retrospectively analyzed with respect to pre-transplant strategies and outcome. Patients with minimal residual disease negative (MRD-) CR at transplant had better 2-y-PFS and 2-y-OS (77% and 88%) than patients with minimal residual disease positive (MRD+) CR (41% and 71%) or patients with active disease (AD) at transplant (20% and 52%). The 2nd line patients with relapse after completing CT responded well to high dose cytarabine based salvage chemotherapy (salvage CT) in contrast to patients relapsing while still on CT (90% vs 20%, P = 0.0170). 2-y-PFS and 2-y-OS was 86% in patients who achieved a 2nd MRD- CR pre alloHSCT. Outcome in NPM1mutAML depends on disease burden at alloHSCT. Time and type of relapse in relation to CT are predictive for response to salvage CT.
Collapse
Affiliation(s)
- Paul Jäger
- Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Medical Faculty, Moorenstr. 5, 40225, Düsseldorf, Germany.
| | - Christina Rautenberg
- Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany
| | - Jennifer Kaivers
- Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany
| | - Annika Kasprzak
- Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Medical Faculty, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Stefanie Geyh
- Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Medical Faculty, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Ben-Niklas Baermann
- Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Medical Faculty, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Rainer Haas
- Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Medical Faculty, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Ulrich Germing
- Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Medical Faculty, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Thomas Schroeder
- Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Medical Faculty, Moorenstr. 5, 40225, Düsseldorf, Germany
- Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany
| | - Guido Kobbe
- Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Medical Faculty, Moorenstr. 5, 40225, Düsseldorf, Germany
| |
Collapse
|
23
|
Liu Y, Wolkin AF, Kresnow MJ, Schroeder T. Addressing health disparities using multiply imputed injury surveillance data. Int J Equity Health 2023; 22:126. [PMID: 37400819 DOI: 10.1186/s12939-023-01940-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Accepted: 06/18/2023] [Indexed: 07/05/2023] Open
Abstract
BACKGROUND Assessing disparities in injury is crucial for injury prevention and for evaluating injury prevention strategies, but efforts have been hampered by missing data. This study aimed to show the utility and reliability of the injury surveillance system as a trustworthy resource for examining disparities by generating multiple imputed companion datasets. METHODS We employed data from the National Electronic Injury Surveillance System-All Injury Program (NEISS-AIP) for the period 2014-2018. A comprehensive simulation study was conducted to identify the appropriate strategy for addressing missing data limitations in NEISS-AIP. To evaluate the imputation performance more quantitatively, a new method based on Brier Skill Score (BSS) was developed to assess the accuracy of predictions by different approaches. We selected the multiple imputations by fully conditional specification (FCS MI) to generate the imputed companion data to NEISS-AIP 2014-2018. We further assessed health disparities systematically in nonfatal assault injuries treated in U.S. hospital emergency departments (EDs) by race and ethnicity, location of injury and sex. RESULTS We found for the first time that significantly higher age-adjusted nonfatal assault injury rates for ED visits per 100,000 population occurred among non-Hispanic Black persons (1306.8, 95% Confidence Interval [CI]: 660.1 - 1953.5), in public settings (286.3, 95% CI: 183.2 - 389.4) and for males (603.5, 95% CI: 409.4 - 797.5). We also observed similar trends in age-adjusted rates (AARs) by different subgroups for non-Hispanic Black persons, injuries occurring in public settings, and for males: AARs of nonfatal assault injury increased significantly from 2014 through 2017, then declined significantly in 2018. CONCLUSIONS Nonfatal assault injury imposes significant health care costs and productivity losses for millions of people each year. This study is the first to specifically look at health disparities in nonfatal assault injuries using multiply imputed companion data. Understanding how disparities differ by various groups may lead to the development of more effective initiatives to prevent such injury.
Collapse
Affiliation(s)
- Yang Liu
- Division of Injury Prevention, National Center for Injury Prevention and Control, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
| | - Amy F Wolkin
- Division of Injury Prevention, National Center for Injury Prevention and Control, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Marcie-Jo Kresnow
- Division of Injury Prevention, National Center for Injury Prevention and Control, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Thomas Schroeder
- Division of Hazard and Injury Data Systems, U.S. Consumer Product Safety Commission, Bethesda, MD, USA
| |
Collapse
|
24
|
Abou Dalle I, Labopin M, Kröger N, Schroeder T, Finke J, Stelljes M, Neubauer A, Blaise D, Yakoub-Agha I, Salmenniemi U, Forcade E, Itäla-Remes M, Dreger P, Bug G, Passweg J, Heuser M, Choi G, Brissot E, Giebel S, Nagler A, Ciceri F, Bazarbachi A, Mohty M. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2023; 58:784-790. [PMID: 37041215 DOI: 10.1038/s41409-023-01961-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2023] [Revised: 02/27/2023] [Accepted: 03/16/2023] [Indexed: 04/13/2023]
Abstract
Pre-transplant detectable measurable residual disease (MRD) is still associated with high risk of relapse and poor outcomes in acute myeloid leukemia (AML). We aimed at evaluating the impact of disease burden on prediction of relapse and survival in patients receiving allogeneic hematopoietic cell transplantation (allo-HCT) in first remission (CR1). We identified a total of 3202 adult AML patients, of these 1776 patients were in CR1 and MRD positive and 1426 patients were primary refractory at time of transplant. After a median follow-up of 24.4 months, non-relapse mortality and relapse rate were significantly higher in the primary refractory group compared to the CR1 MRD positive group (Hazards Ratio (HR) = 1.82 (95% CI: 1.47-2.24) p < 0.001 and HR = 1.54 (95% CI: 1.34-1.77), p < 0.001), respectively. Leukemia-free survival (LFS) and overall survival (OS) were significantly worse in the primary refractory group (HR = 1.61 (95% CI: 1.44-1.81), p < 0.001 and HR = 1.71 (95% CI: 1.51-1.94), p < 0.001, respectively). Our real-life data suggest that patients in CR1 and MRD positive at time of transplant could still be salvaged by allo-HCT with a 2-year OS of 63%, if negative MRD cannot be obtained and their outcomes are significantly better than patients transplanted with active disease.
Collapse
Affiliation(s)
- Iman Abou Dalle
- Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
| | - Myriam Labopin
- Department of Haematology, Hopital Saint-Antoine, INSERM, Paris, France
| | - Nicolaus Kröger
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Thomas Schroeder
- Dept. of Bone Marrow Transplantation, University Hospital, Essen, Germany
| | - Jürgen Finke
- Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine and Medical Center-University of Freiburg, Freiburg, Germany
| | - Matthias Stelljes
- Department of Medicine A/Hematology and Oncology, University of Muenster, Muenster, Germany
| | - Andreas Neubauer
- Klinik für Innere Medizin mit SP Hämatologie, Onkologie und Immunologie, Philipps-Universität, Marburg, Germany
| | | | | | - Urpu Salmenniemi
- Department of Hematology, Helsinki University Hospital, Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland
| | - Edouard Forcade
- CHU Bordeaux, Service d'hématologie Clinique et Thérapie Cellulaire, 33000, Pessac, France
| | - Maija Itäla-Remes
- Department of Medicine, Turku University Central Hospital, PL 52, Turku, Finland
| | - Peter Dreger
- Department Medicine V, University of Heidelberg, Heidelberg, Germany
| | - Gesine Bug
- Department of Medicine II, University Hospital, Frankfurt, Germany
| | - Jakob Passweg
- EBMT Activity Survey Office, Hematology Division, University Hospital, Basel, Switzerland
| | - Michael Heuser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany
| | - Goda Choi
- Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - Eolia Brissot
- Department of Hematology, Hospital Saint Antoine, Paris, France
| | - Sebastian Giebel
- Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Institute, Oncology Center-Gliwice, Gliwice, Poland
| | - Arnon Nagler
- Department of Bone Marrow Transplantation, Chaim Sheba Medical Center-Tel-Hashomer, Tel-Hashomer, Israel
| | - Fabio Ciceri
- Ospedale San Raffaele s.r.l., Haematology and BMT, Milano, Italy
| | - Ali Bazarbachi
- Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
| | - Mohamad Mohty
- Department of Haematology, Hopital Saint-Antoine, INSERM, Paris, France
| |
Collapse
|
25
|
Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati M, Benner A, Schlenk RF, Döhner K, Ganser A. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 2023; 10:e495-e509. [PMID: 37187198 DOI: 10.1016/s2352-3026(23)00089-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2023] [Revised: 03/27/2023] [Accepted: 03/29/2023] [Indexed: 05/17/2023]
Abstract
BACKGROUND Acute myeloid leukaemia with mutated NPM1 is associated with high CD33 expression and intermediate-risk cytogenetics. The aim of this study was to evaluate intensive chemotherapy with or without the anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin in participants with newly diagnosed, NPM1-mutated acute myeloid leukaemia. METHODS This open-label, phase 3 trial was conducted at 56 hospitals in Germany and Austria. Eligible participants were 18 years or older and had newly diagnosed NPM1-mutated acute myeloid leukaemia and an Eastern Cooperative Oncology Group performance status of 0-2. Participants were randomly assigned, using age as a stratification factor (18-60 years vs >60 years), 1:1 to the two treatment groups using allocation concealment; there was no masking of participants and investigators to treatment groups. Participants received two cycles of induction therapy (idarubicin, cytarabine, and etoposide) plus all-trans retinoic acid (ATRA) followed by three consolidation cycles of high-dose cytarabine (or an intermediate dose for those older than 60 years) and ATRA, without or with gemtuzumab ozogamicin (3 mg/m2 administered intravenously on day 1 of induction cycles 1 and 2, and consolidation cycle 1). The primary endpoints were short-term event-free survival and overall survival in the intention-to-treat population (overall survival was added as a co-primary endpoint after amendment four of the protocol on Oct 13, 2013). The secondary endpoints were event-free survival with long-term follow-up, rates of complete remission, complete remission with partial haematological recovery (CRh), and complete remission with incomplete haematological recovery (CRi), cumulative incidences of relapse and death, and number of days in hospital. This trial is registered with ClinicalTrials.gov (NCT00893399) and has been completed. FINDINGS Between May 12, 2010, and Sept 1, 2017, 600 participants were enrolled, of which 588 (315 women and 273 men) were randomly assigned (296 to the standard group and 292 to the gemtuzumab ozogamicin group). No difference was found in short-term event-free survival (short-term event-free survival at 6-month follow-up, 53% [95% CI 47-59] in the standard group and 58% [53-64] in the gemtuzumab ozogamicin group; hazard ratio [HR] 0·83; 95% CI 0·65-1·04; p=0·10) and overall survival between treatment groups (2-year overall survival, 69% [63-74] in the standard group and 73% [68-78] in the gemtuzumab ozogamicin group; 0·90; 0·70-1·16; p=0·43). There was no difference in complete remission or CRi rates (n=267 [90%] in the standard group vs n=251 [86%] in the gemtuzumab ozogamicin group; odds ratio [OR] 0·67; 95% CI 0·40-1·11; p=0·15) and complete remission or CRh rates (n=214 [72%] vs n=195 [67%]; OR 0·77; 0·54-1·10; p=0·18), whereas the complete remission rate was lower with gemtuzumab ozogamicin (n=172 [58%] vs n=136 [47%]; OR 0·63; 0·45-0·80; p=0·0068). Cumulative incidence of relapse was significantly reduced by gemtuzumab ozogamicin (2-year cumulative incidence of relapse, 37% [95% CI 31-43] in the standard group and 25% [20-30] in the gemtuzumab ozogamicin group; cause-specific HR 0·65; 0·49-0·86; p=0·0028), and there was no difference in the cumulative incidence of death (2-year cumulative incidence of death 6% [4-10] in the standard group and 7% [5-11] in the gemtuzumab ozogamicin group; HR 1·03; 0·59-1·81; p=0·91). There were no differences in the number of days in hospital across all cycles between treatment groups. The most common treatment-related grade 3-4 adverse events were febrile neutropenia (n=135 [47%] in the gemtuzumab ozogamicin group vs n=122 [41%] in the standard group), thrombocytopenia (n=261 [90%] vs n=265 [90%]), pneumonia (n=71 [25%] vs n=64 [22%]), sepsis (n=85 [29%] vs n=73 [25%]). Treatment-related deaths were documented in 25 participants (4%; n=8 [3%] in the standard group and n=17 [6%] in the gemtuzumab ozogamicin group), mostly due to sepsis and infections. INTERPRETATION The primary endpoints of the trial of event-free survival and overall survival were not met. However, an anti-leukaemic efficacy of gemtuzumab ozogamicin in participants with NPM1-mutated acute myeloid leukaemia is shown by a significantly lower cumulative incidence of relapse rate, suggesting that the addition of gemtuzumab ozogamicin might reduce the need for salvage therapy in these participants. The results from this study provide further evidence that gemtuzumab ozogamicin should be added in the standard of care treatment in adults with NPM1-mutated acute myeloid leukaemia. FUNDING Pfizer and Amgen.
Collapse
Affiliation(s)
- Hartmut Döhner
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
| | - Daniela Weber
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany
| | - Julia Krzykalla
- Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany
| | - Walter Fiedler
- Hubertus Wald University Cancer Center, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - Michael W M Kühn
- Department of Hematology, Medical Oncology & Pneumology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany
| | - Thomas Schroeder
- Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Karin Mayer
- Department of Hematology, Oncology, University Hospital Bonn, Bonn, Germany
| | - Michael Lübbert
- Department of Medicine I, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Mohammed Wattad
- Klinik für Hämatologie, Internistische Onkologie & Stammzelltransplantation, Evang. Krankenhaus Essen-Werden, Essen-Werden, Germany; Klinikum Hochsauerland, Meschede, Germany
| | - Katharina Götze
- Department of Medicine III, Hematology and Medical Oncology, Technical University of Munich, Munich, Germany
| | - Lars Fransecky
- Department of Internal Medicine II, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
| | - Elisabeth Koller
- Department of Internal Medicine III, Hanusch Krankenhaus Wien, Wien, Austria
| | - Gerald Wulf
- Department of Hematology and Medical Oncology, University Medicine Göttingen, Göttingen, Germany
| | - Jan Schleicher
- Klinik für Hämatologie, Onkologie, Stammzelltransplantation und Palliativmedizin, Klinikum Stuttgart, Stuttgart, Germany
| | - Mark Ringhoffer
- Department of Internal Medicine III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany
| | - Richard Greil
- 3rd Medical Department Paracelsus Medical University Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute Center for Clinical Trials and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria
| | - Bernd Hertenstein
- Department of Hematology and Oncology, Klinikum Bremen-Mitte, Bremen, Germany
| | - Jürgen Krauter
- Medizinische Klinik III, Städtisches Klinikum Braunschweig, Braunschweig, Germany
| | - Uwe M Martens
- Klinik für Innere Medizin III, SLK-Kliniken Heilbronn, Heilbronn, Germany
| | - David Nachbaur
- Universitätsklinik für Innere Medizin V, Medizinische Universität Innsbruck, Innsbruck, Austria
| | - Maisun Abu Samra
- Medizinische Klinik IV, Universitätsklinikum Gießen, Gießen, Germany
| | | | - Nadezda Basara
- Medizinische Klinik I, Malteser Krankenhaus St Franziskus-Hospital Flensburg, Flensburg, Germany
| | - Claudia Leis
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany
| | - Anika Schrade
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany
| | | | - Sibylle Cocciardi
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany
| | - Lars Bullinger
- Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin, Germany
| | - Felicitas Thol
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | - Michael Heuser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | - Peter Paschka
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany
| | - Verena I Gaidzik
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany
| | - Maral Saadati
- Freelance Statistician, Saadati Solutions, Ladenburg, Germany
| | - Axel Benner
- Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany
| | - Richard F Schlenk
- National Center of Tumor Diseases, German Cancer Research Center, Heidelberg, Germany; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - Konstanze Döhner
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany
| | - Arnold Ganser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| |
Collapse
|
26
|
Gagelmann N, Badbaran A, Salit RB, Schroeder T, Gurnari C, Pagliuca S, Panagiota V, Rautenberg C, Cassinat B, Thol F, Wolschke C, Robin M, Heuser M, Rubio MT, Maciejewski JP, Reinhardt HC, Scott BL, Kröger N. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood 2023; 141:2901-2911. [PMID: 36940410 PMCID: PMC10933704 DOI: 10.1182/blood.2023019630] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Revised: 03/07/2023] [Accepted: 03/08/2023] [Indexed: 03/22/2023] Open
Abstract
TP53 mutations (TP53MTs) have been associated with poor outcomes in various hematologic malignancies, but no data exist regarding its role in patients with myelofibrosis undergoing hematopoietic stem cell transplantation (HSCT). Here, we took advantage of a large international multicenter cohort to evaluate the role of TP53MT in this setting. Among 349 included patients, 49 (13%) had detectable TP53MT, of whom 30 showed a multihit configuration. Median variant allele frequency was 20.3%. Cytogenetic risk was favorable (71%), unfavorable (23%), and very high (6%), with complex karyotype present in 36 patients (10%). Median survival of patients with TP53MT was 1.5 vs 13.5 years for those with wild-type TP53 (TP53WT; P < .001). Outcome was driven by multihit TP53MT constellation (P < .001), showing 6-year survival of 56% for individuals with single-hit vs 25% for those with multihit TP53MT vs 64% for those with TP53WT. Outcome was independent of current transplantation-specific risk factors and conditioning intensity. Similarly, cumulative incidence of relapse was 17% for single-hit vs 52% for multihit vs 21% for TP53WT. Ten patients with TP53MT (20%) presented as leukemic transformation vs only 7 (2%) in the TP53WT group (P < .001). Out of the 10 patients with TP53MT, 8 showed multihit constellation. Median time to leukemic transformation was shorter for multihit and single-hit TP53MT (0.7 and 0.5 years, respectively) vs 2.5 years for TP53WT. In summary, multihit TP53MT represents a very high-risk group in patients with myelofibrosis who are undergoing HSCT, whereas single-hit TP53MT alone showed similar outcome to patients with nonmutated TP53, informing prognostication for survival and relapse together with current transplantation-specific tools.
Collapse
Affiliation(s)
- Nico Gagelmann
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Anita Badbaran
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Rachel B. Salit
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Thomas Schroeder
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany
| | - Carmelo Gurnari
- Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
- Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy
| | - Simona Pagliuca
- Department of Hematology, Brabois Hospital, Centre Hospitalier Régional Universitaire, Nancy, France
| | - Victoria Panagiota
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | - Christina Rautenberg
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany
| | - Bruno Cassinat
- Laboratoire de Biologie Cellulaire, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Felicitas Thol
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | - Christine Wolschke
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Marie Robin
- Service d'Hématologie-Greffe, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Michael Heuser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | - Marie-Thérèse Rubio
- Department of Hematology, Brabois Hospital, Centre Hospitalier Régional Universitaire, Nancy, France
| | - Jaroslaw P. Maciejewski
- Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
- Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
| | - Hans Christian Reinhardt
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany
| | - Bart L. Scott
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Nicolaus Kröger
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
27
|
Attiaoui A, Daligou G, Assali S, Skibitzki O, Schroeder T, Moutanabbir O. Polarization-Tuned Fano Resonances in All-Dielectric Short-Wave Infrared Metasurface. Adv Mater 2023:e2300595. [PMID: 37015255 DOI: 10.1002/adma.202300595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Revised: 03/14/2023] [Indexed: 05/28/2023]
Abstract
The short-wave infrared (SWIR) is an underexploited portion of the electromagnetic spectrum in metasurface-based nanophotonics despite its strategic importance in sensing and imaging applications. This is mainly attributed to the lack of material systems to tailor light-matter interactions in this range. Herein, this limitation is addressed and an all-dielectric silicon-integrated metasurface enabling polarization-induced Fano resonance control at SWIR frequencies is demonstrated. The platform consists of a 2D Si/Ge0.9 Sn0.1 core/shell nanowire array on a silicon wafer. By tuning the light polarization, it is shown that the metasurface reflectance can be efficiently engineered due to Fano resonances emerging from the electric and magnetic dipoles competition. The interference of optically induced dipoles in high-index nanowire arrays offers additional degrees of freedom to tailor the directional scattering and the flow of light while enabling sharp polarization-modulated resonances. This tunablity is harnessed in nanosensors yielding an efficient detection of 10-2 changes in the refractive index of the surrounding medium.
Collapse
Affiliation(s)
- Anis Attiaoui
- Department of Engineering Physics, École Polytechnique de Montréal, C.P. 6079, Succ. Centre-Ville, Montréal, Québec, H3C 3A7, Canada
| | - Gérard Daligou
- Department of Engineering Physics, École Polytechnique de Montréal, C.P. 6079, Succ. Centre-Ville, Montréal, Québec, H3C 3A7, Canada
| | - Simone Assali
- Department of Engineering Physics, École Polytechnique de Montréal, C.P. 6079, Succ. Centre-Ville, Montréal, Québec, H3C 3A7, Canada
| | - Oliver Skibitzki
- IHP-Leibniz-Institut für innovative Mikroelektronik, Im Technologiepark 25, 15236, Frankfurt (Oder), Germany
| | - Thomas Schroeder
- Leibniz-Institut für Kristallzüchtung, Max-Born-Straße 2, 12489, Berlin, Germany
| | - Oussama Moutanabbir
- Department of Engineering Physics, École Polytechnique de Montréal, C.P. 6079, Succ. Centre-Ville, Montréal, Québec, H3C 3A7, Canada
| |
Collapse
|
28
|
Giebel S, Labopin M, Schroeder T, Swoboda R, Maertens J, Bourhis JH, Grillo G, Salmenniemi U, Hilgendorf I, Kröger N, Poiré X, Cornelissen JJ, Arat M, Savani B, Spyridonidis A, Nagler A, Mohty M. Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol 2023; 98:580-587. [PMID: 36626592 DOI: 10.1002/ajh.26825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Revised: 12/13/2022] [Accepted: 12/21/2022] [Indexed: 01/12/2023]
Abstract
Total body irradiation (TBI) at a dose of 12 Gy combined with cyclophosphamide (CyTBI12Gy) is one of the standard myeloablative regimens for patients with acute myeloid leukemia (AML) treated with allogeneic hematopoietic cell transplantation (allo-HCT). In clinical practice, cyclophosphamide may be substituted with fludarabine (FluTBI12Gy) to reduce toxicity. We retrospectively compared outcomes of CyTBI12Gy with FluTBI12Gy for patients with AML treated in complete remission (CR) with allo-HCT from either a matched sibling or unrelated donor. Of 1684 adults who met inclusion criteria, 109 patients in each group were included in a matched-pair analysis. The cumulative incidence of relapse at 2 years was 25% in the FluTBI12Gy compared to 28% in the CyTBI12Gy group (p = .44) while non-relapse mortality (NRM) was 17% versus 19%, (p = .89) respectively. The rates of leukemia-free survival and overall survival were 65% versus 54% (p = .28) and 70% versus 60.5% (p = .17). Cumulative incidence of grade 2-4 acute graft-versus-host disease (GVHD) was significantly lower for FluTBI12Gy than CyTBI12Gy (16% vs. 34%, p = .005), while the incidences of grade 3-4 acute GVHD and chronic GVHD did not differ significantly. The probability of GVHD and relapse-free survival was 49% in the FluTBI12Gy and 41% in the CyTBI12Gy group (p = .17). We conclude that for patients with AML treated with allo-HCT in CR, cyclophosphamide may be substituted with fludarabine in a regimen based on TBI at a dose of 12 Gy without negative impact on the efficacy. FluTBI12Gy is associated with reduced risk of grade 2-4 acute GVHD and encouraging survival rates.
Collapse
Affiliation(s)
- Sebastian Giebel
- Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
| | - Myriam Labopin
- AP-HP, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMR-S 938, CRSA, Service d'Hématologie Clinique et Thérapie Cellulaire, Paris, France
| | - Thomas Schroeder
- Dept. of Hematology and Stem Cell Transplantation, University Hospital, Essen, Germany
| | - Ryszard Swoboda
- Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
| | - Johan Maertens
- Dept. of Hematology, University Hospital Gasthuisberg, Leuven, Belgium
| | - Jean Henri Bourhis
- Department of Hematology, Gustave Roussy Cancer Campus BMT Service, Villejuif, France
| | - Giovanni Grillo
- Hematology Department, Asst Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - Urpu Salmenniemi
- Stem Cell Transplantation Unit, HUCH Comprehensive Cancer Center, Helsinki, Finland
| | - Inken Hilgendorf
- Klinik für Innere Medizin II, (Abt. Hämatologie und Onkologie), Universitaetsklinikum Jena, Jena, Germany
| | - Nicolaus Kröger
- Bone Marrow Transplantation Centre, University Hospital Eppendorf, Hamburg, Germany
| | - Xavier Poiré
- Dept. of Haematology, Cliniques Universitaires St. Luc, Brussels, Belgium
| | - Jan J Cornelissen
- Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Mutlu Arat
- Istanbul Florence Nightingale Hospital, Istanbul, Turkey
| | - Bipin Savani
- Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | | | - Arnon Nagler
- Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel
| | - Mohamad Mohty
- AP-HP, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMR-S 938, CRSA, Service d'Hématologie Clinique et Thérapie Cellulaire, Paris, France
- Department of Hematology, Hospital Saint Antoine, Paris, France
| |
Collapse
|
29
|
Tournilhac O, van Gelder M, Eikema DJ, Zinger N, Dreger P, Bornhäuser M, Vucinic V, Scheid C, Cornelissen JJ, Schroeder T, Jindra P, Sengeloev H, Nguyen Quoc S, Stelljes M, Blau IW, Mayer J, Paneesha S, Chevallier P, Forcade E, Kröger N, Blaise D, Gribben J, Nielsen B, Johansson JE, Kyriakou C, Beguin Y, Pioltelli P, Sampol A, McLornan DP, Schetelig J, Hayden PJ, Yakoub-Agha I. The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant 2023:10.1038/s41409-023-01955-z. [PMID: 36977926 PMCID: PMC10044103 DOI: 10.1038/s41409-023-01955-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2022] [Revised: 02/05/2023] [Accepted: 03/10/2023] [Indexed: 03/30/2023]
Abstract
Allogeneic transplantation (allo-HCT) is a curative treatment in CLL whose efficacy including the most severe forms had led to the 2006 EBMT recommendations. The advent after 2014 of targeted therapies has revolutionized CLL management, allowing prolonged control to patients who have failed immunochemotherapy and/or have TP53 alterations. We analysed the pre COVID pandemic 2009-2019 EBMT registry. The yearly number of allo-HCT raised to 458 in 2011 yet dropped from 2013 onwards to an apparent plateau above 100. Within the 10 countries who were under the EMA for drug approval and performed 83.5% of those procedures, large initial differences were found but the annual number converged to 2-3 per 10 million inhabitants during the 3 most recent years suggesting that allo-HCT remains applied in selected patients. Long-term follow-up on targeted therapies shows that most patients relapse, some early, with risk factors and resistance mechanisms being described. The treatment of patients exposed to both BCL2 and BTK inhibitors and especially those with double refractory disease will become a challenge in which allo-HCT remains a solid option in competition with emerging therapies that have yet to demonstrate their long-term effectiveness.
Collapse
Affiliation(s)
- Olivier Tournilhac
- Service d'Hematologie et de Therapie Cellulaire, CHU Estaing, EA 7453, CIC, Universite Clermont Auvergne, Clermont-Ferrand, France.
| | | | | | | | | | | | | | | | | | | | - Pavel Jindra
- Charles University Hospital, Pilsen, Czech Republic
| | | | | | | | - Igor Wolfgang Blau
- Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany
| | - Jiri Mayer
- University Hospital Brno, Brno, Czech Republic
| | | | | | | | | | - Didier Blaise
- Programme de Transplantation & Therapie Cellulaire, Marseille, France
| | - John Gribben
- St. Bartholomew's and The Royal London NHS Trust, London, UK
| | - Bendt Nielsen
- University Department of Hematology, Aarhus, Denmark
| | | | | | - Yves Beguin
- University of Liege and CHU of Liège, Liege, Belgium
| | | | - Antònia Sampol
- Fundació Institut d'Investigació Sanitària Illes Balears-IdISBa, Palma de Mallorca, Spain
| | | | | | - Patrick J Hayden
- Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland
| | | |
Collapse
|
30
|
Swoboda R, Labopin M, Giebel S, Schroeder T, Kröger N, Arat M, Savani B, Spyridonidis A, Hamladji RM, Potter V, Berceanu A, Yakoub-Agha I, Rambaldi A, Ozdogu H, Sanz J, Nagler A, Mohty M. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant 2023; 58:282-287. [PMID: 36460819 DOI: 10.1038/s41409-022-01882-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Revised: 11/16/2022] [Accepted: 11/18/2022] [Indexed: 12/03/2022]
Abstract
Cyclophosphamide is frequently substituted with fludarabine (Flu) in conditioning regimens before allogeneic hematopoietic cell transplantation (allo-HCT). We aimed to compare retrospectively, total body irradiation (12 Gy) plus Flu (FluTBI12) versus busulfan (Bu) plus Flu (FB4) as a myeloablative conditioning before allo-HCT in patients with acute myeloid leukemia (AML). Out of 3203 patients who met the inclusion criteria, 109 patients treated with FluTBI12 and 213 treated with FB4 were included in a final matched-pair analysis. In both groups, median patient age was 41 years, first or second complete remission (CR1/CR2) proportion was 78%/22%, allo-HCT from an unrelated donor was performed in 78% of patients. The probabilities of leukemia-free survival and overall survival at 2 years in FluTBI12 and FB4 groups were 65% vs. 60% (p = 0.64) and 70% vs. 72% (p = 0.87), respectively. The cumulative incidence of relapse was 19% vs. 29% (p = 0.11), while non-relapse mortality was 16% vs. 11%, respectively (p = 0.13). There were no statistical differences in both acute and chronic graft-versus-host disease (GVHD) incidence. The probability of GVHD-free, relapse-free survival (GRFS) was 49% for both groups. FluTBI12 and FB4 are comparable myeloablative regimens before allo-HCT in AML patients transplanted in CR1 and CR2.
Collapse
Affiliation(s)
- Ryszard Swoboda
- Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
| | - Myriam Labopin
- Sorbonne Université, INSERM UMR-S 938, CRSA, Service d'Hématologie et Thérapie Cellulaire, AP-HP, Hôpital Saint-Antoine, 75 012, Paris, France
| | - Sebastian Giebel
- Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
| | - Thomas Schroeder
- Deptartment of Hematology and Stem Cell Transplantation, University Hospital, Essen, Germany
| | - Nicolaus Kröger
- University Hospital Eppendorf, Bone Marrow Transplantation Centre, Hamburg, Germany
| | - Mutlu Arat
- Istanbul Florence Nightingale Hospital, Hematopoietic SCT Unit, Istanbul, Turkey
| | - Bipin Savani
- Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
| | | | - Rose-Marie Hamladji
- Centre Pierre et Marie Curie, Service Hématologie Greffe de Moëlle, Alger, Algeria
| | - Victoria Potter
- Department of Haematological Medicine, Kings College Hospital, King's Denmark Hill Campus, London, UK
| | - Ana Berceanu
- Hopital Jean Minjoz Service d'Hématologie, Besancon, France
| | | | - Alessandro Rambaldi
- Department of Oncology and Hematology, University of Milan and ASST Papa Giovanni XXIII, Bergamo, Italy
| | - Hakan Ozdogu
- Haematology Division, BMT Unit, Haematology Research Laboratory, Training & Medical, Baskent University Hospital, Adana, Turkey
| | - Jaime Sanz
- Hematology Department, University Hospital La Fe, Valencia, Spain
| | - Arnon Nagler
- Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel
| | - Mohamad Mohty
- Department of Hematology, Hospital Saint Antoine, Paris, France
| |
Collapse
|
31
|
Blondeau-Patissier D, Schroeder T, Suresh G, Li Z, Diakogiannis FI, Irving P, Witte C, Steven ADL. Detection of marine oil-like features in Sentinel-1 SAR images by supplementary use of deep learning and empirical methods: Performance assessment for the Great Barrier Reef marine park. Mar Pollut Bull 2023; 188:114598. [PMID: 36773587 DOI: 10.1016/j.marpolbul.2023.114598] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/01/2022] [Revised: 01/05/2023] [Accepted: 01/07/2023] [Indexed: 06/18/2023]
Abstract
Continuous monitoring of oil discharges in coastal and open ocean waters using Earth Observation (EO) has undeniably contributed to diminishing their occurrence wherever a detection system was in place, such as in Europe (EMSA's CleanSeaNet) or in the United States (NOAA's OR&R). This study describes the development and testing of a semi-automated oil slick detection system tailored to the Great Barrier Reef (GBR) marine park solely based on EO data as no such service was routinely available in Australia until recently. In this study, a large, curated, historical global dataset of SAR imagery acquired by Sentinel-1 SAR, now publicly available, is used to assess classification techniques, namely an empirical approach and a deep learning model, to discriminate between oil-like features and look-alikes in the scenes acquired over the marine park. An evaluation of this detection system on 10 Sentinel-1 SAR images of the GBR using two performance metrics - the detection accuracy and the false-positive rate (FPR) - shows that the classifiers perform best when combined (accuracy >98 %; FPR 0.01) rather than when used separately. This study demonstrates the benefit of sequentially combining classifiers to improve the detection and monitoring of unreported oil discharge events in SAR imagery. The workflow has also been tested outside the GBR, demonstrating its robustness when applied to other regions such as Australia's Northwest Shelf, Southeast Asia and the Pacific.
Collapse
Affiliation(s)
| | | | | | - Zhibin Li
- CSIRO Health and Biosecurity, Brisbane, Australia
| | | | - Paul Irving
- Secretariat of the Pacific Regional Environment Programme (SPREP), Apia, Samoa
| | - Christian Witte
- Department of Environment and Science (DES), Brisbane, Australia
| | | |
Collapse
|
32
|
Nagler A, Ngoya M, Galimard JE, Labopin M, Kröger N, Socié G, Gedde-Dahl T, Potter V, Schroeder T, Platzbecker U, Ganser A, Blaise D, Salmenniemi U, Maertens J, Craddock C, Labussière-Wallet H, Yakoub-Agha I, Savani B, Mohty M. Correction: Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT. Bone Marrow Transplant 2022; 57:1856. [DOI: 10.1038/s41409-022-01853-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
33
|
Nagler A, Ngoya M, Galimard JE, Labopin M, Bornhäuser M, Stelljes M, Finke J, Ganser A, Einsele H, Kröger N, Brecht A, Bethge W, Edinger M, Kulagin A, Passweg J, Blau IW, Elmaagacli A, Schäfer-Eckart K, Platzbecker U, Schroeder T, Bunjes D, Tischer J, Martin S, Spyridonidis A, Giebel S, Savani B, Mohty M. Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis. Clin Cancer Res 2022; 28:4258-4266. [PMID: 35670780 DOI: 10.1158/1078-0432.ccr-22-0809] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 05/01/2022] [Accepted: 06/02/2022] [Indexed: 12/14/2022]
Abstract
PURPOSE We evaluated outcomes of unrelated transplantation for primary refractory/relapsed (ref/rel) acute myeloid leukemia (AML), comparing two cohorts according to the year of transplant, 2000-2009 and 2010-2019. PATIENTS AND METHODS Multivariable analyses were performed using the Cox proportional-hazards regression model. RESULTS 3,430 patients were included; 876 underwent a transplant between 2000-2009 and 2554 in 2010-2019. Median follow-up was 8.7 (95% CI, 7.8-9.4) and 3.4 (95% CI, 3.1-3.6) years (P < 0.001). Median age was 52 (18-77) and 56 (18-79) years (P > 0.0001); 45.5% and 55.5% had refractory AML while 54.5% and 44.5% had relapsed AML. Conditioning was myeloablative in 60% and 52%, respectively. Neutrophil recovery and day 100 incidence of acute and 2-year incidence of chronic graft-versus-host disease (GvHD) were similar between the two periods. Two-year relapse incidence was higher for patients undergoing transplant in the 2000-2009 period versus those undergoing transplant in 2010-2019: 50.2% versus 45.1% (HR, 0.85; 95% CI, 0.74-0.97; P = 0. 002). Leukemia-free survival; overall survival; and GvHD-free, relapse-free survival were lower for the 2000-2009 period: 26% versus 32.1% (HR, 0.87; 95% CI, 0.78-0.97; P = 0.01), 32.1% versus 38.1% (HR, 0.86; 95% CI, 0.77-0.96; P = 0.01), and 21.5% versus 25.3% (HR, 0.89; 95% CI, 0.81-0.99; P = 0.03), respectively. Two-year nonrelapse mortality was not significantly different (23.8% vs. 23.7%; HR, 0.91; 95% CI, 0.76-1.11; P = 0.34). CONCLUSIONS Outcome of unrelated transplantation for patients with ref/rel AML has improved in the last two decades, rescuing about one third of the patients. See related commentary by Adrianzen-Herrera and Shastri, p. 4167.
Collapse
Affiliation(s)
- Arnon Nagler
- Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel
| | | | | | - Myriam Labopin
- Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, Paris, France, Sorbonne University, INSERM, Saint-Antoine Research Centre, Paris, France
| | - Martin Bornhäuser
- Universitaetsklinikum Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany
| | - Matthias Stelljes
- University of Muenster, Department of Hematology/Oncology, Muenster, Germany
| | - Jürgen Finke
- University of Freiburg, Department of Medicine-Hematology, Oncology, Freiburg, Germany
| | - Arnold Ganser
- Hannover Medical School Department of Haematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany
| | - Herman Einsele
- Universitaetsklinikum Wuerzburg, Med. Klinik und Poliklinik II, Wuerzburg, Germany
| | - Nicolaus Kröger
- University Hospital Eppendorf, Bone Marrow Transplantation Centre, Hamburg, Germany
| | - Arne Brecht
- Deutsche Klinik fuer Diagnostik, KMT Zentrum, Wiesbaden, Germany
| | - Wolfgang Bethge
- Universitaet Tuebingen, Medizinische Klinik, Tuebingen, Germany
| | - Matthias Edinger
- University Regensburg, Department of Hematology and Oncology, Regensburg, Germany
| | - Aleksandr Kulagin
- First State Pavlov Medical University of St. Petersburg, Raisa Gorbacheva Memorial Research Institute for Paediatric Oncology, Hematology, and Transplantation, St. Petersburg, Russia
| | | | - Igor Wolfgang Blau
- Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Ahmet Elmaagacli
- Asklepios Klinik St. Georg, Department of Haematology, Hamburg, Germany
| | | | - Uwe Platzbecker
- Medical Clinic and Policinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
| | - Thomas Schroeder
- University Hospital Department of Bone Marrow Transplantation, Essen, Germany
| | - Donald Bunjes
- Klinik fuer Innere Medzin III, Universitätsklinikum Ulm, Ulm, Germany
| | | | - Sonja Martin
- Robert_Bosch_Krankenhaus, Abt. Hämatologie / Onkologie, Stuttgart, Germany
| | | | - Sebastian Giebel
- Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Institute-Oncology Center, Gliwice Branch, Gliwice, Poland
| | - Bipin Savani
- Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Mohamad Mohty
- Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, Paris, France, Sorbonne University, INSERM, Saint-Antoine Research Centre, Paris, France
| |
Collapse
|
34
|
Liberatore C, Stanghellini MTL, Lorentino F, Vago L, Carrabba MG, Greco R, Marktel S, Assanelli A, Farina F, Corti C, Bernardi M, Peccatori J, Sockel K, Middeke JM, Schetelig J, Bergmann A, Rautenberg C, Ciceri F, Bornhäuser M, Schroeder T, Stölzel F. Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors. Ther Adv Hematol 2022; 13:20406207221090882. [PMID: 35747461 PMCID: PMC9210096 DOI: 10.1177/20406207221090882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Accepted: 03/14/2022] [Indexed: 11/16/2022] Open
Abstract
Introduction Azacitidine (AZA) either single-agent or with donor lymphocytes infusions (DLI) has been used as a salvage treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) relapsing after allogeneic hematopoietic stem cell transplantation (HSCT). To date, the majority of data come from patients relapsed after HSCT from full-matched donors. Methods We report a multicenter, collaborative, retrospective analysis of 71 patients with hematologic (n = 40, 56%) and molecular relapse (n = 31, 44%) of myeloid neoplasms after HSCT from alternative donors (mismatched unrelated, n = 39, 55%; haploidentical, n = 29, 41%) consecutively treated at three European centers with AZA ± DLI. Results Median time from HSCT to relapse was 9 months. Additional DLI were given to 33 patients (46%). After a median of four cycles, overall response rate (ORR) was 49% and complete response (CR) rate was 38%. CR lasted for a median of 17 months (range 5-89 months). Median follow-up in the entire cohort was 11 months (range 1-115 months). Event-free survival (EFS) and overall survival (OS) at 1 year were 26% and 53%, respectively. Treatment of molecular relapse granted higher CR rate (65% versus 15%; p = 0.0001), 1-year EFS (43% versus 13%; p = 0.006), and 1-year OS (79% versus 34%; p < 0.001) compared to hematologic relapses. Addition of DLI resulted in significantly higher responses and longer 1-year EFS and OS (Mantel-Byar test, p = 0.004 and p = 0.002, respectively). When applied to our cohort, the APSS-R score confirmed its ability to stratify patients into distinct prognostic groups with significantly different response rates (p = 0.0005) and survival (p < 0.0001). Treatment was well tolerated, with the incidence of late acute and chronic graft-versus-host disease of 27% and 18%, respectively. Conclusion AZA ± DLI proved feasible and effective in AML and MDS relapsing after HSCT from alternative donors. Despite modest efficacy among hematologic relapses, pre-emptive treatment with AZA ± DLI fared better in molecular relapse. Additional DLI contributed to improving efficacy and ensuring longer survival.
Collapse
Affiliation(s)
- Carmine Liberatore
- Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | | | - Francesca Lorentino
- Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Luca Vago
- Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Matteo Giovanni Carrabba
- Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Raffaella Greco
- Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Sarah Marktel
- Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Andrea Assanelli
- Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Francesca Farina
- Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Consuelo Corti
- Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Massimo Bernardi
- Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Jacopo Peccatori
- Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Katja Sockel
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Jan Moritz Middeke
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Johannes Schetelig
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Anika Bergmann
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf, Germany
| | - Christina Rautenberg
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf, Germany
| | - Fabio Ciceri
- Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, via Olgettina 60, Milano 20132, Italy
| | - Martin Bornhäuser
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Thomas Schroeder
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf, Germany
| | - Friedrich Stölzel
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| |
Collapse
|
35
|
Röth A, Bertram S, Schroeder T, Haverkamp T, Voigt S, Holtkamp C, Klump H, Wörmann B, Reinhardt HC, Alashkar F. Acquired aplastic anemia following SARS-CoV-2 vaccination. Eur J Haematol 2022; 109:186-194. [PMID: 35592930 PMCID: PMC9347507 DOI: 10.1111/ejh.13788] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 05/05/2022] [Accepted: 05/09/2022] [Indexed: 01/01/2023]
Abstract
COVID‐19 is a potential life‐threatening viral disease caused by SARS‐CoV‐2 and was declared a pandemic by the WHO in March 2020. mRNA‐based SARS‐CoV‐2 vaccines are routinely recommended in immune‐compromised patients, including patients with AA, as these patients are at increased risk of contracting COVID‐19 and developing a more severe course of disease. Between March 2021 and November 2021 relapse of AA occurred in four (age [median]: 53 years, range 30–84 years) out of 135 patients currently registered at our department and two de novo cases of AA in temporal context to vaccination against SARS‐CoV‐2, were documented. Median time after first COVID‐19 vaccination and relapse of AA was 77 days. All relapsed patients were vaccinated with the mRNA‐based vaccine Comirnaty®. Relapse in two out of the four patients was refractory to CsA/eltrombopag, favoring IST with hATG/CsA or BMT, respectively. Our observations should prompt clinicians to take vaccine‐induced relapse of AA or de novo AA after SARS‐CoV‐2 vaccination into account. Furthermore, careful clinical monitoring and vigilance for signs or symptoms that may indicate relapse of AA (e.g., bleeding complications) are indicated.
Collapse
Affiliation(s)
- Alexander Röth
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany
| | - Stefanie Bertram
- Institute of Pathology and Neuropathology, University Hospital Essen, Essen, Germany
| | - Thomas Schroeder
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany
| | | | - Sebastian Voigt
- Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Caroline Holtkamp
- Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Hannes Klump
- Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Bernhard Wörmann
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany.,German Society of Hematology and Medical Oncology, Berlin, Germany
| | - Hans Christian Reinhardt
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany
| | - Ferras Alashkar
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany
| |
Collapse
|
36
|
Favetti M, Schroeder T, Montagner AF, Moraes RR, Pereira-Cenci T, Cenci MS. NaOCl Application after Acid Etching and Retention of Cervical Restorations: A 3-Year Randomized Clinical Trial. Oper Dent 2022; 47:268-278. [PMID: 35584331 DOI: 10.2341/20-166-c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/25/2021] [Indexed: 11/23/2022]
Abstract
This study evaluated the retention of composite resin restorations in noncarious cervical lesions (NCCLs) performed with or without pretreatment with 10% NaOCl solution (deproteinization). A randomized, controlled, split-mouth, doubleblinded trial was carried out. Thirty patients with at least two NCCLs were included in the study. The NCCLs were randomly allocated into two treatment groups: control (acid etching with 37% phosphoric acid + placebo solution + Adper Single Bond 2/3M Oral Care + Filtek Z350/3M Oral Care) or experimental group (acid etching with 37% phosphoric acid + 10% NaOCl solution + Adper Single Bond 2 + Filtek Z350). A calibrated examiner evaluated the restorations at baseline (1 week) and recalls (6, 12, 24, and 36 months) using the FDI criteria. The primary outcome evaluated was retention of the restorations. Data were analyzed by the Kaplan-Meier method and the log-rank test (α=0.05). After 3 years, 64 restorations were evaluated in 23 patients. The annual failure rate was 9% for the control group and 17.8% for the experimental group (deproteinization technique). Considering the failures and their distribution among the characteristics of the patients and NCCLs, no statistically significant differences were observed for the control and experimental treatment groups (p=0.077) or the number of teeth in the mouth (p=0.320). Restorations in the mandible (p=0.039) and premolars (p=0.013) showed significantly lower clinical survival rates. The deproteinization pretreatment with a 10% NaOCl solution did not promote additional retention of restorations in NCCLs. (clinicaltrials. gov: NCT03086720).
Collapse
Affiliation(s)
- M Favetti
- Morgana Favetti, DDS, MS, PhD student, Graduate Program in Dentistry, School of Dentistry, Federal University of Pelotas, Brazil
| | - T Schroeder
- Thaiane Schroeder, DDS, Graduate Program in Dentistry, School of Dentistry, Federal University of Pelotas, Brazil
| | - A F Montagner
- *Anelise Fernandes Montagner, DDS, MS, PhD, Graduate Program in Dentistry, School of Dentistry, Federal University of Pelotas, Brazil
| | - R R Moraes
- Rafael Ratto Moraes, DDS, MS, PhD, Graduate Program in Dentistry, School of Dentistry, Federal University of Pelotas, Brazil
| | - T Pereira-Cenci
- Tatiana Pereira-Cenci, DDS, MS, PhD, associate professor, Graduate Program in Dentistry, School of Dentistry, Federal University of Pelotas, Brazil
| | - M S Cenci
- Maximiliano Sergio Cenci, DDS, MS, PhD, associate professor, Graduate Program in Dentistry, School of Dentistry, Federal University of Pelotas, Brazil
| |
Collapse
|
37
|
McLornan DP, Gras L, Martin I, Sirait T, Schroeder T, Blau IW, Kuball J, Byrne J, Collin M, Stadler M, Desmier D, Salmenniemi U, Jindra P, Mikhailova N, Lenhoff S, Rifón J, Robin M, Rovira M, Veelken H, Sadowska-Klasa A, Zecca M, Hayden PJ, Czerw T, Hernández-Boluda JC, Yakoub-Agha I. Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT. Br J Haematol 2022; 198:209-213. [PMID: 35482558 DOI: 10.1111/bjh.18219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Revised: 04/14/2022] [Accepted: 04/15/2022] [Indexed: 11/29/2022]
Affiliation(s)
- Donal P McLornan
- Department of Stem Cell Transplantation and Haematology, University College London Hospitals, London, UK
| | - Luuk Gras
- EBMT Statistical Unit, Leiden, The Netherlands
| | | | | | - Thomas Schroeder
- Department of Haematology and Stem Cell Transplantation, University Hospital, Essen, Germany
| | - Igor Wolfgang Blau
- Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany
| | | | - Jenny Byrne
- Department of Haematology, Nottingham University Hospital, Nottingham, UK
| | - Matthew Collin
- Northern Centre for Bone Marrow Transplantation, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK
| | | | - Déborah Desmier
- Department of Stem Cell Transplant, Hopital La Miletrie, Poitiers, France
| | | | - Pavel Jindra
- Department of Haematology&Oncology, Charles University Hospital, Pilsen, Czech Republic
| | - Natalia Mikhailova
- RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia
| | | | - Jose Rifón
- Clínica Universitaria de Navarra, Pamplona, Spain
| | - Marie Robin
- Hôpital Saint-Louis, APHP, Université de Paris, Paris, France
| | - Montserrat Rovira
- Bone Marrow Transplant Unit, Haematology Department, ICHMO, Hospital Clinic, IDIBAPS, Josep Carreras Leukaemia Research Institute, Barcelona, Spain
| | | | - Alicja Sadowska-Klasa
- Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland
| | - Marco Zecca
- Paediatric Haematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Patrick J Hayden
- Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland
| | - Tomasz Czerw
- Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland
| | | | | |
Collapse
|
38
|
Lees JP, Poireau V, Tisserand V, Grauges E, Palano A, Eigen G, Brown DN, Kolomensky YG, Fritsch M, Koch H, Schroeder T, Cheaib R, Hearty C, Mattison TS, McKenna JA, So RY, Blinov VE, Buzykaev AR, Druzhinin VP, Golubev VB, Kozyrev EA, Kravchenko EA, Onuchin AP, Serednyakov SI, Skovpen YI, Solodov EP, Todyshev KY, Lankford AJ, Dey B, Gary JW, Long O, Eisner AM, Lockman WS, Panduro Vazquez W, Chao DS, Cheng CH, Echenard B, Flood KT, Hitlin DG, Kim J, Li Y, Lin DX, Middleton S, Miyashita TS, Ongmongkolkul P, Oyang J, Porter FC, Röhrken M, Huard Z, Meadows BT, Pushpawela BG, Sokoloff MD, Sun L, Smith JG, Wagner SR, Bernard D, Verderi M, Bettoni D, Bozzi C, Calabrese R, Cibinetto G, Fioravanti E, Garzia I, Luppi E, Santoro V, Calcaterra A, de Sangro R, Finocchiaro G, Martellotti S, Patteri P, Peruzzi IM, Piccolo M, Rotondo M, Zallo A, Passaggio S, Patrignani C, Flood I, Nguyen N, Shuve BJ, Lacker HM, Bhuyan B, Mallik U, Chen C, Cochran J, Prell S, Gritsan AV, Arnaud N, Davier M, Le Diberder F, Lutz AM, Wormser G, Lange DJ, Wright DM, Coleman JP, Gabathuler E, Hutchcroft DE, Payne DJ, Touramanis C, Bevan AJ, Di Lodovico F, Sacco R, Cowan G, Banerjee S, Brown DN, Davis CL, Denig AG, Gradl W, Griessinger K, Hafner A, Schubert KR, Barlow RJ, Lafferty GD, Cenci R, Jawahery A, Roberts DA, Cowan R, Robertson SH, Seddon RM, Neri N, Palombo F, Cremaldi L, Godang R, Summers DJ, Taras P, De Nardo G, Sciacca C, Raven G, Jessop CP, LoSecco JM, Honscheid K, Kass R, Gaz A, Margoni M, Posocco M, Simi G, Simonetto F, Stroili R, Akar S, Ben-Haim E, Bomben M, Bonneaud GR, Calderini G, Chauveau J, Marchiori G, Ocariz J, Biasini M, Manoni E, Rossi A, Batignani G, Bettarini S, Carpinelli M, Casarosa G, Chrzaszcz M, De Nuccio M, Forti F, Giorgi MA, Lusiani A, Oberhof B, Paoloni E, Rama M, Rizzo G, Walsh JJ, Zani L, Smith AJS, Anulli F, Faccini R, Ferrarotto F, Ferroni F, Pilloni A, Piredda G, Bünger C, Dittrich S, Grünberg O, Heß M, Leddig T, Voß C, Waldi R, Adye T, Wilson FF, Emery S, Vasseur G, Aston D, Cartaro C, Convery MR, Dorfan J, Dunwoodie W, Ebert M, Field RC, Fulsom BG, Graham MT, Hast C, Innes WR, Kim P, Leith DWGS, Luitz S, MacFarlane DB, Muller DR, Neal H, Ratcliff BN, Roodman A, Sullivan MK, Va'vra J, Wisniewski WJ, Purohit MV, Wilson JR, Randle-Conde A, Sekula SJ, Ahmed H, Tasneem N, Bellis M, Burchat PR, Puccio EMT, Alam MS, Ernst JA, Gorodeisky R, Guttman N, Peimer DR, Soffer A, Spanier SM, Ritchie JL, Schwitters RF, Izen JM, Lou XC, Bianchi F, De Mori F, Filippi A, Gamba D, Lanceri L, Vitale L, Martinez-Vidal F, Oyanguren A, Albert J, Beaulieu A, Bernlochner FU, King GJ, Kowalewski R, Lueck T, Miller C, Nugent IM, Roney JM, Sobie RJ, Gershon TJ, Harrison PF, Latham TE, Prepost R, Wu SL. Search for an Axionlike Particle in B Meson Decays. Phys Rev Lett 2022; 128:131802. [PMID: 35426701 DOI: 10.1103/physrevlett.128.131802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Revised: 01/31/2022] [Accepted: 03/07/2022] [Indexed: 06/14/2023]
Abstract
Axionlike particles (ALPs) are predicted in many extensions of the standard model, and their masses can naturally be well below the electroweak scale. In the presence of couplings to electroweak bosons, these particles could be emitted in flavor-changing B meson decays. We report herein a search for an ALP, a, in the reaction B^{±}→K^{±}a, a→γγ using data collected by the BABAR experiment at SLAC. No significant signal is observed, and 90% confidence level upper limits on the ALP coupling to electroweak bosons are derived as a function of ALP mass, improving current constraints by several orders of magnitude in the range 0.175 GeV<m_{a}<4.78 GeV.
Collapse
Affiliation(s)
- J P Lees
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - V Poireau
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - V Tisserand
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - E Grauges
- Universitat de Barcelona, Facultat de Fisica, Departament ECM, E-08028 Barcelona, Spain
| | - A Palano
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - G Eigen
- University of Bergen, Institute of Physics, N-5007 Bergen, Norway
| | - D N Brown
- Lawrence Berkeley National Laboratory and University of California, Berkeley, California 94720, USA
| | - Yu G Kolomensky
- Lawrence Berkeley National Laboratory and University of California, Berkeley, California 94720, USA
| | - M Fritsch
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - H Koch
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - T Schroeder
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - R Cheaib
- University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z1
| | - C Hearty
- Institute of Particle Physics, Vancouver, British Columbia, Canada V6T 1Z1
- University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z1
| | - T S Mattison
- University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z1
| | - J A McKenna
- University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z1
| | - R Y So
- University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z1
| | - V E Blinov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
- Novosibirsk State Technical University, Novosibirsk 630092, Russia
| | - A R Buzykaev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
| | - V P Druzhinin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - V B Golubev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E A Kozyrev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E A Kravchenko
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - A P Onuchin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
- Novosibirsk State Technical University, Novosibirsk 630092, Russia
| | - S I Serednyakov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - Yu I Skovpen
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E P Solodov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - K Yu Todyshev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - A J Lankford
- University of California at Irvine, Irvine, California 92697, USA
| | - B Dey
- University of California at Riverside, Riverside, California 92521, USA
| | - J W Gary
- University of California at Riverside, Riverside, California 92521, USA
| | - O Long
- University of California at Riverside, Riverside, California 92521, USA
| | - A M Eisner
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - W S Lockman
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - W Panduro Vazquez
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - D S Chao
- California Institute of Technology, Pasadena, California 91125, USA
| | - C H Cheng
- California Institute of Technology, Pasadena, California 91125, USA
| | - B Echenard
- California Institute of Technology, Pasadena, California 91125, USA
| | - K T Flood
- California Institute of Technology, Pasadena, California 91125, USA
| | - D G Hitlin
- California Institute of Technology, Pasadena, California 91125, USA
| | - J Kim
- California Institute of Technology, Pasadena, California 91125, USA
| | - Y Li
- California Institute of Technology, Pasadena, California 91125, USA
| | - D X Lin
- California Institute of Technology, Pasadena, California 91125, USA
| | - S Middleton
- California Institute of Technology, Pasadena, California 91125, USA
| | - T S Miyashita
- California Institute of Technology, Pasadena, California 91125, USA
| | - P Ongmongkolkul
- California Institute of Technology, Pasadena, California 91125, USA
| | - J Oyang
- California Institute of Technology, Pasadena, California 91125, USA
| | - F C Porter
- California Institute of Technology, Pasadena, California 91125, USA
| | - M Röhrken
- California Institute of Technology, Pasadena, California 91125, USA
| | - Z Huard
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - B T Meadows
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | | | - M D Sokoloff
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - L Sun
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - J G Smith
- University of Colorado, Boulder, Colorado 80309, USA
| | - S R Wagner
- University of Colorado, Boulder, Colorado 80309, USA
| | - D Bernard
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS/IN2P3, F-91128 Palaiseau, France
| | - M Verderi
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS/IN2P3, F-91128 Palaiseau, France
| | - D Bettoni
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - C Bozzi
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - R Calabrese
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrarab, I-44122 Ferrara, Italy
| | - G Cibinetto
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrarab, I-44122 Ferrara, Italy
| | - E Fioravanti
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrarab, I-44122 Ferrara, Italy
| | - I Garzia
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrarab, I-44122 Ferrara, Italy
| | - E Luppi
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrarab, I-44122 Ferrara, Italy
| | - V Santoro
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - A Calcaterra
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - R de Sangro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - G Finocchiaro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S Martellotti
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - P Patteri
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - I M Peruzzi
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - M Piccolo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - M Rotondo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - A Zallo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S Passaggio
- INFN Sezione di Genova, I-16146 Genova, Italy
| | | | - I Flood
- Harvey Mudd College, Claremont, California 91711, USA
| | - N Nguyen
- Harvey Mudd College, Claremont, California 91711, USA
| | - B J Shuve
- Harvey Mudd College, Claremont, California 91711, USA
| | - H M Lacker
- Humboldt-Universität zu Berlin, Institut für Physik, D-12489 Berlin, Germany
| | - B Bhuyan
- Indian Institute of Technology Guwahati, Guwahati, Assam, 781 039, India
| | - U Mallik
- University of Iowa, Iowa City, Iowa 52242, USA
| | - C Chen
- Iowa State University, Ames, Iowa 50011, USA
| | - J Cochran
- Iowa State University, Ames, Iowa 50011, USA
| | - S Prell
- Iowa State University, Ames, Iowa 50011, USA
| | - A V Gritsan
- Johns Hopkins University, Baltimore, Maryland 21218, USA
| | - N Arnaud
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - M Davier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - F Le Diberder
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - A M Lutz
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - G Wormser
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - D J Lange
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D M Wright
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J P Coleman
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - E Gabathuler
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - D E Hutchcroft
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - D J Payne
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - C Touramanis
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - A J Bevan
- Queen Mary, University of London, London E1 4NS, United Kingdom
| | - F Di Lodovico
- Queen Mary, University of London, London E1 4NS, United Kingdom
| | - R Sacco
- Queen Mary, University of London, London E1 4NS, United Kingdom
| | - G Cowan
- University of London, Royal Holloway and Bedford New College, Egham, Surrey TW20 0EX, United Kingdom
| | - Sw Banerjee
- University of Louisville, Louisville, Kentucky 40292, USA
| | - D N Brown
- University of Louisville, Louisville, Kentucky 40292, USA
| | - C L Davis
- University of Louisville, Louisville, Kentucky 40292, USA
| | - A G Denig
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - W Gradl
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - K Griessinger
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - A Hafner
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - K R Schubert
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - R J Barlow
- University of Manchester, Manchester M13 9PL, United Kingdom
| | - G D Lafferty
- University of Manchester, Manchester M13 9PL, United Kingdom
| | - R Cenci
- University of Maryland, College Park, Maryland 20742, USA
| | - A Jawahery
- University of Maryland, College Park, Maryland 20742, USA
| | - D A Roberts
- University of Maryland, College Park, Maryland 20742, USA
| | - R Cowan
- Massachusetts Institute of Technology, Laboratory for Nuclear Science, Cambridge, Massachusetts 02139, USA
| | - S H Robertson
- Institute of Particle Physics, Montréal, Québec, Canada H3A 2T8
- McGill University, Montréal, Québec, Canada H3A 2T8
| | - R M Seddon
- McGill University, Montréal, Québec, Canada H3A 2T8
| | - N Neri
- INFN Sezione di Milano, I-20133 Milano, Italy
| | - F Palombo
- INFN Sezione di Milano, I-20133 Milano, Italy
- Dipartimento di Fisica, Università di Milano, I-20133 Milano, Italy
| | - L Cremaldi
- University of Mississippi, University, Mississippi 38677, USA
| | - R Godang
- University of Mississippi, University, Mississippi 38677, USA
| | - D J Summers
- University of Mississippi, University, Mississippi 38677, USA
| | - P Taras
- Université de Montréal, Physique des Particules, Montréal, Québec, Canada H3C 3J7
| | - G De Nardo
- INFN Sezione di Napoli and Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - C Sciacca
- INFN Sezione di Napoli and Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - G Raven
- NIKHEF, National Institute for Nuclear Physics and High Energy Physics, NL-1009 DB Amsterdam, The Netherlands
| | - C P Jessop
- University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - J M LoSecco
- University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - K Honscheid
- Ohio State University, Columbus, Ohio 43210, USA
| | - R Kass
- Ohio State University, Columbus, Ohio 43210, USA
| | - A Gaz
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - M Margoni
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - M Posocco
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - G Simi
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - F Simonetto
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - R Stroili
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - S Akar
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - E Ben-Haim
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - M Bomben
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G R Bonneaud
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G Calderini
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - J Chauveau
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G Marchiori
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - J Ocariz
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - M Biasini
- INFN Sezione di Perugia, I-06123 Perugia, Italy
- Dipartimento di Fisica, Università di Perugia, I-06123 Perugia, Italy
| | - E Manoni
- INFN Sezione di Perugia, I-06123 Perugia, Italy
| | - A Rossi
- INFN Sezione di Perugia, I-06123 Perugia, Italy
| | - G Batignani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - S Bettarini
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M Carpinelli
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - G Casarosa
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | | | - M De Nuccio
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - F Forti
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M A Giorgi
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - A Lusiani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Scuola Normale Superiore di Pisa, I-56127 Pisa, Italy
| | - B Oberhof
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - E Paoloni
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M Rama
- INFN Sezione di Pisa, I-56127 Pisa, Italy
| | - G Rizzo
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - J J Walsh
- INFN Sezione di Pisa, I-56127 Pisa, Italy
| | - L Zani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - A J S Smith
- Princeton University, Princeton, New Jersey 08544, USA
| | - F Anulli
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - R Faccini
- INFN Sezione di Roma, I-00185 Roma, Italy
- Dipartimento di Fisica, Università di Roma La Sapienza, I-00185 Roma, Italy
| | | | - F Ferroni
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - A Pilloni
- INFN Sezione di Roma, I-00185 Roma, Italy
- Dipartimento di Fisica, Università di Roma La Sapienza, I-00185 Roma, Italy
| | - G Piredda
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - C Bünger
- Universität Rostock, D-18051 Rostock, Germany
| | - S Dittrich
- Universität Rostock, D-18051 Rostock, Germany
| | - O Grünberg
- Universität Rostock, D-18051 Rostock, Germany
| | - M Heß
- Universität Rostock, D-18051 Rostock, Germany
| | - T Leddig
- Universität Rostock, D-18051 Rostock, Germany
| | - C Voß
- Universität Rostock, D-18051 Rostock, Germany
| | - R Waldi
- Universität Rostock, D-18051 Rostock, Germany
| | - T Adye
- Rutherford Appleton Laboratory, Chilton, Didcot, Oxon OX11 0QX, United Kingdom
| | - F F Wilson
- Rutherford Appleton Laboratory, Chilton, Didcot, Oxon OX11 0QX, United Kingdom
| | - S Emery
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - G Vasseur
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - D Aston
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - C Cartaro
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M R Convery
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - J Dorfan
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - W Dunwoodie
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M Ebert
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - R C Field
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - B G Fulsom
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M T Graham
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - C Hast
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - W R Innes
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - P Kim
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - D W G S Leith
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - S Luitz
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - D B MacFarlane
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - D R Muller
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - H Neal
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - B N Ratcliff
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - A Roodman
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M K Sullivan
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - J Va'vra
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - W J Wisniewski
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M V Purohit
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - J R Wilson
- University of South Carolina, Columbia, South Carolina 29208, USA
| | | | - S J Sekula
- Southern Methodist University, Dallas, Texas 75275, USA
| | - H Ahmed
- St. Francis Xavier University, Antigonish, Nova Scotia, Canada B2G 2W5
| | - N Tasneem
- St. Francis Xavier University, Antigonish, Nova Scotia, Canada B2G 2W5
| | - M Bellis
- Stanford University, Stanford, California 94305, USA
| | - P R Burchat
- Stanford University, Stanford, California 94305, USA
| | - E M T Puccio
- Stanford University, Stanford, California 94305, USA
| | - M S Alam
- State University of New York, Albany, New York 12222, USA
| | - J A Ernst
- State University of New York, Albany, New York 12222, USA
| | - R Gorodeisky
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - N Guttman
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - D R Peimer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - A Soffer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - S M Spanier
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - J L Ritchie
- University of Texas at Austin, Austin, Texas 78712, USA
| | | | - J M Izen
- University of Texas at Dallas, Richardson, Texas 75083, USA
| | - X C Lou
- University of Texas at Dallas, Richardson, Texas 75083, USA
| | - F Bianchi
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - F De Mori
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - A Filippi
- INFN Sezione di Torino, I-10125 Torino, Italy
| | - D Gamba
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - L Lanceri
- INFN Sezione di Trieste and Dipartimento di Fisica, Università di Trieste, I-34127 Trieste, Italy
| | - L Vitale
- INFN Sezione di Trieste and Dipartimento di Fisica, Università di Trieste, I-34127 Trieste, Italy
| | | | - A Oyanguren
- IFIC, Universitat de Valencia-CSIC, E-46071 Valencia, Spain
| | - J Albert
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - A Beaulieu
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - F U Bernlochner
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - G J King
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - R Kowalewski
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - T Lueck
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - C Miller
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - I M Nugent
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - J M Roney
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - R J Sobie
- Institute of Particle Physics, Victoria, British Columbia, Canada V8W 3P6
- University of Victoria, Victoria, British Columbia, Canada V8W 3P6
| | - T J Gershon
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - P F Harrison
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - T E Latham
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - R Prepost
- University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S L Wu
- University of Wisconsin, Madison, Wisconsin 53706, USA
| |
Collapse
|
39
|
Boquoi A, Banahan SM, Mohring A, Savickaite I, Strapatsas J, Hildebrandt B, Kobbe G, Gattermann N, Haas R, Schroeder T, Germing U, Fenk R. Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis. Ann Hematol 2022; 101:1031-1038. [PMID: 35262868 PMCID: PMC8993729 DOI: 10.1007/s00277-022-04775-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Accepted: 01/25/2022] [Indexed: 11/25/2022]
Abstract
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) can be late complications following mutagenic treatment. Limited data is available on the outcome of patients developing therapy-related MDS and AML after treatment for multiple myeloma (MM). We identified 250 patients with therapy-associated MDS or AML in the Duesseldorf MDS registry. Of those, 50 patients were previously diagnosed with multiple myeloma (mm-MDS/AML). We compared them to patients with de novo MDS (n = 4862) and to patients with MDS following other underlying diseases (tMDS) (n = 200). mm-MDS patients and tMDS patients showed similar karyotypes and degrees of cytopenia. However, mm-MDS patients had significantly higher blast counts and more often belonged to the high-risk group according to the International Prognostic Scoring System (IPSS) (both p < 0.05). Although the rate of progression to AML was similar in mm-MDS and tMDS, both transformed significantly more often than de novo MDS (p < 0.05). Median overall survival of patients with mm-MDS (13 months; range: 1–99) and tMDS (13 months; range 0–160) was also similar yet significantly shorter than patients with de novo MDS (32 months; range 0–345 months; p < 0.05). Furthermore, survival of mm-MDS patients was not affected by myeloma activity. Despite significantly more high-risk disease and higher blast cell counts, myeloma-associated MDS-patients show features akin to other tMDS. Survival is similar to other tMDS and irrespective of myeloma remission status or transformation to AML. Thus, patient outcome is not determined by competing clones but rather by MDS governing the stem cell niche.
Collapse
Affiliation(s)
- A Boquoi
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Heinrich-Heine-University, Duesseldorf, Germany.
| | - S M Banahan
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Heinrich-Heine-University, Duesseldorf, Germany
| | - A Mohring
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Heinrich-Heine-University, Duesseldorf, Germany
| | - I Savickaite
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Heinrich-Heine-University, Duesseldorf, Germany
| | - J Strapatsas
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Heinrich-Heine-University, Duesseldorf, Germany
| | - B Hildebrandt
- Institute of Human Genetics, Heinrich-Heine-University, Duesseldorf, Germany
| | - G Kobbe
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Heinrich-Heine-University, Duesseldorf, Germany
| | - N Gattermann
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Heinrich-Heine-University, Duesseldorf, Germany
| | - R Haas
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Heinrich-Heine-University, Duesseldorf, Germany
| | - T Schroeder
- Department of Hematology and Stem Cell Transplantation, University Medicine Essen, Essen, Germany
| | - U Germing
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Heinrich-Heine-University, Duesseldorf, Germany
| | - R Fenk
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Heinrich-Heine-University, Duesseldorf, Germany
| |
Collapse
|
40
|
Lees JP, Poireau V, Tisserand V, Grauges E, Palano A, Eigen G, Brown DN, Kolomensky YG, Fritsch M, Koch H, Schroeder T, Cheaib R, Hearty C, Mattison TS, McKenna JA, So RY, Blinov VE, Buzykaev AR, Druzhinin VP, Golubev VB, Kozyrev EA, Kravchenko EA, Onuchin AP, Serednyakov SI, Skovpen YI, Solodov EP, Todyshev KY, Lankford AJ, Dey B, Gary JW, Long O, Eisner AM, Lockman WS, Panduro Vazquez W, Chao DS, Cheng CH, Echenard B, Flood KT, Hitlin DG, Kim J, Li Y, Lin DX, Middleton S, Miyashita TS, Ongmongkolkul P, Oyang J, Porter FC, Röhrken M, Huard Z, Meadows BT, Pushpawela BG, Sokoloff MD, Sun L, Smith JG, Wagner SR, Bernard D, Verderi M, Bettoni D, Bozzi C, Calabrese R, Cibinetto G, Fioravanti E, Garzia I, Luppi E, Santoro V, Calcaterra A, de Sangro R, Finocchiaro G, Martellotti S, Patteri P, Peruzzi IM, Piccolo M, Rotondo M, Zallo A, Passaggio S, Patrignani C, Shuve BJ, Lacker HM, Bhuyan B, Mallik U, Chen C, Cochran J, Prell S, Gritsan AV, Arnaud N, Davier M, Le Diberder F, Lutz AM, Wormser G, Lange DJ, Wright DM, Coleman JP, Gabathuler E, Hutchcroft DE, Payne DJ, Touramanis C, Bevan AJ, Di Lodovico F, Sacco R, Cowan G, Banerjee S, Brown DN, Davis CL, Denig AG, Gradl W, Griessinger K, Hafner A, Schubert KR, Barlow RJ, Lafferty GD, Cenci R, Jawahery A, Roberts DA, Cowan R, Robertson SH, Seddon RM, Neri N, Palombo F, Cremaldi L, Godang R, Summers DJ, Taras P, De Nardo G, Sciacca C, Raven G, Jessop CP, LoSecco JM, Honscheid K, Kass R, Gaz A, Margoni M, Posocco M, Simi G, Simonetto F, Stroili R, Akar S, Ben-Haim E, Bomben M, Bonneaud GR, Calderini G, Chauveau J, Marchiori G, Ocariz J, Biasini M, Manoni E, Rossi A, Batignani G, Bettarini S, Carpinelli M, Casarosa G, Chrzaszcz M, Forti F, Giorgi MA, Lusiani A, Oberhof B, Paoloni E, Rama M, Rizzo G, Walsh JJ, Zani L, Smith AJS, Anulli F, Faccini R, Ferrarotto F, Ferroni F, Pilloni A, Piredda G, Bünger C, Dittrich S, Grünberg O, Heß M, Leddig T, Voß C, Waldi R, Adye T, Wilson FF, Emery S, Vasseur G, Aston D, Cartaro C, Convery MR, Dorfan J, Dunwoodie W, Ebert M, Field RC, Fulsom BG, Graham MT, Hast C, Innes WR, Kim P, Leith DWGS, Luitz S, MacFarlane DB, Muller DR, Neal H, Ratcliff BN, Roodman A, Sullivan MK, Va'vra J, Wisniewski WJ, Purohit MV, Wilson JR, Randle-Conde A, Sekula SJ, Ahmed H, Bellis M, Burchat PR, Puccio EMT, Alam MS, Ernst JA, Gorodeisky R, Guttman N, Peimer DR, Soffer A, Spanier SM, Ritchie JL, Schwitters RF, Izen JM, Lou XC, Bianchi F, De Mori F, Filippi A, Gamba D, Lanceri L, Vitale L, Martinez-Vidal F, Oyanguren A, Albert J, Beaulieu A, Bernlochner FU, King GJ, Kowalewski R, Lueck T, Nugent IM, Roney JM, Sobie RJ, Tasneem N, Gershon TJ, Harrison PF, Latham TE, Prepost R, Wu SL. Search for Lepton Flavor Violation in ϒ(3S)→e^{±}μ^{∓}. Phys Rev Lett 2022; 128:091804. [PMID: 35302790 DOI: 10.1103/physrevlett.128.091804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Accepted: 01/27/2022] [Indexed: 06/14/2023]
Abstract
We report on the first search for electron-muon lepton flavor violation (LFV) in the decay of a b quark and b antiquark bound state. We look for the LFV decay ϒ(3S)→e^{±}μ^{∓} in a sample of 118 million ϒ(3S) mesons from 27 fb^{-1} of data collected with the BABAR detector at the SLAC PEP-II e^{+}e^{-} collider operating with a 10.36 GeV center-of-mass energy. No evidence for a signal is found, and we set a limit on the branching fraction B[ϒ(3S)→e^{±}μ^{∓}]<3.6×10^{-7} at 90% C. L. This result can be interpreted as a limit Λ_{NP}/g_{NP}^{2}>80 TeV on the energy scale Λ_{NP} divided by the coupling-squared g_{NP}^{2} of relevant new physics (NP).
Collapse
Affiliation(s)
- J P Lees
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - V Poireau
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - V Tisserand
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - E Grauges
- Universitat de Barcelona, Facultat de Fisica, Departament ECM, E-08028 Barcelona, Spain
| | - A Palano
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - G Eigen
- University of Bergen, Institute of Physics, N-5007 Bergen, Norway
| | - D N Brown
- Lawrence Berkeley National Laboratory and University of California, Berkeley, California 94720, USA
| | - Yu G Kolomensky
- Lawrence Berkeley National Laboratory and University of California, Berkeley, California 94720, USA
| | - M Fritsch
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - H Koch
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - T Schroeder
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - R Cheaib
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - C Hearty
- Institute of Particle Physics, Vancouver, British Columbia V6T 1Z1, Canada
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - T S Mattison
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - J A McKenna
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - R Y So
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - V E Blinov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
- Novosibirsk State Technical University, Novosibirsk 630092, Russia
| | - A R Buzykaev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
| | - V P Druzhinin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - V B Golubev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E A Kozyrev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E A Kravchenko
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - A P Onuchin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
- Novosibirsk State Technical University, Novosibirsk 630092, Russia
| | - S I Serednyakov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - Yu I Skovpen
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E P Solodov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - K Yu Todyshev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - A J Lankford
- University of California at Irvine, Irvine, California 92697, USA
| | - B Dey
- University of California at Riverside, Riverside, California 92521, USA
| | - J W Gary
- University of California at Riverside, Riverside, California 92521, USA
| | - O Long
- University of California at Riverside, Riverside, California 92521, USA
| | - A M Eisner
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - W S Lockman
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - W Panduro Vazquez
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - D S Chao
- California Institute of Technology, Pasadena, California 91125, USA
| | - C H Cheng
- California Institute of Technology, Pasadena, California 91125, USA
| | - B Echenard
- California Institute of Technology, Pasadena, California 91125, USA
| | - K T Flood
- California Institute of Technology, Pasadena, California 91125, USA
| | - D G Hitlin
- California Institute of Technology, Pasadena, California 91125, USA
| | - J Kim
- California Institute of Technology, Pasadena, California 91125, USA
| | - Y Li
- California Institute of Technology, Pasadena, California 91125, USA
| | - D X Lin
- California Institute of Technology, Pasadena, California 91125, USA
| | - S Middleton
- California Institute of Technology, Pasadena, California 91125, USA
| | - T S Miyashita
- California Institute of Technology, Pasadena, California 91125, USA
| | - P Ongmongkolkul
- California Institute of Technology, Pasadena, California 91125, USA
| | - J Oyang
- California Institute of Technology, Pasadena, California 91125, USA
| | - F C Porter
- California Institute of Technology, Pasadena, California 91125, USA
| | - M Röhrken
- California Institute of Technology, Pasadena, California 91125, USA
| | - Z Huard
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - B T Meadows
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | | | - M D Sokoloff
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - L Sun
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - J G Smith
- University of Colorado, Boulder, Colorado 80309, USA
| | - S R Wagner
- University of Colorado, Boulder, Colorado 80309, USA
| | - D Bernard
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS/IN2P3, F-91128 Palaiseau, France
| | - M Verderi
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS/IN2P3, F-91128 Palaiseau, France
| | - D Bettoni
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - C Bozzi
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - R Calabrese
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - G Cibinetto
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - E Fioravanti
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - I Garzia
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - E Luppi
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - V Santoro
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - A Calcaterra
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - R de Sangro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - G Finocchiaro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S Martellotti
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - P Patteri
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - I M Peruzzi
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - M Piccolo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - M Rotondo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - A Zallo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S Passaggio
- INFN Sezione di Genova, I-16146 Genova, Italy
| | | | - B J Shuve
- Harvey Mudd College, Claremont, California 91711, USA
| | - H M Lacker
- Humboldt-Universität zu Berlin, Institut für Physik, D-12489 Berlin, Germany
| | - B Bhuyan
- Indian Institute of Technology Guwahati, Guwahati, Assam 781 039, India
| | - U Mallik
- University of Iowa, Iowa City, Iowa 52242, USA
| | - C Chen
- Iowa State University, Ames, Iowa 50011, USA
| | - J Cochran
- Iowa State University, Ames, Iowa 50011, USA
| | - S Prell
- Iowa State University, Ames, Iowa 50011, USA
| | - A V Gritsan
- Johns Hopkins University, Baltimore, Maryland 21218, USA
| | - N Arnaud
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - M Davier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - F Le Diberder
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - A M Lutz
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - G Wormser
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - D J Lange
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D M Wright
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J P Coleman
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - E Gabathuler
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - D E Hutchcroft
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - D J Payne
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - C Touramanis
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - A J Bevan
- Queen Mary, University of London, London E1 4NS, United Kingdom
| | - F Di Lodovico
- Queen Mary, University of London, London E1 4NS, United Kingdom
| | - R Sacco
- Queen Mary, University of London, London E1 4NS, United Kingdom
| | - G Cowan
- University of London, Royal Holloway and Bedford New College, Egham, Surrey TW20 0EX, United Kingdom
| | - Sw Banerjee
- University of Louisville, Louisville, Kentucky 40292, USA
| | - D N Brown
- University of Louisville, Louisville, Kentucky 40292, USA
| | - C L Davis
- University of Louisville, Louisville, Kentucky 40292, USA
| | - A G Denig
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - W Gradl
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - K Griessinger
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - A Hafner
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - K R Schubert
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - R J Barlow
- University of Manchester, Manchester M13 9PL, United Kingdom
| | - G D Lafferty
- University of Manchester, Manchester M13 9PL, United Kingdom
| | - R Cenci
- University of Maryland, College Park, Maryland 20742, USA
| | - A Jawahery
- University of Maryland, College Park, Maryland 20742, USA
| | - D A Roberts
- University of Maryland, College Park, Maryland 20742, USA
| | - R Cowan
- Massachusetts Institute of Technology, Laboratory for Nuclear Science, Cambridge, Massachusetts 02139, USA
| | - S H Robertson
- Institute of Particle Physics, Montréal, Québec H3A 2T8, Canada
- McGill University, Montréal, Québec H3A 2T8, Canada
| | - R M Seddon
- Institute of Particle Physics, Montréal, Québec H3A 2T8, Canada
| | - N Neri
- INFN Sezione di Milano, I-20133 Milano, Italy
| | - F Palombo
- INFN Sezione di Milano, I-20133 Milano, Italy
- Dipartimento di Fisica, Università di Milano, I-20133 Milano, Italy
| | - L Cremaldi
- University of Mississippi, University, Mississippi 38677, USA
| | - R Godang
- University of Mississippi, University, Mississippi 38677, USA
| | - D J Summers
- University of Mississippi, University, Mississippi 38677, USA
| | - P Taras
- Université de Montréal, Physique des Particules, Montréal, Québec H3C 3J7, Canada
| | - G De Nardo
- INFN Sezione di Napoli and Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - C Sciacca
- INFN Sezione di Napoli and Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - G Raven
- NIKHEF, National Institute for Nuclear Physics and High Energy Physics, NL-1009 DB Amsterdam, Netherlands
| | - C P Jessop
- University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - J M LoSecco
- University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - K Honscheid
- Ohio State University, Columbus, Ohio 43210, USA
| | - R Kass
- Ohio State University, Columbus, Ohio 43210, USA
| | - A Gaz
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - M Margoni
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - M Posocco
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - G Simi
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - F Simonetto
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - R Stroili
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - S Akar
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - E Ben-Haim
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - M Bomben
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G R Bonneaud
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G Calderini
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - J Chauveau
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G Marchiori
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - J Ocariz
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - M Biasini
- Dipartimento di Fisica, Università di Perugia, I-06123 Perugia, Italy
| | - E Manoni
- INFN Sezione di Perugia, I-06123 Perugia, Italy
| | - A Rossi
- INFN Sezione di Perugia, I-06123 Perugia, Italy
| | - G Batignani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - S Bettarini
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M Carpinelli
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - G Casarosa
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | | | - F Forti
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M A Giorgi
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - A Lusiani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Scuola Normale Superiore di Pisa, I-56127 Pisa, Italy
| | - B Oberhof
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - E Paoloni
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M Rama
- INFN Sezione di Pisa, I-56127 Pisa, Italy
| | - G Rizzo
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - J J Walsh
- INFN Sezione di Pisa, I-56127 Pisa, Italy
| | - L Zani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - A J S Smith
- Princeton University, Princeton, New Jersey 08544, USA
| | - F Anulli
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - R Faccini
- INFN Sezione di Roma, I-00185 Roma, Italy
- Dipartimento di Fisica, Università di Roma La Sapienza, I-00185 Roma, Italy
| | | | - F Ferroni
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - A Pilloni
- INFN Sezione di Roma, I-00185 Roma, Italy
- Dipartimento di Fisica, Università di Roma La Sapienza, I-00185 Roma, Italy
| | - G Piredda
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - C Bünger
- Universität Rostock, D-18051 Rostock, Germany
| | - S Dittrich
- Universität Rostock, D-18051 Rostock, Germany
| | - O Grünberg
- Universität Rostock, D-18051 Rostock, Germany
| | - M Heß
- Universität Rostock, D-18051 Rostock, Germany
| | - T Leddig
- Universität Rostock, D-18051 Rostock, Germany
| | - C Voß
- Universität Rostock, D-18051 Rostock, Germany
| | - R Waldi
- Universität Rostock, D-18051 Rostock, Germany
| | - T Adye
- Rutherford Appleton Laboratory, Chilton, Didcot, Oxon OX11 0QX, United Kingdom
| | - F F Wilson
- Rutherford Appleton Laboratory, Chilton, Didcot, Oxon OX11 0QX, United Kingdom
| | - S Emery
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - G Vasseur
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - D Aston
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - C Cartaro
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - M R Convery
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - J Dorfan
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - W Dunwoodie
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - M Ebert
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - R C Field
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - B G Fulsom
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - M T Graham
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - C Hast
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - W R Innes
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - P Kim
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - D W G S Leith
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - S Luitz
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - D B MacFarlane
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - D R Muller
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - H Neal
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - B N Ratcliff
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - A Roodman
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - M K Sullivan
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - J Va'vra
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - W J Wisniewski
- SLAC National Accelerator Laboratory, Stanford, California 94309, USA
| | - M V Purohit
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - J R Wilson
- University of South Carolina, Columbia, South Carolina 29208, USA
| | | | - S J Sekula
- Southern Methodist University, Dallas, Texas 75275, USA
| | - H Ahmed
- St. Francis Xavier University, Antigonish, Nova Scotia B2G 2W5, Canada
| | - M Bellis
- Stanford University, Stanford, California 94305, USA
| | - P R Burchat
- Stanford University, Stanford, California 94305, USA
| | - E M T Puccio
- Stanford University, Stanford, California 94305, USA
| | - M S Alam
- State University of New York, Albany, New York 12222, USA
| | - J A Ernst
- State University of New York, Albany, New York 12222, USA
| | - R Gorodeisky
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - N Guttman
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - D R Peimer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - A Soffer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - S M Spanier
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - J L Ritchie
- University of Texas at Austin, Austin, Texas 78712, USA
| | | | - J M Izen
- University of Texas at Dallas, Richardson, Texas 75083, USA
| | - X C Lou
- University of Texas at Dallas, Richardson, Texas 75083, USA
| | - F Bianchi
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - F De Mori
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - A Filippi
- INFN Sezione di Torino, I-10125 Torino, Italy
| | - D Gamba
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - L Lanceri
- INFN Sezione di Trieste and Dipartimento di Fisica, Università di Trieste, I-34127 Trieste, Italy
| | - L Vitale
- INFN Sezione di Trieste and Dipartimento di Fisica, Università di Trieste, I-34127 Trieste, Italy
| | | | - A Oyanguren
- IFIC, Universitat de Valencia-CSIC, E-46071 Valencia, Spain
| | - J Albert
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - A Beaulieu
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - F U Bernlochner
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - G J King
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - R Kowalewski
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - T Lueck
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - I M Nugent
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - J M Roney
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - R J Sobie
- Institute of Particle Physics, Victoria, British Columbia V8W 3P6, Canada
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - N Tasneem
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - T J Gershon
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - P F Harrison
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - T E Latham
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - R Prepost
- University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S L Wu
- University of Wisconsin, Madison, Wisconsin 53706, USA
| |
Collapse
|
41
|
Nagler A, Ngoya M, Labopin M, Bornhauser M, Stelljes M, Finke J, Ganser A, Einsele H, Kroger N, Brecht A, Bethge W, Edinger M, Kulagin A, Passweg J, Elmaagacli A, Schafer-Eckart K, Platzbecker U, Schroeder T, Bunjes D, Tischer J, Martin S, Spyridonidis A, Giebel S, Savani B, Mohty M. Evaluation of Trends in Outcome over 2 Decades of Patients with Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplantation from Unrelated Donors: An ALWP/EBMT Analysis. Transplant Cell Ther 2022. [DOI: 10.1016/s2666-6367(22)00302-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Lees JP, Poireau V, Tisserand V, Grauges E, Palano A, Eigen G, Brown DN, Kolomensky YG, Fritsch M, Koch H, Schroeder T, Cheaib R, Hearty C, Mattison TS, McKenna JA, So RY, Blinov VE, Buzykaev AR, Druzhinin VP, Golubev VB, Kozyrev EA, Kravchenko EA, Onuchin AP, Serednyakov SI, Skovpen YI, Solodov EP, Todyshev KY, Lankford AJ, Dey B, Gary JW, Long O, Eisner AM, Lockman WS, Panduro Vazquez W, Chao DS, Cheng CH, Echenard B, Flood KT, Hitlin DG, Kim J, Li Y, Lin DX, Miyashita TS, Ongmongkolkul P, Oyang J, Porter FC, Röhrken M, Huard Z, Meadows BT, Pushpawela BG, Sokoloff MD, Sun L, Smith JG, Wagner SR, Bernard D, Verderi M, Bettoni D, Bozzi C, Calabrese R, Cibinetto G, Fioravanti E, Garzia I, Luppi E, Santoro V, Calcaterra A, de Sangro R, Finocchiaro G, Martellotti S, Patteri P, Peruzzi IM, Piccolo M, Rotondo M, Zallo A, Passaggio S, Patrignani C, Shuve BJ, Lacker HM, Bhuyan B, Mallik U, Chen C, Cochran J, Prell S, Gritsan AV, Arnaud N, Davier M, Le Diberder F, Lutz AM, Wormser G, Lange DJ, Wright DM, Coleman JP, Gabathuler E, Hutchcroft DE, Payne DJ, Touramanis C, Bevan AJ, Di Lodovico F, Sacco R, Cowan G, Banerjee S, Brown DN, Davis CL, Denig AG, Gradl W, Griessinger K, Hafner A, Schubert KR, Barlow RJ, Lafferty GD, Cenci R, Jawahery A, Roberts DA, Cowan R, Robertson SH, Seddon RM, Neri N, Palombo F, Cremaldi L, Godang R, Summers DJ, Taras P, De Nardo G, Sciacca C, Raven G, Jessop CP, LoSecco JM, Honscheid K, Kass R, Gaz A, Margoni M, Posocco M, Simi G, Simonetto F, Stroili R, Akar S, Ben-Haim E, Bomben M, Bonneaud GR, Calderini G, Chauveau J, Marchiori G, Ocariz J, Biasini M, Manoni E, Rossi A, Batignani G, Bettarini S, Carpinelli M, Casarosa G, Chrzaszcz M, Forti F, Giorgi MA, Lusiani A, Oberhof B, Paoloni E, Rama M, Rizzo G, Walsh JJ, Zani L, Smith AJS, Anulli F, Faccini R, Ferrarotto F, Ferroni F, Pilloni A, Piredda G, Bünger C, Dittrich S, Grünberg O, Heß M, Leddig T, Voß C, Waldi R, Adye T, Wilson FF, Emery S, Vasseur G, Aston D, Cartaro C, Convery MR, Dorfan J, Dunwoodie W, Ebert M, Field RC, Fulsom BG, Graham MT, Hast C, Innes WR, Kim P, Leith DWGS, Luitz S, MacFarlane DB, Muller DR, Neal H, Ratcliff BN, Roodman A, Sullivan MK, Va'vra J, Wisniewski WJ, Purohit MV, Wilson JR, Randle-Conde A, Sekula SJ, Ahmed H, Bellis M, Burchat PR, Puccio EMT, Alam MS, Ernst JA, Gorodeisky R, Guttman N, Peimer DR, Soffer A, Spanier SM, Ritchie JL, Schwitters RF, Izen JM, Lou XC, Bianchi F, De Mori F, Filippi A, Gamba D, Lanceri L, Vitale L, Martinez-Vidal F, Oyanguren A, Albert J, Beaulieu A, Bernlochner FU, King GJ, Kowalewski R, Lueck T, Nugent IM, Roney JM, Sobie RJ, Tasneem N, Gershon TJ, Harrison PF, Latham TE, Prepost R, Wu SL. Search for Darkonium in e^{+}e^{-} Collisions. Phys Rev Lett 2022; 128:021802. [PMID: 35089770 DOI: 10.1103/physrevlett.128.021802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Revised: 09/17/2021] [Accepted: 12/13/2021] [Indexed: 06/14/2023]
Abstract
Collider searches for dark sectors, new particles interacting only feebly with ordinary matter, have largely focused on identifying signatures of new mediators, leaving much of dark sector structures unexplored. In particular, the existence of dark matter bound states (darkonia) remains to be investigated. This possibility could arise in a simple model in which a dark photon (A^{'}) is light enough to generate an attractive force between dark fermions. We report herein a search for a J^{PC}=1^{--} darkonium state, the ϒ_{D}, produced in the reaction e^{+}e^{-}→γϒ_{D}, ϒ_{D}→A^{'}A^{'}A^{'}, where the dark photons subsequently decay into pairs of leptons or pions, using 514 fb^{-1} of data collected with the BABAR detector. No significant signal is observed, and we set bounds on the γ-A^{'} kinetic mixing as a function of the dark sector coupling constant for 0.001<m_{A^{'}}<3.16 GeV and 0.05<m_{ϒ_{D}}<9.5 GeV.
Collapse
Affiliation(s)
- J P Lees
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - V Poireau
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - V Tisserand
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), Université de Savoie, CNRS/IN2P3, F-74941 Annecy-Le-Vieux, France
| | - E Grauges
- Universitat de Barcelona, Facultat de Fisica, Departament ECM, E-08028 Barcelona, Spain
| | - A Palano
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - G Eigen
- University of Bergen, Institute of Physics, N-5007 Bergen, Norway
| | - D N Brown
- Lawrence Berkeley National Laboratory and University of California, Berkeley, California 94720, USA
| | - Yu G Kolomensky
- Lawrence Berkeley National Laboratory and University of California, Berkeley, California 94720, USA
| | - M Fritsch
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - H Koch
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - T Schroeder
- Ruhr Universität Bochum, Institut für Experimentalphysik 1, D-44780 Bochum, Germany
| | - R Cheaib
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - C Hearty
- Institute of Particle Physics, Vancouver, British Columbia V6T 1Z1, Canada
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - T S Mattison
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - J A McKenna
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - R Y So
- University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - V E Blinov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
- Novosibirsk State Technical University, Novosibirsk 630092, Russia
| | - A R Buzykaev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
| | - V P Druzhinin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - V B Golubev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E A Kozyrev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E A Kravchenko
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - A P Onuchin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
- Novosibirsk State Technical University, Novosibirsk 630092, Russia
| | - S I Serednyakov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - Yu I Skovpen
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - E P Solodov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - K Yu Todyshev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russia
- Novosibirsk State University, Novosibirsk 630090, Russia
| | - A J Lankford
- University of California at Irvine, Irvine, California 92697, USA
| | - B Dey
- University of California at Riverside, Riverside, California 92521, USA
| | - J W Gary
- University of California at Riverside, Riverside, California 92521, USA
| | - O Long
- University of California at Riverside, Riverside, California 92521, USA
| | - A M Eisner
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - W S Lockman
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - W Panduro Vazquez
- University of California at Santa Cruz, Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - D S Chao
- California Institute of Technology, Pasadena, California 91125, USA
| | - C H Cheng
- California Institute of Technology, Pasadena, California 91125, USA
| | - B Echenard
- California Institute of Technology, Pasadena, California 91125, USA
| | - K T Flood
- California Institute of Technology, Pasadena, California 91125, USA
| | - D G Hitlin
- California Institute of Technology, Pasadena, California 91125, USA
| | - J Kim
- California Institute of Technology, Pasadena, California 91125, USA
| | - Y Li
- California Institute of Technology, Pasadena, California 91125, USA
| | - D X Lin
- California Institute of Technology, Pasadena, California 91125, USA
| | - T S Miyashita
- California Institute of Technology, Pasadena, California 91125, USA
| | - P Ongmongkolkul
- California Institute of Technology, Pasadena, California 91125, USA
| | - J Oyang
- California Institute of Technology, Pasadena, California 91125, USA
| | - F C Porter
- California Institute of Technology, Pasadena, California 91125, USA
| | - M Röhrken
- California Institute of Technology, Pasadena, California 91125, USA
| | - Z Huard
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - B T Meadows
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | | | - M D Sokoloff
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - L Sun
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - J G Smith
- University of Colorado, Boulder, Colorado 80309, USA
| | - S R Wagner
- University of Colorado, Boulder, Colorado 80309, USA
| | - D Bernard
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS/IN2P3, F-91128 Palaiseau, France
| | - M Verderi
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS/IN2P3, F-91128 Palaiseau, France
| | - D Bettoni
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - C Bozzi
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - R Calabrese
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - G Cibinetto
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - E Fioravanti
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - I Garzia
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - E Luppi
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
- Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, I-44122 Ferrara, Italy
| | - V Santoro
- INFN Sezione di Ferrara, I-44122 Ferrara, Italy
| | - A Calcaterra
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - R de Sangro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - G Finocchiaro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S Martellotti
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - P Patteri
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - I M Peruzzi
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - M Piccolo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - M Rotondo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - A Zallo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S Passaggio
- INFN Sezione di Genova, I-16146 Genova, Italy
| | | | - B J Shuve
- Harvey Mudd College, Claremont, California 91711, USA
| | - H M Lacker
- Humboldt-Universität zu Berlin, Institut für Physik, D-12489 Berlin, Germany
| | - B Bhuyan
- Indian Institute of Technology Guwahati, Guwahati, Assam 781 039, India
| | - U Mallik
- University of Iowa, Iowa City, Iowa 52242, USA
| | - C Chen
- Iowa State University, Ames, Iowa 50011, USA
| | - J Cochran
- Iowa State University, Ames, Iowa 50011, USA
| | - S Prell
- Iowa State University, Ames, Iowa 50011, USA
| | - A V Gritsan
- Johns Hopkins University, Baltimore, Maryland 21218, USA
| | - N Arnaud
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - M Davier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - F Le Diberder
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - A M Lutz
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - G Wormser
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
| | - D J Lange
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D M Wright
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J P Coleman
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - E Gabathuler
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - D E Hutchcroft
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - D J Payne
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - C Touramanis
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - A J Bevan
- Queen Mary, University of London, London, E1 4NS, United Kingdom
| | - F Di Lodovico
- Queen Mary, University of London, London, E1 4NS, United Kingdom
| | - R Sacco
- Queen Mary, University of London, London, E1 4NS, United Kingdom
| | - G Cowan
- University of London, Royal Holloway and Bedford New College, Egham, Surrey TW20 0EX, United Kingdom
| | - Sw Banerjee
- University of Louisville, Louisville, Kentucky 40292, USA
| | - D N Brown
- University of Louisville, Louisville, Kentucky 40292, USA
| | - C L Davis
- University of Louisville, Louisville, Kentucky 40292, USA
| | - A G Denig
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - W Gradl
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - K Griessinger
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - A Hafner
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - K R Schubert
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz, Germany
| | - R J Barlow
- University of Manchester, Manchester M13 9PL, United Kingdom
| | - G D Lafferty
- University of Manchester, Manchester M13 9PL, United Kingdom
| | - R Cenci
- University of Maryland, College Park, Maryland 20742, USA
| | - A Jawahery
- University of Maryland, College Park, Maryland 20742, USA
| | - D A Roberts
- University of Maryland, College Park, Maryland 20742, USA
| | - R Cowan
- Massachusetts Institute of Technology, Laboratory for Nuclear Science, Cambridge, Massachusetts 02139, USA
| | - S H Robertson
- Institute of Particle Physics, Montréal, Québec, Canada H3A 2T8
- McGill University, Montréal, Québec, Canada H3A 2T8
| | - R M Seddon
- McGill University, Montréal, Québec, Canada H3A 2T8
| | - N Neri
- INFN Sezione di Milano, I-20133 Milano, Italy
| | - F Palombo
- INFN Sezione di Milano, I-20133 Milano, Italy
- Dipartimento di Fisica, Università di Milano, I-20133 Milano, Italy
| | - L Cremaldi
- University of Mississippi, University, Mississippi 38677, USA
| | - R Godang
- University of Mississippi, University, Mississippi 38677, USA
| | - D J Summers
- University of Mississippi, University, Mississippi 38677, USA
| | - P Taras
- Université de Montréal, Physique des Particules, Montréal, Québec H3C 3J7, Canada
| | - G De Nardo
- INFN Sezione di Napoli and Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - C Sciacca
- INFN Sezione di Napoli and Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - G Raven
- NIKHEF, National Institute for Nuclear Physics and High Energy Physics, NL-1009 DB Amsterdam, Netherlands
| | - C P Jessop
- University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - J M LoSecco
- University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - K Honscheid
- The Ohio State University, Columbus, Ohio 43210, USA
| | - R Kass
- The Ohio State University, Columbus, Ohio 43210, USA
| | - A Gaz
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - M Margoni
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - M Posocco
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - G Simi
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - F Simonetto
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - R Stroili
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica, Università di Padova, I-35131 Padova, Italy
| | - S Akar
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - E Ben-Haim
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - M Bomben
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G R Bonneaud
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G Calderini
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - J Chauveau
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - G Marchiori
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - J Ocariz
- Laboratoire de Physique Nucléaire et de Hautes Energies, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, F-75252 Paris, France
| | - M Biasini
- INFN Sezione di Perugia, I-06123 Perugia, Italy
- Dipartimento di Fisica, Università di Perugia, I-06123 Perugia, Italy
| | - E Manoni
- INFN Sezione di Perugia, I-06123 Perugia, Italy
| | - A Rossi
- INFN Sezione di Perugia, I-06123 Perugia, Italy
| | - G Batignani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - S Bettarini
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M Carpinelli
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - G Casarosa
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | | | - F Forti
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M A Giorgi
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - A Lusiani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Scuola Normale Superiore di Pisa, I-56127 Pisa, Italy
| | - B Oberhof
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - E Paoloni
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - M Rama
- INFN Sezione di Pisa, I-56127 Pisa, Italy
| | - G Rizzo
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - J J Walsh
- INFN Sezione di Pisa, I-56127 Pisa, Italy
| | - L Zani
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - A J S Smith
- Princeton University, Princeton, New Jersey 08544, USA
| | - F Anulli
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - R Faccini
- INFN Sezione di Roma, I-00185 Roma, Italy
- Dipartimento di Fisica, Università di Roma La Sapienza, I-00185 Roma, Italy
| | | | - F Ferroni
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - A Pilloni
- INFN Sezione di Roma, I-00185 Roma, Italy
- Dipartimento di Fisica, Università di Roma La Sapienza, I-00185 Roma, Italy
| | - G Piredda
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - C Bünger
- Universität Rostock, D-18051 Rostock, Germany
| | - S Dittrich
- Universität Rostock, D-18051 Rostock, Germany
| | - O Grünberg
- Universität Rostock, D-18051 Rostock, Germany
| | - M Heß
- Universität Rostock, D-18051 Rostock, Germany
| | - T Leddig
- Universität Rostock, D-18051 Rostock, Germany
| | - C Voß
- Universität Rostock, D-18051 Rostock, Germany
| | - R Waldi
- Universität Rostock, D-18051 Rostock, Germany
| | - T Adye
- Rutherford Appleton Laboratory, Chilton, Didcot, Oxon OX11 0QX, United Kingdom
| | - F F Wilson
- Rutherford Appleton Laboratory, Chilton, Didcot, Oxon OX11 0QX, United Kingdom
| | - S Emery
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - G Vasseur
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - D Aston
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - C Cartaro
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M R Convery
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - J Dorfan
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - W Dunwoodie
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M Ebert
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - R C Field
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - B G Fulsom
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M T Graham
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - C Hast
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - W R Innes
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - P Kim
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - D W G S Leith
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - S Luitz
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - D B MacFarlane
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - D R Muller
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - H Neal
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - B N Ratcliff
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - A Roodman
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M K Sullivan
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - J Va'vra
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - W J Wisniewski
- SLAC National Accelerator Laboratory, Stanford, California 94309 USA
| | - M V Purohit
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - J R Wilson
- University of South Carolina, Columbia, South Carolina 29208, USA
| | | | - S J Sekula
- Southern Methodist University, Dallas, Texas 75275, USA
| | - H Ahmed
- St. Francis Xavier University, Antigonish, Nova Scotia B2G 2W5, Canada
| | - M Bellis
- Stanford University, Stanford, California 94305, USA
| | - P R Burchat
- Stanford University, Stanford, California 94305, USA
| | - E M T Puccio
- Stanford University, Stanford, California 94305, USA
| | - M S Alam
- State University of New York, Albany, New York 12222, USA
| | - J A Ernst
- State University of New York, Albany, New York 12222, USA
| | - R Gorodeisky
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - N Guttman
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - D R Peimer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - A Soffer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978, Israel
| | - S M Spanier
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - J L Ritchie
- University of Texas at Austin, Austin, Texas 78712, USA
| | | | - J M Izen
- University of Texas at Dallas, Richardson, Texas 75083, USA
| | - X C Lou
- University of Texas at Dallas, Richardson, Texas 75083, USA
| | - F Bianchi
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - F De Mori
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - A Filippi
- INFN Sezione di Torino, I-10125 Torino, Italy
| | - D Gamba
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - L Lanceri
- INFN Sezione di Trieste and Dipartimento di Fisica, Università di Trieste, I-34127 Trieste, Italy
| | - L Vitale
- INFN Sezione di Trieste and Dipartimento di Fisica, Università di Trieste, I-34127 Trieste, Italy
| | | | - A Oyanguren
- IFIC, Universitat de Valencia-CSIC, E-46071 Valencia, Spain
| | - J Albert
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - A Beaulieu
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - F U Bernlochner
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - G J King
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - R Kowalewski
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - T Lueck
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - I M Nugent
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - J M Roney
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - R J Sobie
- Institute of Particle Physics, Victoria, British Columbia V8W 3P6, Canada
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - N Tasneem
- University of Victoria, Victoria, British Columbia V8W 3P6, Canada
| | - T J Gershon
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - P F Harrison
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - T E Latham
- Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - R Prepost
- University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S L Wu
- University of Wisconsin, Madison, Wisconsin 53706, USA
| |
Collapse
|
43
|
Kaivers J, Peters J, Rautenberg C, Schroeder T, Kobbe G, Hildebrandt B, Haas R, Germing U, Bennett JM. The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T. Leuk Res 2021; 112:106757. [PMID: 34864369 DOI: 10.1016/j.leukres.2021.106757] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 11/23/2021] [Accepted: 11/24/2021] [Indexed: 10/19/2022]
Abstract
We studied 79 patients with AML-MRC or RAEB-T, who were later reclassified according to the WHO classification. Marrow slides were examined cytomorphologically with regard to dysplasia. Patients were followed up until March 2020. Thirty-one patients underwent allogeneic stem cell transplantation (median survival (ms) 16 months), 14 were treated with induction chemotherapy (ms 8.4 months), 18 received hypomethylating agents (ms 9.2 months), 16 received low dose chemotherapy or best supportive care (ms 2.4 months). Only 30.4 % fulfilled the morphologic WHO criteria. 46.8 % were classified as AML-MRC by an antecedent MDS, 54.4 % of the pts were classified by MDS-related chromosomal abnormalities. 5 % did not fulfill any of the criteria and were entered based on 20-29 % medullary blasts. There was no difference in ms between pts presenting with > 50 % dysplasia as compared to pts with dysplasia between 10 % and 50 % (ms 9.1 vs 9.9 months, p = n.s.) or for pts with antecedent MDS (ms 9.1 vs 8.9 months, p = n.s.). Myelodysplasia-related cytogenetic abnormalities were associated with a worse outcome (ms 8.1 vs 13.5 months, p = 0.026). AML-MRC in its current definition is a heterogenous entity. Dysplasia of ≥ 50 % in ≥ two lineages is not helpful for diagnostics and prognostication and therefore should be deleted in future classifications. We recommend utilizing the WHO guidelines for defining dysplasia (10 % or greater in ≥ 1 of the three myeloid cell lines) assisting in establishing the diagnosis of MDS.
Collapse
Affiliation(s)
- J Kaivers
- Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany.
| | - J Peters
- Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany
| | - C Rautenberg
- Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany; Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Medical Faculty, University Duisburg-Essen, Essen, Germany
| | - T Schroeder
- Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany; Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Medical Faculty, University Duisburg-Essen, Essen, Germany
| | - G Kobbe
- Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany
| | - B Hildebrandt
- Institute of Human Genetics, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany
| | - R Haas
- Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany
| | - U Germing
- Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany
| | - J M Bennett
- Department of Pathology, Hematopathology Unit and James P Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
| |
Collapse
|
44
|
Schroeder T, Plambeck B, Bowdino C, DiMaio D, Christiansen A. Metastasis of Rectal Adenocarcinoma to the Penis and Scrotum in an Adult. Cureus 2021; 13:e18454. [PMID: 34745779 PMCID: PMC8563144 DOI: 10.7759/cureus.18454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/02/2021] [Indexed: 11/05/2022] Open
Abstract
We present a unique case of a 74-year-old male with rectal adenocarcinoma and subsequent cutaneous metastases to the penis and scrotum. Although penile and scrotal metastases have been described separately in the literature, no report has documented simultaneous metastases to both sites. Here, we describe our patient's clinical course, treatment, and intervention throughout the timeline of his disease. We also discuss the presentation, evaluation, management, and prognosis of cutaneous metastasis to the penis and scrotum.
Collapse
Affiliation(s)
- Thomas Schroeder
- Division of Urologic Surgery, University of Nebraska Medical Center, Omaha, USA
| | - Benjamin Plambeck
- Division of Urologic Surgery, University of Nebraska Medical Center, Omaha, USA
| | - Cole Bowdino
- Division of Urologic Surgery, University of Nebraska Medical Center, Omaha, USA
| | - Dominick DiMaio
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
| | - Andrew Christiansen
- Division of Urologic Surgery, University of Nebraska Medical Center, Omaha, USA
| |
Collapse
|
45
|
Lees J, Poireau V, Tisserand V, Grauges E, Palano A, Eigen G, Brown D, Kolomensky Y, Fritsch M, Koch H, Schroeder T, Cheaib R, Hearty C, Mattison T, McKenna J, So R, Blinov V, Buzykaev A, Druzhinin V, Golubev V, Kozyrev E, Kravchenko E, Onuchin A, Serednyakov S, Skovpen Y, Solodov E, Todyshev K, Lankford A, Dey B, Gary J, Long O, Eisner A, Lockman W, Panduro Vazquez W, Chao D, Cheng C, Echenard B, Flood K, Hitlin D, Kim J, Li Y, Lin D, Miyashita T, Ongmongkolkul P, Oyang J, Porter F, Röhrken M, Huard Z, Meadows B, Pushpawela B, Sokoloff M, Sun L, Smith J, Wagner S, Bernard D, Verderi M, Bettoni D, Bozzi C, Calabrese R, Cibinetto G, Fioravanti E, Garzia I, Luppi E, Santoro V, Calcaterra A, de Sangro R, Finocchiaro G, Martellotti S, Patteri P, Peruzzi I, Piccolo M, Rotondo M, Zallo A, Passaggio S, Patrignani C, Shuve B, Lacker H, Bhuyan B, Mallik U, Chen C, Cochran J, Prell S, Gritsan A, Arnaud N, Davier M, Le Diberder F, Lutz A, Wormser G, Lange D, Wright D, Coleman J, Gabathuler E, Hutchcroft D, Payne D, Touramanis C, Bevan A, Di Lodovico F, Sacco R, Cowan G, Banerjee S, Brown D, Davis C, Denig A, Gradl W, Griessinger K, Hafner A, Schubert K, Barlow R, Lafferty G, Cenci R, Jawahery A, Roberts D, Cowan R, Robertson S, Seddon R, Neri N, Palombo F, Cremaldi L, Godang R, Summers D, Taras P, De Nardo G, Sciacca C, Raven G, Jessop C, LoSecco J, Honscheid K, Kass R, Gaz A, Margoni M, Posocco M, Simi G, Simonetto F, Stroili R, Akar S, Ben-Haim E, Bomben M, Bonneaud G, Calderini G, Chauveau J, Marchiori G, Ocariz J, Biasini M, Manoni E, Rossi A, Batignani G, Bettarini S, Carpinelli M, Casarosa G, Chrzaszcz M, Forti F, Giorgi M, Lusiani A, Oberhof B, Paoloni E, Rama M, Rizzo G, Walsh J, Zani L, Smith A, Anulli F, Faccini R, Ferrarotto F, Ferroni F, Pilloni A, Piredda G, Bünger C, Dittrich S, Grünberg O, Heß M, Leddig T, Voß C, Waldi R, Adye T, Wilson F, Emery S, Vasseur G, Aston D, Cartaro C, Convery M, Dorfan J, Dunwoodie W, Ebert M, Field R, Fulsom B, Graham M, Hast C, Innes W, Kim P, Leith D, Luitz S, MacFarlane D, Muller D, Neal H, Ratcliff B, Roodman A, Sullivan M, Va’vra J, Wisniewski W, Purohit M, Wilson J, Randle-Conde A, Sekula S, Ahmed H, Bellis M, Burchat P, Puccio E, Alam M, Ernst J, Gorodeisky R, Guttman N, Peimer D, Soffer A, Spanier S, Ritchie J, Schwitters R, Izen J, Lou X, Bianchi F, De Mori F, Filippi A, Gamba D, Lanceri L, Vitale L, Martinez-Vidal F, Oyanguren A, Albert J, Beaulieu A, Bernlochner F, King G, Kowalewski R, Lueck T, Nugent I, Roney J, Sobie R, Tasneem N, Gershon T, Harrison P, Latham T, Prepost R, Wu S. Light meson spectroscopy from Dalitz plot analyses of
ηc
decays to
η′K+K−
,
η′π+π−
, and
ηπ+π−
produced in two-photon interactions. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.104.072002] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
46
|
Feurstein S, Churpek JE, Walsh T, Keel S, Hakkarainen M, Schroeder T, Germing U, Geyh S, Heuser M, Thol F, Pohlkamp C, Haferlach T, Gao J, Owen C, Goehring G, Schlegelberger B, Verma D, Krause DS, Gao G, Cronin T, Gulsuner S, Lee M, Pritchard CC, Subramanian HP, Del Gaudio D, Li Z, Das S, Kilpivaara O, Wartiovaara-Kautto U, Wang ES, Griffiths EA, Döhner K, Döhner H, King MC, Godley LA. Germline variants drive myelodysplastic syndrome in young adults. Leukemia 2021; 35:2439-2444. [PMID: 33510405 PMCID: PMC8725861 DOI: 10.1038/s41375-021-01137-0] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 12/17/2020] [Accepted: 01/11/2021] [Indexed: 01/29/2023]
Affiliation(s)
- Simone Feurstein
- Department of Medicine, Section of Hematology/Oncology, The University of Chicago Comprehensive Cancer Center, The University of Chicago, Chicago, IL, USA
| | - Jane E Churpek
- Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, The University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
| | - Tom Walsh
- Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA, USA
| | - Sioban Keel
- Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA
| | - Marja Hakkarainen
- Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
- Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland
| | - Thomas Schroeder
- Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany
| | - Ulrich Germing
- Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany
| | - Stefanie Geyh
- Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany
| | - Michael Heuser
- Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | - Felicitas Thol
- Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | | | | | - Juehua Gao
- Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Carolyn Owen
- Division of Hematology and Hematological Malignancies, University of Calgary, Calgary, AB, Canada
| | - Gudrun Goehring
- Department of Human Genetics, Hannover Medical School, Hannover, Germany
| | | | - Divij Verma
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Medicine, Frankfurt, Germany
- Department of Medicine, Albert Einstein College of Medicine, New York, NY, USA
| | - Daniela S Krause
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Medicine, Frankfurt, Germany
| | - Guimin Gao
- Department of Public Health Sciences, The University of Chicago, Chicago, IL, USA
| | - Tara Cronin
- Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Suleyman Gulsuner
- Department of Genome Sciences, University of Washington, Seattle, WA, USA
| | - Ming Lee
- Department of Genome Sciences, University of Washington, Seattle, WA, USA
| | - Colin C Pritchard
- Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
| | | | - Daniela Del Gaudio
- Department of Human Genetics, The University of Chicago, Chicago, IL, USA
| | - Zejuan Li
- Department of Pathology and Genomic Medicine, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, TX, USA
| | - Soma Das
- Department of Human Genetics, The University of Chicago, Chicago, IL, USA
| | - Outi Kilpivaara
- Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
- Department of Medical and Clinical Genetics/Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - Ulla Wartiovaara-Kautto
- Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
- Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland
| | - Eunice S Wang
- Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | | | - Konstanze Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Hartmut Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Mary-Claire King
- Department of Genome Sciences, University of Washington, Seattle, WA, USA
| | - Lucy A Godley
- Department of Medicine, Section of Hematology/Oncology, The University of Chicago Comprehensive Cancer Center, The University of Chicago, Chicago, IL, USA.
| |
Collapse
|
47
|
Schuler E, Wagner-Drouet EM, Ajib S, Bug G, Crysandt M, Dressler S, Hausmann A, Heidenreich D, Hirschbühl K, Hoepting M, Jost E, Kaivers J, Klein S, Koldehoff M, Kordelas L, Kriege O, Müller LP, Rautenberg C, Schaffrath J, Schmid C, Wolff D, Haas R, Bornhäuser M, Schroeder T, Kobbe G. Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol 2021; 100:2141-2142. [PMID: 34160650 DOI: 10.1007/s00277-021-04564-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Esther Schuler
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany.
| | - Eva-Maria Wagner-Drouet
- Department of Hematology, Oncology, Pneumology, Medical Clinic III, UCT Johannes Gutenberg-University Mainz, Mainz, Germany
| | - Salem Ajib
- Department of Medicine II, Goethe University, Frankfurt am Main, Germany
| | - Gesine Bug
- Department of Medicine II, Goethe University, Frankfurt am Main, Germany
| | - Martina Crysandt
- Department of Hematology, Oncology, Hemostasiology and Stem Cell Transplantation, Medical Clinic IV, University Hospital RWTH Aachen, Aachen, Germany
| | - Sabine Dressler
- Bone Marrow Transplantation Unit, Medical Clinic 5, Nürnberg, Germany
| | - Andreas Hausmann
- Department of Hematology, Oncology, Immunology, Palliative Care, Munich Clinic Schwabing, Munich, Germany
| | | | - Klaus Hirschbühl
- Department of Hematology and Oncology, Medical Clinic II, University Hospital Augsburg, Augsburg, Germany
| | - Matthias Hoepting
- Medical Clinic III, University Medicine Regensburg, Regensburg, Germany
| | - Edgar Jost
- Department of Hematology, Oncology, Hemostasiology and Stem Cell Transplantation, Medical Clinic IV, University Hospital RWTH Aachen, Aachen, Germany
| | - Jennifer Kaivers
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Stefan Klein
- Medical Clinic III, University Medicine Mannheim, Mannheim, Germany
| | - Michael Koldehoff
- Clinic for Bone Marrow Transplantation, University Hospital Essen, Essen, Germany
| | - Lambros Kordelas
- Clinic for Bone Marrow Transplantation, University Hospital Essen, Essen, Germany
| | - Oliver Kriege
- Department of Hematology, Oncology, Pneumology, Medical Clinic III, UCT Johannes Gutenberg-University Mainz, Mainz, Germany
| | - Lutz P Müller
- Department of Internal Medicine IV, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Halle, Germany
| | - Christina Rautenberg
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Judith Schaffrath
- Department of Internal Medicine IV, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Halle, Germany
| | - Christoph Schmid
- Department of Hematology and Oncology, Medical Clinic II, University Hospital Augsburg, Augsburg, Germany
| | - Daniel Wolff
- Medical Clinic III, University Medicine Regensburg, Regensburg, Germany
| | - Rainer Haas
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Martin Bornhäuser
- Department of Internal Medicine I, University Hospital Carl Gustav Carus at the Technische Universität, Dresden, Germany
| | - Thomas Schroeder
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Guido Kobbe
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
| |
Collapse
|
48
|
Panagiota V, Meggendorfer M, Kubasch AS, Gabdoulline R, Krönke J, Mies A, Shahswar R, Kandziora C, Klement P, Schiller J, Göhring G, Haferlach C, Ganster C, Shirneshan K, Gutermuth A, Thiede C, Germing U, Schroeder T, Kobbe G, Klesse S, Koenecke C, Schlegelberger B, Kröger N, Haase D, Döhner K, Sperr WR, Valent P, Ganser A, Thol F, Haferlach T, Platzbecker U, Heuser M. Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. Am J Hematol 2021; 96:E207-E210. [PMID: 33725366 DOI: 10.1002/ajh.26162] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Revised: 03/12/2021] [Accepted: 03/12/2021] [Indexed: 11/06/2022]
Affiliation(s)
- Victoria Panagiota
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany
| | | | - Anne Sophie Kubasch
- Department of Hematology and Cell Therapy Medical Clinic and Policlinic I, Leipzig University Hospital Leipzig Germany
| | - Razif Gabdoulline
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany
| | - Jan Krönke
- Department of Internal Medicine III University Hospital Medical Center Ulm Germany
| | - Anna Mies
- Department of Internal Medicine I University Hospital Carl Gustav Carus, Technical University Dresden Dresden Germany
| | - Rabia Shahswar
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany
| | - Christian Kandziora
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany
| | - Piroska Klement
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany
| | - Johannes Schiller
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany
| | - Gudrun Göhring
- Department of Human Genetics Hannover Medical School Hannover Germany
| | | | - Christina Ganster
- Department of Hematology and Oncology Georg‐August‐Universität‐Göttingen Göttingen Germany
| | - Katayoon Shirneshan
- Department of Hematology and Oncology Georg‐August‐Universität‐Göttingen Göttingen Germany
| | - Annika Gutermuth
- Department of Hematology and Oncology Georg‐August‐Universität‐Göttingen Göttingen Germany
| | - Christian Thiede
- Department of Internal Medicine I University Hospital Carl Gustav Carus, Technical University Dresden Dresden Germany
| | - Ulrich Germing
- Department of Hematology, Oncology and Clinical Immunology Medical Faculty, University of Duesseldorf Duesseldorf Germany
| | - Thomas Schroeder
- Department of Hematology, Oncology and Clinical Immunology Medical Faculty, University of Duesseldorf Duesseldorf Germany
| | - Guido Kobbe
- Department of Hematology, Oncology and Clinical Immunology Medical Faculty, University of Duesseldorf Duesseldorf Germany
| | - Sabrina Klesse
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany
| | - Christian Koenecke
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany
| | | | - Nicolaus Kröger
- Department of Stem Cell Transplantation University Medical Center Hamburg‐Eppendorf Hamburg Germany
| | - Detlef Haase
- Department of Hematology and Oncology Georg‐August‐Universität‐Göttingen Göttingen Germany
| | - Konstanze Döhner
- Department of Internal Medicine III University Hospital Medical Center Ulm Germany
| | - Wolfgang R. Sperr
- Department of Internal Medicine I, Division of Hematology & Hemostaseology Medical University of Vienna Vienna Austria
- Ludwig Boltzmann Institute for Hematology and Oncology Medical University of Vienna Vienna Austria
| | - Peter Valent
- Department of Internal Medicine I, Division of Hematology & Hemostaseology Medical University of Vienna Vienna Austria
- Ludwig Boltzmann Institute for Hematology and Oncology Medical University of Vienna Vienna Austria
| | - Arnold Ganser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany
| | - Felicitas Thol
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany
| | | | - Uwe Platzbecker
- Department of Hematology and Cell Therapy Medical Clinic and Policlinic I, Leipzig University Hospital Leipzig Germany
| | - Michael Heuser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany
| |
Collapse
|
49
|
Rautenberg C, Lauseker M, Kaivers J, Jäger P, Fischermanns C, Pechtel S, Haas R, Kobbe G, Germing U, Schroeder T. Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS. Eur J Haematol 2021; 107:283-292. [PMID: 33987857 DOI: 10.1111/ejh.13664] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2021] [Revised: 05/07/2021] [Accepted: 05/10/2021] [Indexed: 12/17/2022]
Abstract
OBJECTIVE As peripheral blood (PB) Wilm's Tumor 1 (WT1)-mRNA expression is established as MRD-marker during conventional AML chemotherapy, impact of pretransplant WT1 expression remains unclear. Therefore, we aimed to assess prognostic impact of pretransplant WT1 expression on post-transplant outcome in patients with AML/MDS. METHODS In 64 AML/MDS patients, pretransplant WT1 expression was retrospectively analyzed using a standardized assay offering high sensitivity, specificity, and a validated cut-off. Patients were divided into three groups determined by pretransplant remission and WT1 expression. Post-transplant outcome of these groups was compared regarding cumulative incidence of relapse (CIR), relapse-free (RFS), and overall survival (OS). RESULTS Pretransplant forty-six patients (72%) showed hematologic remission, including 21 (46%) MRD-negative and 25 (54%) MRD-positive patients indicated by WT1 expression, while 18 refractory patients (28%) showed active disease. Two-year estimates of post-transplant CIR, RFS, and OS were similar in MRD-positive (61%, 37%, 54%) and refractory patients (70%, 26%, 56%), but significantly inferior compared with MRD-negative patients (10%, 89%, 90%). After multivariable adjustment, pretransplant MRD negativity measured by WT1 expression retained its prognostic impact on CIR (P = .008), RFS (P = .005), and OS (P = .049). CONCLUSIONS PB WT1 expression represents a useful method to estimate pretransplant MRD, which is highly predictable for post-transplant outcome and may help improving peri-transplant management in AML/MDS patients.
Collapse
Affiliation(s)
- Christina Rautenberg
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf, Germany
| | - Michael Lauseker
- Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-University, Munich, Germany
| | - Jennifer Kaivers
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf, Germany
| | - Paul Jäger
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf, Germany
| | - Carolin Fischermanns
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf, Germany
| | - Sabrina Pechtel
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf, Germany
| | - Rainer Haas
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf, Germany
| | - Guido Kobbe
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf, Germany
| | - Ulrich Germing
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf, Germany
| | - Thomas Schroeder
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine - University, Duesseldorf, Germany.,Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Medical Faculty, University Duisburg-Essen, Essen, Germany
| |
Collapse
|
50
|
Teich K, Krzykalla J, Kapp-Schwoerer S, Gaidzik VI, Schlenk RF, Paschka P, Weber D, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Ramachandran D, Benner A, Ganser A, Döhner H, Heuser M, Döhner K, Thol F. Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. Haematologica 2021; 106:2986-2989. [PMID: 34047179 PMCID: PMC8561276 DOI: 10.3324/haematol.2021.278894] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Indexed: 11/09/2022] Open
Affiliation(s)
- Katrin Teich
- Department of Hematology, Hemostaseology, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover
| | - Julia Krzykalla
- Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg
| | | | - Verena I Gaidzik
- Department of Internal Medicine III, University Hospital of Ulm, Ulm
| | - Richard F Schlenk
- Nationales Centrum für Tumorerkrankungen Trial Center, National Center of Tumor Diseases, German Cancer Research Center, Heidelberg; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg
| | - Peter Paschka
- Department of Internal Medicine III, University Hospital of Ulm, Ulm
| | - Daniela Weber
- Department of Internal Medicine III, University Hospital of Ulm, Ulm
| | - Walter Fiedler
- Department of Internal Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg
| | - Michael W M Kühn
- Department of Hematology, Medical Oncology and Pneumology, University Medical Center Mainz, Mainz
| | - Thomas Schroeder
- Department of Hematology, Oncology, and Clinical Immunology, University of Düsseldorf, Medical Faculty, Düsseldorf
| | - Karin Mayer
- Internal Medicine III, University Hospital of Bonn, Bonn
| | - Michael Lübbert
- Klinik für Innere Medizin I, Universitätsklinikum Freiburg, Faculty of Medicine, Freiburg
| | | | - Axel Benner
- Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg
| | - Arnold Ganser
- Department of Hematology, Hemostaseology, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover
| | - Hartmut Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm
| | - Michael Heuser
- Department of Hematology, Hemostaseology, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover
| | - Konstanze Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm
| | - Felicitas Thol
- Department of Hematology, Hemostaseology, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover
| |
Collapse
|